成人免费xx,国产又黄又湿又刺激不卡网站,成人性视频app菠萝网站,色天天天天

  2. Anti-infection Autophagy Metabolic Enzyme/Protease
  3. Reverse Transcriptase HIV Autophagy Endogenous Metabolite Parasite
  4. Efavirenz

Efavirenz  (Synonyms: 依法韋侖; DMP 266; EFV; L-743726)

目錄號: HY-10572 純度: 99.93%
COA 產(chǎn)品使用指南 技術(shù)支持

Efavirenz (DMP 266) 是一種有效的野生型 HIV-1 RT 抑制劑，Ki 為 2.93 nM，抑制 HIV-1 復制，IC95 為 1.5 nM。

MCE 的所有產(chǎn)品僅用作科學研究或藥證申報，我們不為任何個人用途提供產(chǎn)品和服務(wù)

Efavirenz Chemical Structure

Efavirenz Chemical Structure

CAS No. : 154598-52-4

1.  客戶無需承擔相應(yīng)的運輸費用。

2.  同一機構(gòu)（單位）同一產(chǎn)品試用裝僅限申領(lǐng)一次，同一機構(gòu)（單位）一年內(nèi)

     可免費申領(lǐng)三個不同產(chǎn)品的試用裝。

3.  試用裝只面向終端客戶。

規(guī)格 價格 是否有貨 數(shù)量
10 mM * 1 mL in DMSO ￥430
In-stock
5 mg ￥391
In-stock
10 mg ￥566
In-stock
25 mg ￥930
In-stock
50 mg ￥1488
In-stock
100 mg ￥2083
In-stock
500 mg ￥5725
In-stock
1 g 現(xiàn)貨 詢價
5 g   詢價  
10 g   詢價  

* Please select Quantity before adding items.

Customer Review

Other Forms of Efavirenz:

    Efavirenz purchased from MCE. Usage Cited in: Cell Physiol Biochem. 2015;37(6):2496-507.  [Abstract]

    Arithmetic means±SEM (n=19) of erythrocyte annexin-V-binding (black bars) following incubation for 48 hours to Ringer solution without (white bar) or with (black bars) presence of Efavirenz (1-4 μg/mL).

    查看 HIV 亞型特異性產(chǎn)品:

    查看 Parasite 亞型特異性產(chǎn)品:

    • 生物活性

    • 實驗參考方法

    • 純度 & 產(chǎn)品資料

    • 參考文獻

    生物活性

    Efavirenz (DMP 266) is a potent inhibitor of the wild-type HIV-1 reverse transcriptase with a Ki of 2.93 nM and exhibits an IC95 of 1.5 nM for the inhibition of HIV-1 replicative spread in cell culture[1].

    IC50 & Target

    HIV-1

     

    細胞效力
    (Cellular Effect)
    Cell Line Type Value Description References
    C8166 EC50
    0.0027 μM
    Compound: efavirenz
    Antiviral activity against HIV1 3B infected human C8166 cells assessed as inhibition of syncytia formation by p24 antigen based assay
    Antiviral activity against HIV1 3B infected human C8166 cells assessed as inhibition of syncytia formation by p24 antigen based assay
    		[PMID: 19170521]
    C8166 EC50
    183.63 μM
    Compound: EFV
    Antiviral activity against HIV1 A17 infected in human C8166 cells assessed as reduction in p24 antigen level incubated for 4 hrs followed by cell plating for 72 hrs by ELISA method
    Antiviral activity against HIV1 A17 infected in human C8166 cells assessed as reduction in p24 antigen level incubated for 4 hrs followed by cell plating for 72 hrs by ELISA method
    		[PMID: 27039251]
    CCRF-CEM CC50
    > 100 μM
    Compound: EFV
    Cytotoxicity against HIV1 infected human CEM cells assessed as reduction in cell viability after 7 days by MTT assay
    Cytotoxicity against HIV1 infected human CEM cells assessed as reduction in cell viability after 7 days by MTT assay
    		[PMID: 27390064]
    CCRF-CEM EC50
    > 10000 nM
    Compound: EFV
    Antiviral activity against HIV2 isolate ROD infected in human CEM cells assessed as inhibition of virus-induced cytopathicity after 4 days by microscopic analysis
    Antiviral activity against HIV2 isolate ROD infected in human CEM cells assessed as inhibition of virus-induced cytopathicity after 4 days by microscopic analysis
    		[PMID: 21366296]
    CCRF-CEM EC50
    > 10000 nM
    Compound: EFV, DMP-266
    Antiviral activity against HIV2 ROD infected in human CEM cells assessed as protection against virus-induced cytopathicity by giant cell formation assay
    Antiviral activity against HIV2 ROD infected in human CEM cells assessed as protection against virus-induced cytopathicity by giant cell formation assay
    		[PMID: 25418038]
    CCRF-CEM EC50
    > 10000 nM
    Compound: EFV, DMP-266
    Antiviral activity against HIV-2 ROD infected in human CEM cells assessed as protection of cells monitored by giant cell formation by microscopy
    Antiviral activity against HIV-2 ROD infected in human CEM cells assessed as protection of cells monitored by giant cell formation by microscopy
    		[PMID: 24769348]
    CCRF-CEM CC50
    > 10000 μM
    Compound: EFV
    Cytotoxicity against human CEM cells by coulter counter analysis
    Cytotoxicity against human CEM cells by coulter counter analysis
    		[PMID: 21366296]
    CCRF-CEM EC50
    1.5 nM
    Compound: EFV
    Antiviral activity against wild type HIV1 3B infected in human CEM cells assessed as inhibition of virus-induced cytopathicity after 4 days by microscopic analysis
    Antiviral activity against wild type HIV1 3B infected in human CEM cells assessed as inhibition of virus-induced cytopathicity after 4 days by microscopic analysis
    		[PMID: 21366296]
    CCRF-CEM EC50
    1.5 nM
    Compound: EFV, DMP-266
    Antiviral activity against HIV1 3B infected in human CEM cells assessed as protection against virus-induced cytopathicity by giant cell formation assay
    Antiviral activity against HIV1 3B infected in human CEM cells assessed as protection against virus-induced cytopathicity by giant cell formation assay
    		[PMID: 25418038]
    CCRF-CEM EC50
    1.5 nM
    Compound: EFV, DMP-266
    Antiviral activity against HIV1 3B infected in human CEM cells assessed as protection of cells monitored by giant cell formation by microscopy
    Antiviral activity against HIV1 3B infected in human CEM cells assessed as protection of cells monitored by giant cell formation by microscopy
    		[PMID: 24769348]
    CEM-SS EC50
    0.005 μM
    Compound: efavirenz
    Antiviral activity against HIV1 RF in human CEM-SS cells by XTT assay
    Antiviral activity against HIV1 RF in human CEM-SS cells by XTT assay
    		[PMID: 17803290]
    CEM-SS CC50
    0.55 μM
    Compound: Efavirenz
    Cytotoxicity against human CEM-SS cells by MTS assay
    Cytotoxicity against human CEM-SS cells by MTS assay
    		10.1039/C4MD00282B
    CEM-SS EC50
    0.92 nM
    Compound: Efavirenz
    Antiviral activity against HIV1 RF infected in CEM-SS cells assessed as inhibition of virus-induced cytopathic effect by MTS assay
    Antiviral activity against HIV1 RF infected in CEM-SS cells assessed as inhibition of virus-induced cytopathic effect by MTS assay
    		10.1039/C4MD00282B
    HEK-293T CC50
    > 30 μM
    Compound: Efavirenz
    Cytotoxicity against human HEK 293T cells assessed as reduction in cell viability measured after 48 hrs by Celltiter-glo assay
    Cytotoxicity against human HEK 293T cells assessed as reduction in cell viability measured after 48 hrs by Celltiter-glo assay
    		[PMID: 32004936]
    HEK-293T EC50
    0.0005 μM
    Compound: efavirenz
    Antiviral activity against HIV in HEK293T cells after 48 hrs
    Antiviral activity against HIV in HEK293T cells after 48 hrs
    		[PMID: 17035019]
    HEK-293T IC50
    0.00084 μM
    Compound: EFV
    Antiviral activity against wild type HIV1 infected in HEK293T cells transfected with plasmid VSV-G/pNL4-3.luc.R-E- assessed as inhibition of viral replication after 48 hrs by luciferase reporter gene assay
    Antiviral activity against wild type HIV1 infected in HEK293T cells transfected with plasmid VSV-G/pNL4-3.luc.R-E- assessed as inhibition of viral replication after 48 hrs by luciferase reporter gene assay
    		[PMID: 25072874]
    HEK-293T IC50
    0.00104 μM
    Compound: EFV
    Antiviral activity against wild-type HIV-1 NL4-3 harboring vesicular stomatitis virus glycoprotein infected in HEK293T cells pretreated with cells for 15 mins followed by viral infection measured after 48 hrs by luciferase reporter gene assay
    Antiviral activity against wild-type HIV-1 NL4-3 harboring vesicular stomatitis virus glycoprotein infected in HEK293T cells pretreated with cells for 15 mins followed by viral infection measured after 48 hrs by luciferase reporter gene assay
    		[PMID: 27484516]
    HEK-293T IC50
    0.00565 μM
    Compound: EFV
    Antiviral activity against HIV1 harboring reverse transcriptase Y181C mutant infected in HEK293T cells transfected with plasmid VSV-G/pNL4-3.luc.R-E- assessed as inhibition of viral replication after 48 hrs by luciferase reporter gene assay
    Antiviral activity against HIV1 harboring reverse transcriptase Y181C mutant infected in HEK293T cells transfected with plasmid VSV-G/pNL4-3.luc.R-E- assessed as inhibition of viral replication after 48 hrs by luciferase reporter gene assay
    		[PMID: 25072874]
    HEK-293T IC50
    0.00565 μM
    Compound: EFV
    Antiviral activity against HIV-1 NL4-3 harboring RT-Y181C mutant infected in HEK293T cells coexpressing vesicular stomatitis virus glycoprotein pretreated with cells for 15 mins followed by viral infection measured after 48 hrs by luciferase reporter gene
    Antiviral activity against HIV-1 NL4-3 harboring RT-Y181C mutant infected in HEK293T cells coexpressing vesicular stomatitis virus glycoprotein pretreated with cells for 15 mins followed by viral infection measured after 48 hrs by luciferase reporter gene
    		[PMID: 27484516]
    HEK-293T IC50
    0.056 μM
    Compound: EFV
    Antiviral activity against HIV1 harboring reverse transcriptase K103N/G190A double mutant infected in HEK293T cells transfected with plasmid VSV-G/pNL4-3.luc.R-E- assessed as inhibition of viral replication after 48 hrs by luciferase reporter gene assay
    Antiviral activity against HIV1 harboring reverse transcriptase K103N/G190A double mutant infected in HEK293T cells transfected with plasmid VSV-G/pNL4-3.luc.R-E- assessed as inhibition of viral replication after 48 hrs by luciferase reporter gene assay
    		[PMID: 25072874]
    HEK-293T IC50
    0.056 μM
    Compound: EFV
    Antiviral activity against HIV-1 NL4-3 harboring RT-K103N/G190A double mutant infected in HEK293T cells coexpressing vesicular stomatitis virus glycoprotein pretreated with cells for 15 mins followed by viral infection measured after 48 hrs by luciferase
    Antiviral activity against HIV-1 NL4-3 harboring RT-K103N/G190A double mutant infected in HEK293T cells coexpressing vesicular stomatitis virus glycoprotein pretreated with cells for 15 mins followed by viral infection measured after 48 hrs by luciferase
    		[PMID: 27484516]
    HEK-293T IC50
    0.0587 μM
    Compound: EFV
    Antiviral activity against HIV-1 NL4-3 harboring RT-K103N/Y181C double mutant infected in HEK293T cells coexpressing vesicular stomatitis virus glycoprotein pretreated with cells for 15 mins followed by viral infection measured after 48 hrs by luciferase
    Antiviral activity against HIV-1 NL4-3 harboring RT-K103N/Y181C double mutant infected in HEK293T cells coexpressing vesicular stomatitis virus glycoprotein pretreated with cells for 15 mins followed by viral infection measured after 48 hrs by luciferase
    		[PMID: 27484516]
    HEK-293T IC50
    0.0588 μM
    Compound: EFV
    Antiviral activity against HIV1 harboring reverse transcriptase K103N mutant infected in HEK293T cells transfected with plasmid VSV-G/pNL4-3.luc.R-E- assessed as inhibition of viral replication after 48 hrs by luciferase reporter gene assay
    Antiviral activity against HIV1 harboring reverse transcriptase K103N mutant infected in HEK293T cells transfected with plasmid VSV-G/pNL4-3.luc.R-E- assessed as inhibition of viral replication after 48 hrs by luciferase reporter gene assay
    		[PMID: 25072874]
    HEK-293T IC50
    0.0588 μM
    Compound: EFV
    Antiviral activity against HIV-1 NL4-3 harboring RT-K103N mutant infected in HEK293T cells coexpressing vesicular stomatitis virus glycoprotein pretreated with cells for 15 mins followed by viral infection measured after 48 hrs by luciferase reporter gene
    Antiviral activity against HIV-1 NL4-3 harboring RT-K103N mutant infected in HEK293T cells coexpressing vesicular stomatitis virus glycoprotein pretreated with cells for 15 mins followed by viral infection measured after 48 hrs by luciferase reporter gene
    		[PMID: 27484516]
    HEK-293T IC50
    0.083 μM
    Compound: EFV
    Antiviral activity against HIV1 harboring reverse transcriptase K103N/V108I double mutant infected in HEK293T cells transfected with plasmid VSV-G/pNL4-3.luc.R-E- assessed as inhibition of viral replication after 48 hrs by luciferase reporter gene assay
    Antiviral activity against HIV1 harboring reverse transcriptase K103N/V108I double mutant infected in HEK293T cells transfected with plasmid VSV-G/pNL4-3.luc.R-E- assessed as inhibition of viral replication after 48 hrs by luciferase reporter gene assay
    		[PMID: 25072874]
    HEK-293T IC50
    0.083 μM
    Compound: EFV
    Antiviral activity against HIV-1 NL4-3 harboring RT-K103N/V108I double mutant infected in HEK293T cells coexpressing vesicular stomatitis virus glycoprotein pretreated with cells for 15 mins followed by viral infection measured after 48 hrs by luciferase
    Antiviral activity against HIV-1 NL4-3 harboring RT-K103N/V108I double mutant infected in HEK293T cells coexpressing vesicular stomatitis virus glycoprotein pretreated with cells for 15 mins followed by viral infection measured after 48 hrs by luciferase
    		[PMID: 27484516]
    HEK-293T IC50
    0.16 μM
    Compound: EFV
    Antiviral activity against HIV1 harboring reverse transcriptase K103N/P225H double mutant infected in HEK293T cells transfected with plasmid VSV-G/pNL4-3.luc.R-E- assessed as inhibition of viral replication after 48 hrs by luciferase reporter gene assay
    Antiviral activity against HIV1 harboring reverse transcriptase K103N/P225H double mutant infected in HEK293T cells transfected with plasmid VSV-G/pNL4-3.luc.R-E- assessed as inhibition of viral replication after 48 hrs by luciferase reporter gene assay
    		[PMID: 25072874]
    HEK-293T IC50
    0.16 μM
    Compound: EFV
    Antiviral activity against HIV-1 NL4-3 harboring RT-K103N/P225H double mutant infected in HEK293T cells coexpressing vesicular stomatitis virus glycoprotein pretreated with cells for 15 mins followed by viral infection measured after 48 hrs by luciferase
    Antiviral activity against HIV-1 NL4-3 harboring RT-K103N/P225H double mutant infected in HEK293T cells coexpressing vesicular stomatitis virus glycoprotein pretreated with cells for 15 mins followed by viral infection measured after 48 hrs by luciferase
    		[PMID: 27484516]
    HEK-293T IC50
    0.48 μM
    Compound: EFV
    Antiviral activity against HIV1 harboring reverse transcriptase Y188L mutant infected in HEK293T cells transfected with plasmid VSV-G/pNL4-3.luc.R-E- assessed as inhibition of viral replication after 48 hrs by luciferase reporter gene assay
    Antiviral activity against HIV1 harboring reverse transcriptase Y188L mutant infected in HEK293T cells transfected with plasmid VSV-G/pNL4-3.luc.R-E- assessed as inhibition of viral replication after 48 hrs by luciferase reporter gene assay
    		[PMID: 25072874]
    HEK-293T IC50
    0.48 μM
    Compound: EFV
    Antiviral activity against HIV-1 NL4-3 harboring RT-Y188L mutant infected in HEK293T cells coexpressing vesicular stomatitis virus glycoprotein pretreated with cells for 15 mins followed by viral infection measured after 48 hrs by luciferase reporter gene
    Antiviral activity against HIV-1 NL4-3 harboring RT-Y188L mutant infected in HEK293T cells coexpressing vesicular stomatitis virus glycoprotein pretreated with cells for 15 mins followed by viral infection measured after 48 hrs by luciferase reporter gene
    		[PMID: 27484516]
    HEK-293T CC50
    10 μM
    Compound: efavirenz
    Cytotoxicity against HEK293T cells after 48 hrs
    Cytotoxicity against HEK293T cells after 48 hrs
    		[PMID: 17035019]
    HEK-293T IC50
    13.8 μM
    Compound: EFV
    Antiviral activity against HIV-1 NL4-3 harboring RT-K103N/Y188L double mutant infected in HEK293T cells coexpressing vesicular stomatitis virus glycoprotein pretreated with cells for 15 mins followed by viral infection measured after 48 hrs by luciferase
    Antiviral activity against HIV-1 NL4-3 harboring RT-K103N/Y188L double mutant infected in HEK293T cells coexpressing vesicular stomatitis virus glycoprotein pretreated with cells for 15 mins followed by viral infection measured after 48 hrs by luciferase
    		[PMID: 27484516]
    HEK-293T IC50
    2.49 μM
    Compound: EFV
    Antiviral activity against HIV1 harboring reverse transcriptase L1001/K103N double mutant infected in HEK293T cells transfected with plasmid VSV-G/pNL4-3.luc.R-E- assessed as inhibition of viral replication after 48 hrs by luciferase reporter gene assay
    Antiviral activity against HIV1 harboring reverse transcriptase L1001/K103N double mutant infected in HEK293T cells transfected with plasmid VSV-G/pNL4-3.luc.R-E- assessed as inhibition of viral replication after 48 hrs by luciferase reporter gene assay
    		[PMID: 25072874]
    HEK-293T IC50
    2.49 μM
    Compound: EFV
    Antiviral activity against HIV-1 NL4-3 harboring RT-L100I/K103N double mutant infected in HEK293T cells coexpressing vesicular stomatitis virus glycoprotein pretreated with cells for 15 mins followed by viral infection measured after 48 hrs by luciferase
    Antiviral activity against HIV-1 NL4-3 harboring RT-L100I/K103N double mutant infected in HEK293T cells coexpressing vesicular stomatitis virus glycoprotein pretreated with cells for 15 mins followed by viral infection measured after 48 hrs by luciferase
    		[PMID: 27484516]
    HEK-293T EC50
    889 nM
    Compound: EFV
    Antiviral activity against multidrug-resistant HIV1 695-RT infected in HEK293T cells assessed as inhibition of viral replication after 4 days by beta-galactosidase reporter gene assay
    Antiviral activity against multidrug-resistant HIV1 695-RT infected in HEK293T cells assessed as inhibition of viral replication after 4 days by beta-galactosidase reporter gene assay
    		[PMID: 22148316]
    HeLa EC50
    > 0.002 μM
    Compound: EFV
    Antiviral activity against HIV1 bearing HIV1 NL4-3 envelope infected in human HeLa CD4 cells coexpressing LTR/beta-Gal gene assessed as reduction in virus-induced beta-galactosidase reporter gene activity after 72 hrs by single-cycle infection assay
    Antiviral activity against HIV1 bearing HIV1 NL4-3 envelope infected in human HeLa CD4 cells coexpressing LTR/beta-Gal gene assessed as reduction in virus-induced beta-galactosidase reporter gene activity after 72 hrs by single-cycle infection assay
    		[PMID: 17646410]
    HeLa EC50
    0.0001 μM
    Compound: Efavirenz
    Antiviral activity against HIV1 infected in human HeLa cells expressing CD4-LTR assessed as inhibition of viral entry-related beta galactosidase expression treated for 2 hrs measured after 48 hrs by MAGI assay
    Antiviral activity against HIV1 infected in human HeLa cells expressing CD4-LTR assessed as inhibition of viral entry-related beta galactosidase expression treated for 2 hrs measured after 48 hrs by MAGI assay
    		[PMID: 17967909]
    HeLa EC50
    0.0006 μM
    Compound: EFV
    Antiviral activity against wild type HIV1 infected in human HeLa cells assessed as decrease in viral infection after 72 hrs by beta-galactosidase reporter gene assay
    Antiviral activity against wild type HIV1 infected in human HeLa cells assessed as decrease in viral infection after 72 hrs by beta-galactosidase reporter gene assay
    		[PMID: 19805571]
    HeLa EC50
    0.0006 μM
    Compound: EFV
    Antiviral activity against HIV1 harboring capsid I201V mutant protein infected in human HeLa cells assessed as decrease in viral infection after 72 hrs by beta-galactosidase reporter gene assay
    Antiviral activity against HIV1 harboring capsid I201V mutant protein infected in human HeLa cells assessed as decrease in viral infection after 72 hrs by beta-galactosidase reporter gene assay
    		[PMID: 19805571]
    HeLa EC50
    0.001 μM
    Compound: EFV
    Antiviral activity against HIV1 NL4-3 infected in human HeLa cells assessed as decrease in single-cycle viral infection after 72 hrs by beta-galactosidase reporter gene assay
    Antiviral activity against HIV1 NL4-3 infected in human HeLa cells assessed as decrease in single-cycle viral infection after 72 hrs by beta-galactosidase reporter gene assay
    		[PMID: 19805571]
    HeLa EC50
    0.001 μM
    Compound: EFV
    Antiviral activity against HIV1 harboring spacer peptide A1V mutant protein infected in human HeLa cells assessed as decrease in viral infection after 72 hrs by beta-galactosidase reporter gene assay
    Antiviral activity against HIV1 harboring spacer peptide A1V mutant protein infected in human HeLa cells assessed as decrease in viral infection after 72 hrs by beta-galactosidase reporter gene assay
    		[PMID: 19805571]
    HeLa EC50
    0.0011 μM
    Compound: EFV
    Antiviral activity against HIV1 bearing VSV envelope infected in human HeLa CD4 cells coexpressing LTR/beta-Gal gene assessed as reduction in virus-induced beta-galactosidase reporter gene activity after 72 hrs by single-cycle infection assay
    Antiviral activity against HIV1 bearing VSV envelope infected in human HeLa CD4 cells coexpressing LTR/beta-Gal gene assessed as reduction in virus-induced beta-galactosidase reporter gene activity after 72 hrs by single-cycle infection assay
    		[PMID: 17646410]
    HeLa IC50
    0.4 nM
    Compound: efavirenz, EFV
    Antiviral activity against wild type HIV1 in HeLa cells by MAGI assay
    Antiviral activity against wild type HIV1 in HeLa cells by MAGI assay
    		[PMID: 18665583]
    HeLa IC50
    0.6 nM
    Compound: efavirenz, EFV
    Antiviral activity against NNRTI-resistant HIV1 with reverse transcriptase P236L mutant in HeLa cells by MAGI assay
    Antiviral activity against NNRTI-resistant HIV1 with reverse transcriptase P236L mutant in HeLa cells by MAGI assay
    		[PMID: 18665583]
    HeLa IC50
    0.8 nM
    Compound: efavirenz, EFV
    Antiviral activity against NNRTI-resistant HIV1 with reverse transcriptase Y181C mutant in HeLa cells by MAGI assay
    Antiviral activity against NNRTI-resistant HIV1 with reverse transcriptase Y181C mutant in HeLa cells by MAGI assay
    		[PMID: 18665583]
    HeLa IC50
    0.8 nM
    Compound: efavirenz, EFV
    Antiviral activity against NNRTI-resistant HIV1 with reverse transcriptase V106A mutant in HeLa cells by MAGI assay
    Antiviral activity against NNRTI-resistant HIV1 with reverse transcriptase V106A mutant in HeLa cells by MAGI assay
    		[PMID: 18665583]
    HeLa IC50
    0.9 nM
    Compound: efavirenz, EFV
    Antiviral activity against NNRTI-resistant HIV1 with reverse transcriptase V106I mutant in HeLa cells by MAGI assay
    Antiviral activity against NNRTI-resistant HIV1 with reverse transcriptase V106I mutant in HeLa cells by MAGI assay
    		[PMID: 18665583]
    HeLa IC50
    1 nM
    Compound: efavirenz, EFV
    Antiviral activity against NNRTI-resistant HIV1 with reverse transcriptase G190E mutant in HeLa cells by MAGI assay
    Antiviral activity against NNRTI-resistant HIV1 with reverse transcriptase G190E mutant in HeLa cells by MAGI assay
    		[PMID: 18665583]
    HeLa IC50
    1.2 nM
    Compound: efavirenz, EFV
    Antiviral activity against NNRTI-resistant HIV1 with reverse transcriptase E138K mutant in HeLa cells by MAGI assay
    Antiviral activity against NNRTI-resistant HIV1 with reverse transcriptase E138K mutant in HeLa cells by MAGI assay
    		[PMID: 18665583]
    HeLa IC50
    1.2 nM
    Compound: efavirenz, EFV
    Antiviral activity against NNRTI-resistant HIV1 with reverse transcriptase Y188C mutant in HeLa cells by MAGI assay
    Antiviral activity against NNRTI-resistant HIV1 with reverse transcriptase Y188C mutant in HeLa cells by MAGI assay
    		[PMID: 18665583]
    HeLa IC50
    1.3 nM
    Compound: efavirenz, EFV
    Antiviral activity against NNRTI-resistant HIV1 with reverse transcriptase P225H mutant in HeLa cells by MAGI assay
    Antiviral activity against NNRTI-resistant HIV1 with reverse transcriptase P225H mutant in HeLa cells by MAGI assay
    		[PMID: 18665583]
    HeLa IC50
    1.8 nM
    Compound: efavirenz, EFV
    Antiviral activity against NNRTI-resistant HIV1 with reverse transcriptase V108I mutant in HeLa cells by MAGI assay
    Antiviral activity against NNRTI-resistant HIV1 with reverse transcriptase V108I mutant in HeLa cells by MAGI assay
    		[PMID: 18665583]
    HeLa IC50
    1198 nM
    Compound: efavirenz, EFV
    Antiviral activity against NNRTI-resistant HIV1 with reverse transcriptase K103N/L100I mutant in HeLa cells by MAGI assay
    Antiviral activity against NNRTI-resistant HIV1 with reverse transcriptase K103N/L100I mutant in HeLa cells by MAGI assay
    		[PMID: 18665583]
    HeLa IC50
    140 nM
    Compound: efavirenz, EFV
    Antiviral activity against NNRTI-resistant HIV1 with reverse transcriptase K103N/P225H mutant in HeLa cells by MAGI assay
    Antiviral activity against NNRTI-resistant HIV1 with reverse transcriptase K103N/P225H mutant in HeLa cells by MAGI assay
    		[PMID: 18665583]
    HeLa IC50
    154 nM
    Compound: efavirenz, EFV
    Antiviral activity against NNRTI-resistant HIV1 with reverse transcriptase Y188L mutant in HeLa cells by MAGI assay
    Antiviral activity against NNRTI-resistant HIV1 with reverse transcriptase Y188L mutant in HeLa cells by MAGI assay
    		[PMID: 18665583]
    HeLa IC50
    17 nM
    Compound: efavirenz, EFV
    Antiviral activity against NNRTI-resistant HIV1 with reverse transcriptase K103N mutant in HeLa cells by MAGI assay
    Antiviral activity against NNRTI-resistant HIV1 with reverse transcriptase K103N mutant in HeLa cells by MAGI assay
    		[PMID: 18665583]
    HeLa IC50
    2 nM
    Compound: efavirenz, EFV
    Antiviral activity against NNRTI-resistant HIV1 with reverse transcriptase V106A/Y181C mutant in HeLa cells by MAGI assay
    Antiviral activity against NNRTI-resistant HIV1 with reverse transcriptase V106A/Y181C mutant in HeLa cells by MAGI assay
    		[PMID: 18665583]
    HeLa IC50
    2.3 nM
    Compound: efavirenz, EFV
    Antiviral activity against NNRTI-resistant HIV1 with reverse transcriptase K101E mutant in HeLa cells by MAGI assay
    Antiviral activity against NNRTI-resistant HIV1 with reverse transcriptase K101E mutant in HeLa cells by MAGI assay
    		[PMID: 18665583]
    HeLa IC50
    2.7 nM
    Compound: efavirenz, EFV
    Antiviral activity against NNRTI-resistant HIV1 with reverse transcriptase V108I/Y181C mutant in HeLa cells by MAGI assay
    Antiviral activity against NNRTI-resistant HIV1 with reverse transcriptase V108I/Y181C mutant in HeLa cells by MAGI assay
    		[PMID: 18665583]
    HeLa IC50
    21 nM
    Compound: efavirenz, EFV
    Antiviral activity against NNRTI-resistant HIV1 with reverse transcriptase L100I mutant in HeLa cells by MAGI assay
    Antiviral activity against NNRTI-resistant HIV1 with reverse transcriptase L100I mutant in HeLa cells by MAGI assay
    		[PMID: 18665583]
    HeLa IC50
    3 nM
    Compound: efavirenz, EFV
    Antiviral activity against NNRTI-resistant HIV1 with reverse transcriptase V106I/Y181C mutant in HeLa cells by MAGI assay
    Antiviral activity against NNRTI-resistant HIV1 with reverse transcriptase V106I/Y181C mutant in HeLa cells by MAGI assay
    		[PMID: 18665583]
    HeLa IC50
    44 nM
    Compound: efavirenz, EFV
    Antiviral activity against NNRTI-resistant HIV1 with reverse transcriptase K103N/Y181C mutant in HeLa cells by MAGI assay
    Antiviral activity against NNRTI-resistant HIV1 with reverse transcriptase K103N/Y181C mutant in HeLa cells by MAGI assay
    		[PMID: 18665583]
    HeLa IC50
    485 nM
    Compound: efavirenz, EFV
    Antiviral activity against NNRTI-resistant HIV1 with reverse transcriptase K103N/G190A mutant in HeLa cells by MAGI assay
    Antiviral activity against NNRTI-resistant HIV1 with reverse transcriptase K103N/G190A mutant in HeLa cells by MAGI assay
    		[PMID: 18665583]
    HeLa IC50
    5.9 nM
    Compound: efavirenz, EFV
    Antiviral activity against NNRTI-resistant HIV1 with reverse transcriptase G190A mutant in HeLa cells by MAGI assay
    Antiviral activity against NNRTI-resistant HIV1 with reverse transcriptase G190A mutant in HeLa cells by MAGI assay
    		[PMID: 18665583]
    HeLa IC50
    7.2 nM
    Compound: efavirenz, EFV
    Antiviral activity against NNRTI-resistant HIV1 with reverse transcriptase V106M mutant in HeLa cells by MAGI assay
    Antiviral activity against NNRTI-resistant HIV1 with reverse transcriptase V106M mutant in HeLa cells by MAGI assay
    		[PMID: 18665583]
    HeLa IC50
    89 nM
    Compound: efavirenz, EFV
    Antiviral activity against NNRTI-resistant HIV1 with reverse transcriptase G190S mutant in HeLa cells by MAGI assay
    Antiviral activity against NNRTI-resistant HIV1 with reverse transcriptase G190S mutant in HeLa cells by MAGI assay
    		[PMID: 18665583]
    HeLa IC50
    94 nM
    Compound: efavirenz, EFV
    Antiviral activity against NNRTI-resistant HIV1 with reverse transcriptase K103N/V108I mutant in HeLa cells by MAGI assay
    Antiviral activity against NNRTI-resistant HIV1 with reverse transcriptase K103N/V108I mutant in HeLa cells by MAGI assay
    		[PMID: 18665583]
    MRC5 IC50
    25.84 μM
    Compound: Efavirenz
    Cytotoxicity against human MRC5 SV2 cells assessed as reduction in cell growth after 72 hrs
    Cytotoxicity against human MRC5 SV2 cells assessed as reduction in cell growth after 72 hrs
    		[PMID: 25199582]
    MRC5 IC50
    8.56 μM
    Compound: Efavirenz
    Trypanocidal activity against nifurtimox-sensitive Trypanosoma cruzi Tulahuen CL2 infected in human MRC5 SV2 cells assessed as parasite growth inhibition after 168 hrs by beta-galactosidase assay
    Trypanocidal activity against nifurtimox-sensitive Trypanosoma cruzi Tulahuen CL2 infected in human MRC5 SV2 cells assessed as parasite growth inhibition after 168 hrs by beta-galactosidase assay
    		[PMID: 25199582]
    MT2 CC50
    > 0.1 μM
    Compound: Evafirenz
    Cytotoxicity against human MT2 cells by MTT assay
    Cytotoxicity against human MT2 cells by MTT assay
    		[PMID: 20304641]
    MT2 CC50
    > 0.1 μM
    Compound: Evafirenz
    Cytotoxicity against human MT2 cells infected with HIV1 harboring reverse transcriptase Y181C mutation by MTT assay
    Cytotoxicity against human MT2 cells infected with HIV1 harboring reverse transcriptase Y181C mutation by MTT assay
    		[PMID: 20304641]
    MT2 CC50
    > 0.1 μM
    Compound: Evafirenz
    Cytotoxicity against human MT2 cells infected with HIV1 harboring reverse transcriptase K103N/Y181C mutation by MTT assay
    Cytotoxicity against human MT2 cells infected with HIV1 harboring reverse transcriptase K103N/Y181C mutation by MTT assay
    		[PMID: 20304641]
    MT2 EC50
    0.0001 μM
    Compound: EFV
    Antiviral activity against HIV1 subtype B-3B infected in 1 hr-pretreated human MT2 cells assessed as inhibition of multicycle replication measured on day 5 postinfection by RT SPA
    Antiviral activity against HIV1 subtype B-3B infected in 1 hr-pretreated human MT2 cells assessed as inhibition of multicycle replication measured on day 5 postinfection by RT SPA
    		[PMID: 18316521]
    MT2 EC50
    0.0002 μM
    Compound: EFV
    Antiviral activity against 0.005 MOI wild type HIV1 NL4-3 infected in human MT2 cells measured after 5 days by RT SPA
    Antiviral activity against 0.005 MOI wild type HIV1 NL4-3 infected in human MT2 cells measured after 5 days by RT SPA
    		[PMID: 18316521]
    MT2 EC50
    0.0002 μM
    Compound: EFV
    Antiviral activity against HIV1 subtype B-LAI infected in 1 hr-pretreated human MT2 cells assessed as inhibition of multicycle replication measured on day 5 postinfection by RT SPA
    Antiviral activity against HIV1 subtype B-LAI infected in 1 hr-pretreated human MT2 cells assessed as inhibition of multicycle replication measured on day 5 postinfection by RT SPA
    		[PMID: 18316521]
    MT2 EC50
    0.0003 μM
    Compound: EFV
    Antiviral activity against 0.01 MOI wild type HIV1 NL4-3 infected in human MT2 cells measured after 5 days by RT SPA
    Antiviral activity against 0.01 MOI wild type HIV1 NL4-3 infected in human MT2 cells measured after 5 days by RT SPA
    		[PMID: 18316521]
    MT2 EC50
    0.0003 μM
    Compound: EFV
    Antiviral activity against HIV1 subtype B-HXB2 infected in 1 hr-pretreated human MT2 cells assessed as inhibition of multicycle replication measured on day 5 postinfection by RT SPA
    Antiviral activity against HIV1 subtype B-HXB2 infected in 1 hr-pretreated human MT2 cells assessed as inhibition of multicycle replication measured on day 5 postinfection by RT SPA
    		[PMID: 18316521]
    MT2 EC50
    0.0003 μM
    Compound: EFV
    Antiviral activity against HIV1 subtype B-RF infected in 1 hr-pretreated human MT2 cells assessed as inhibition of multicycle replication measured on day 5 postinfection by RT SPA
    Antiviral activity against HIV1 subtype B-RF infected in 1 hr-pretreated human MT2 cells assessed as inhibition of multicycle replication measured on day 5 postinfection by RT SPA
    		[PMID: 18316521]
    MT2 EC50
    0.0003 μM
    Compound: EFV
    Antiviral activity against HIV1 subtype B-NL4-3 infected in 1 hr-pretreated human MT2 cells assessed as inhibition of multicycle replication measured on day 5 postinfection by RT SPA
    Antiviral activity against HIV1 subtype B-NL4-3 infected in 1 hr-pretreated human MT2 cells assessed as inhibition of multicycle replication measured on day 5 postinfection by RT SPA
    		[PMID: 18316521]
    MT2 EC50
    0.00034 μM
    Compound: EFV
    Antiviral activity against pseudotype HIV1 NL-RLuc infected in human MT2 cells measured on day 5 postinfection by luciferase reporter gene assay
    Antiviral activity against pseudotype HIV1 NL-RLuc infected in human MT2 cells measured on day 5 postinfection by luciferase reporter gene assay
    		[PMID: 18316521]
    MT2 EC50
    0.0004 μM
    Compound: EFV
    Antiviral activity against 0.005 MOI wild type HIV1 NL4-3 infected in human MT2 cells measured after 5 days by MTS assay
    Antiviral activity against 0.005 MOI wild type HIV1 NL4-3 infected in human MT2 cells measured after 5 days by MTS assay
    		[PMID: 18316521]
    MT2 EC50
    0.0004 μM
    Compound: EFV
    Antiviral activity against 0.02 MOI wild type HIV1 NL4-3 infected in human MT2 cells measured after 5 days by RT SPA
    Antiviral activity against 0.02 MOI wild type HIV1 NL4-3 infected in human MT2 cells measured after 5 days by RT SPA
    		[PMID: 18316521]
    MT2 EC50
    0.0004 μM
    Compound: EFV
    Antiviral activity against HIV1 subtype B-SF-2 infected in 1 hr-pretreated human MT2 cells assessed as inhibition of multicycle replication measured on day 5 postinfection by RT SPA
    Antiviral activity against HIV1 subtype B-SF-2 infected in 1 hr-pretreated human MT2 cells assessed as inhibition of multicycle replication measured on day 5 postinfection by RT SPA
    		[PMID: 18316521]
    MT2 EC50
    0.0007 μM
    Compound: EFV
    Antiviral activity against 0.01 MOI wild type HIV1 NL4-3 infected in human MT2 cells measured after 5 days by MTS assay
    Antiviral activity against 0.01 MOI wild type HIV1 NL4-3 infected in human MT2 cells measured after 5 days by MTS assay
    		[PMID: 18316521]
    MT2 EC50
    0.0007 μM
    Compound: EFV
    Antiviral activity against 0.05 MOI wild type HIV1 NL4-3 infected in human MT2 cells measured after 5 days by RT SPA
    Antiviral activity against 0.05 MOI wild type HIV1 NL4-3 infected in human MT2 cells measured after 5 days by RT SPA
    		[PMID: 18316521]
    MT2 EC50
    0.0008 μM
    Compound: EFV
    Antiviral activity against 0.02 MOI wild type HIV1 NL4-3 infected in human MT2 cells measured after 5 days by MTS assay
    Antiviral activity against 0.02 MOI wild type HIV1 NL4-3 infected in human MT2 cells measured after 5 days by MTS assay
    		[PMID: 18316521]
    MT2 EC50
    0.0009 μM
    Compound: EFV
    Antiviral activity against 0.005 MOI wild type HIV1 NL4-3 infected in 2 hr-pretreated human MT2 cells measured after 5 days by RT SPA
    Antiviral activity against 0.005 MOI wild type HIV1 NL4-3 infected in 2 hr-pretreated human MT2 cells measured after 5 days by RT SPA
    		[PMID: 18316521]
    MT2 EC50
    0.0009 μM
    Compound: EFV
    Antiviral activity against 0.01 MOI wild type HIV1 NL4-3 infected in 2 hr-pretreated human MT2 cells measured after 5 days by RT SPA
    Antiviral activity against 0.01 MOI wild type HIV1 NL4-3 infected in 2 hr-pretreated human MT2 cells measured after 5 days by RT SPA
    		[PMID: 18316521]
    MT2 EC50
    0.001 μM
    Compound: EFV
    Antiviral activity against 0.05 MOI wild type HIV1 NL4-3 infected in human MT2 cells measured after 5 days by MTS assay
    Antiviral activity against 0.05 MOI wild type HIV1 NL4-3 infected in human MT2 cells measured after 5 days by MTS assay
    		[PMID: 18316521]
    MT2 EC50
    0.0011 μM
    Compound: EFV
    Antiviral activity against 0.005 MOI wild type HIV1 NL4-3 infected in 2 hr-pretreated human MT2 cells measured after 5 days by MTS assay
    Antiviral activity against 0.005 MOI wild type HIV1 NL4-3 infected in 2 hr-pretreated human MT2 cells measured after 5 days by MTS assay
    		[PMID: 18316521]
    MT2 EC50
    0.0012 μM
    Compound: EFV
    Antiviral activity against 0.01 MOI wild type HIV1 NL4-3 infected in 2 hr-pretreated human MT2 cells measured after 5 days by MTS assay
    Antiviral activity against 0.01 MOI wild type HIV1 NL4-3 infected in 2 hr-pretreated human MT2 cells measured after 5 days by MTS assay
    		[PMID: 18316521]
    MT2 EC50
    0.0012 μM
    Compound: EFV
    Antiviral activity against 0.02 MOI wild type HIV1 NL4-3 infected in 2 hr-pretreated human MT2 cells measured after 5 days by RT SPA
    Antiviral activity against 0.02 MOI wild type HIV1 NL4-3 infected in 2 hr-pretreated human MT2 cells measured after 5 days by RT SPA
    		[PMID: 18316521]
    MT2 EC50
    0.0013 μM
    Compound: EFV
    Antiviral activity against 0.02 MOI wild type HIV1 NL4-3 infected in 2 hr-pretreated human MT2 cells measured after 5 days by MTS assay
    Antiviral activity against 0.02 MOI wild type HIV1 NL4-3 infected in 2 hr-pretreated human MT2 cells measured after 5 days by MTS assay
    		[PMID: 18316521]
    MT2 EC50
    0.0017 μM
    Compound: EFV
    Antiviral activity against 0.05 MOI wild type HIV1 NL4-3 infected in 2 hr-pretreated human MT2 cells measured after 5 days by MTS assay
    Antiviral activity against 0.05 MOI wild type HIV1 NL4-3 infected in 2 hr-pretreated human MT2 cells measured after 5 days by MTS assay
    		[PMID: 18316521]
    MT2 EC50
    0.002 μM
    Compound: efv
    Antiviral activity against wild type HIV1 3B infected in human MT2 cells assessed as protection from virus-induced cytopathicity by MTT assay
    Antiviral activity against wild type HIV1 3B infected in human MT2 cells assessed as protection from virus-induced cytopathicity by MTT assay
    		[PMID: 25408842]
    MT2 EC50
    0.002 μM
    Compound: Efavirenz
    Antiviral activity against wild type HIV1 3B infected in human MT2 cells assessed as protection against virus-induced effect by MTT assay
    Antiviral activity against wild type HIV1 3B infected in human MT2 cells assessed as protection against virus-induced effect by MTT assay
    		[PMID: 23937980]
    MT2 EC50
    0.002 μM
    Compound: Efavirenz
    Antiviral activity against HIV1 3B infected in human MT2 cells assessed as protection against virus-induced cytopathogenicity by MTT assay
    Antiviral activity against HIV1 3B infected in human MT2 cells assessed as protection against virus-induced cytopathogenicity by MTT assay
    		[PMID: 23899617]
    MT2 EC50
    0.002 μM
    Compound: Evafirenz
    Antiviral activity against HIV1 3B infected in human MT2 cells assessed as inhibition of virus replication by MTT assay
    Antiviral activity against HIV1 3B infected in human MT2 cells assessed as inhibition of virus replication by MTT assay
    		[PMID: 20304641]
    MT2 EC50
    0.002 μM
    Compound: Efavirenz
    Antiviral activity against multidrug resistant HIV1 IIIB containing reverse transcriptase infected in human MT2 cells assessed as cytoprotection from infection by MTT colorimetric method
    Antiviral activity against multidrug resistant HIV1 IIIB containing reverse transcriptase infected in human MT2 cells assessed as cytoprotection from infection by MTT colorimetric method
    		[PMID: 23298809]
    MT2 EC50
    0.003 μM
    Compound: EFV
    Antiviral activity against 0.05 MOI wild type HIV1 NL4-3 infected in 2 hr-pretreated human MT2 cells measured after 5 days by RT SPA
    Antiviral activity against 0.05 MOI wild type HIV1 NL4-3 infected in 2 hr-pretreated human MT2 cells measured after 5 days by RT SPA
    		[PMID: 18316521]
    MT2 EC50
    0.005 nM
    Compound: EFV, DMP-266, L-743, L-726
    Antiviral activity against HIV1 NL4-3 infected in human MT2 cells assessed as inhibition of virus-induced cell death at 0.005 multiplicities of infection after 6 days
    Antiviral activity against HIV1 NL4-3 infected in human MT2 cells assessed as inhibition of virus-induced cell death at 0.005 multiplicities of infection after 6 days
    		[PMID: 20660667]
    MT2 EC50
    0.01 μM
    Compound: efv
    Antiviral activity against wild type HIV1 harboring reverse transcriptase Y181C mutant infected in human MT2 cells assessed as protection from virus-induced cytopathicity by MTT assay
    Antiviral activity against wild type HIV1 harboring reverse transcriptase Y181C mutant infected in human MT2 cells assessed as protection from virus-induced cytopathicity by MTT assay
    		[PMID: 25408842]
    MT2 EC50
    0.01 μM
    Compound: Efavirenz
    Antiviral activity against HIV1 3B harboring reverse transcriptase Y181C mutant infected in human MT2 cells assessed as protection against virus-induced effect by MTT assay
    Antiviral activity against HIV1 3B harboring reverse transcriptase Y181C mutant infected in human MT2 cells assessed as protection against virus-induced effect by MTT assay
    		[PMID: 23937980]
    MT2 EC50
    0.01 μM
    Compound: Evafirenz
    Antiviral activity against HIV1 reverse transcriptase Y181C mutant infected in human MT2 cells assessed as inhibition of viral replication by MTT assay
    Antiviral activity against HIV1 reverse transcriptase Y181C mutant infected in human MT2 cells assessed as inhibition of viral replication by MTT assay
    		[PMID: 20304641]
    MT2 EC50
    0.01 μM
    Compound: Efavirenz
    Antiviral activity against multidrug resistant HIV1 IIIB containing reverse transcriptase Y181C mutation infected in human MT2 cells assessed as cytoprotection from infection by MTT colorimetric method
    Antiviral activity against multidrug resistant HIV1 IIIB containing reverse transcriptase Y181C mutation infected in human MT2 cells assessed as cytoprotection from infection by MTT colorimetric method
    		[PMID: 23298809]
    MT2 EC50
    0.03 μM
    Compound: efv
    Antiviral activity against wild type HIV1 harboring reverse transcriptase K103N/Y181C mutant infected in human MT2 cells assessed as protection from virus-induced cytopathicity by MTT assay
    Antiviral activity against wild type HIV1 harboring reverse transcriptase K103N/Y181C mutant infected in human MT2 cells assessed as protection from virus-induced cytopathicity by MTT assay
    		[PMID: 25408842]
    MT2 EC50
    0.03 μM
    Compound: Efavirenz
    Antiviral activity against HIV1 3B harboring reverse transcriptase K103N/Y181C double mutant infected in human MT2 cells assessed as protection against virus-induced effect by MTT assay
    Antiviral activity against HIV1 3B harboring reverse transcriptase K103N/Y181C double mutant infected in human MT2 cells assessed as protection against virus-induced effect by MTT assay
    		[PMID: 23937980]
    MT2 EC50
    0.03 μM
    Compound: Evafirenz
    Antiviral activity against HIV1 reverse transcriptase K103N/Y181C double mutant infected in human MT2 cells assessed as inhibition of viral replication by MTT assay
    Antiviral activity against HIV1 reverse transcriptase K103N/Y181C double mutant infected in human MT2 cells assessed as inhibition of viral replication by MTT assay
    		[PMID: 20304641]
    MT2 EC50
    0.03 μM
    Compound: Efavirenz
    Antiviral activity against multidrug resistant HIV1 IIIB containing reverse transcriptase K103N and Y181C mutation infected in human MT2 cells assessed as cytoprotection from infection by MTT colorimetric method
    Antiviral activity against multidrug resistant HIV1 IIIB containing reverse transcriptase K103N and Y181C mutation infected in human MT2 cells assessed as cytoprotection from infection by MTT colorimetric method
    		[PMID: 23298809]
    MT2 EC50
    0.05 nM
    Compound: EFV, DMP-266, L-743, L-726
    Antiviral activity against HIV1 NL4-3 infected in human MT2 cells assessed as inhibition of virus-induced cell death at 0.05 multiplicities of infection after 6 days
    Antiviral activity against HIV1 NL4-3 infected in human MT2 cells assessed as inhibition of virus-induced cell death at 0.05 multiplicities of infection after 6 days
    		[PMID: 20660667]
    MT2 EC50
    0.5 nM
    Compound: EFV, DMP-266, L-743, L-726
    Antiviral activity against HIV1 NL4-3 infected in human MT2 cells assessed as inhibition of virus-induced cell death at 0.5 multiplicities of infection after 6 days
    Antiviral activity against HIV1 NL4-3 infected in human MT2 cells assessed as inhibition of virus-induced cell death at 0.5 multiplicities of infection after 6 days
    		[PMID: 20660667]
    MT2 EC50
    1.2 nM
    Compound: EFV
    Antiviral activity against vesicular stomatitis virus G-pseudotyped Human immunodeficiency virus 1 NL4-3 infected in human MT2 cells assessed as inhibition of viral replication after 48 hrs by luciferase activity reporter gene assay
    Antiviral activity against vesicular stomatitis virus G-pseudotyped Human immunodeficiency virus 1 NL4-3 infected in human MT2 cells assessed as inhibition of viral replication after 48 hrs by luciferase activity reporter gene assay
    		[PMID: 21745701]
    MT2 EC50
    15 μM
    Compound: Efavirenz
    Cytotoxicity against human MT2 cells assessed as cell viability by MTT assay
    Cytotoxicity against human MT2 cells assessed as cell viability by MTT assay
    		[PMID: 35175760]
    MT2 CC50
    15 μM
    Compound: Efavirenz
    Cytotoxicity against human MT2 cells assessed as growth inhibition by MTT method
    Cytotoxicity against human MT2 cells assessed as growth inhibition by MTT method
    		[PMID: 27485603]
    MT2 CC50
    15 μM
    Compound: efv
    Cytotoxicity against human MT2 cells assessed as reduction in cell viability by MTT assay
    Cytotoxicity against human MT2 cells assessed as reduction in cell viability by MTT assay
    		[PMID: 25408842]
    MT2 CC50
    15 μM
    Compound: Efavirenz
    Cytotoxicity against human MT2 cells by MTT assay
    Cytotoxicity against human MT2 cells by MTT assay
    		[PMID: 23899617]
    MT2 CC50
    15 μM
    Compound: Efavirenz
    Cytotoxicity against human MT2 cells infected with HIV1 NL4.3 by MTT assay
    Cytotoxicity against human MT2 cells infected with HIV1 NL4.3 by MTT assay
    		[PMID: 22081993]
    MT2 CC50
    3 μM
    Compound: 5
    Cytotoxicity against human MT2 cells by MTT assay
    Cytotoxicity against human MT2 cells by MTT assay
    		[PMID: 17918923]
    MT2 EC50
    6.8 nM
    Compound: EFV
    Antiviral activity against HIV1 3B infected in human MT-2 cells by two fold dilution method in presence of 10% FBS
    Antiviral activity against HIV1 3B infected in human MT-2 cells by two fold dilution method in presence of 10% FBS
    		[PMID: 19104010]
    MT4 EC50
    < 1 nM
    Compound: EFV
    Antiviral activity against NNRTI-resistant HIV HXB2 with reverse transcriptase 236L mutation in human MT4 cells assessed as protection against virus-induced cell death after 5 days by MTT assay
    Antiviral activity against NNRTI-resistant HIV HXB2 with reverse transcriptase 236L mutation in human MT4 cells assessed as protection against virus-induced cell death after 5 days by MTT assay
    		[PMID: 19007201]
    MT4 EC50
    > 0.003 μM
    Compound: EFV
    Antiviral activity against Human immunodeficiency virus 1 infected human MT4 cells assessed as inhibition of virus-induced cytopathogenicity after 4 days by MTT assay
    Antiviral activity against Human immunodeficiency virus 1 infected human MT4 cells assessed as inhibition of virus-induced cytopathogenicity after 4 days by MTT assay
    		10.1007/s00044-008-9149-5
    MT4 CC50
    > 0.00633 μM
    Compound: EFV
    Cytotoxicity against human MT4 cells assessed as cell viability after 5 days by MTT assay
    Cytotoxicity against human MT4 cells assessed as cell viability after 5 days by MTT assay
    		[PMID: 28481112]
    MT4 CC50
    > 0.3 μM
    Compound: EFV, efavirenz
    Cytotoxicity against MT4 cells after 4 days by MTT method
    Cytotoxicity against MT4 cells after 4 days by MTT method
    		[PMID: 17910429]
    MT4 CC50
    > 0.32 μM
    Compound: Efavirenz
    Cytotoxicity against human MT4 cells by MTT assay
    Cytotoxicity against human MT4 cells by MTT assay
    		[PMID: 19140683]
    MT4 CC50
    > 0.32 μM
    Compound: Efavirenz
    Cytotoxicity against MT4 cells by MTT assay
    Cytotoxicity against MT4 cells by MTT assay
    		[PMID: 16621553]
    MT4 CC50
    > 0.32 μM
    Compound: EVZ
    Cytotoxicity against MT4 cells by MTT method
    Cytotoxicity against MT4 cells by MTT method
    		[PMID: 16335924]
    MT4 CC50
    > 1 μg/mL
    Compound: EFV
    Cytotoxicity against human MT4 cells after 5 days by MTT assay
    Cytotoxicity against human MT4 cells after 5 days by MTT assay
    		[PMID: 22652226]
    MT4 IC50
    > 10 μM
    Compound: Efavirenz
    Anti-HIV-1 activity against K103N+K1001 strain was determined in MT-4 cells by the MTT method
    Anti-HIV-1 activity against K103N+K1001 strain was determined in MT-4 cells by the MTT method
    		[PMID: 14643315]
    MT4 EC50
    > 10 μM
    Compound: EFV, efavirenz
    Antiviral activity against HIV1 with reverse transcriptase Y188L mutation in MT4 cells assessed as inhibition of viral induced cytopathic effect by MTT method
    Antiviral activity against HIV1 with reverse transcriptase Y188L mutation in MT4 cells assessed as inhibition of viral induced cytopathic effect by MTT method
    		[PMID: 17910429]
    MT4 EC50
    > 10 μM
    Compound: efavirenz
    Antiviral activity against HIV1 NL4-3 with double K103N/L100I mutant in human MT4 cells assessed as inhibition of virus-induced cytopathicity after 5 days by multiple round replication assay
    Antiviral activity against HIV1 NL4-3 with double K103N/L100I mutant in human MT4 cells assessed as inhibition of virus-induced cytopathicity after 5 days by multiple round replication assay
    		[PMID: 19469474]
    MT4 EC50
    > 100 nM
    Compound: EFV
    Antiviral activity against NNRTI-resistant HIV HXB2 with reverse transcriptase 190S mutation in human MT4 cells assessed as protection against virus-induced cell death after 5 days by MTT assay
    Antiviral activity against NNRTI-resistant HIV HXB2 with reverse transcriptase 190S mutation in human MT4 cells assessed as protection against virus-induced cell death after 5 days by MTT assay
    		[PMID: 19007201]
    MT4 IC50
    > 100 nM
    Compound: Efavirenz
    Antiviral activity against HIV1 harboring reverse transcriptase Y188L mutant infected in human MT4 cells assessed as reduction of virus-induced cytopathic effect by replication assay in presence of 10% FBS
    Antiviral activity against HIV1 harboring reverse transcriptase Y188L mutant infected in human MT4 cells assessed as reduction of virus-induced cytopathic effect by replication assay in presence of 10% FBS
    		[PMID: 20829038]
    MT4 IC50
    > 100 nM
    Compound: Efavirenz
    Antiviral activity against HIV1 harboring reverse transcriptase K103N/L100I double mutant infected in human MT4 cells assessed as reduction of virus-induced cytopathic effect by replication assay in presence of 10% FBS
    Antiviral activity against HIV1 harboring reverse transcriptase K103N/L100I double mutant infected in human MT4 cells assessed as reduction of virus-induced cytopathic effect by replication assay in presence of 10% FBS
    		[PMID: 20829038]
    MT4 CC50
    > 15839 nM
    Compound: EFV
    Cytotoxicity against mock-infected human MT4 cells measured after 5 days by MTT assay
    Cytotoxicity against mock-infected human MT4 cells measured after 5 days by MTT assay
    		[PMID: 22712652]
    MT4 CC50
    > 15839 nM
    Compound: EFV
    Cytotoxicity against human MT-4 cells assessed as reduction in cell viability by MTT assay
    Cytotoxicity against human MT-4 cells assessed as reduction in cell viability by MTT assay
    		[PMID: 32883642]
    MT4 CC50
    > 15839 nM
    Compound: EFV
    Cytotoxicity against human MT4 cells assessed as cell viability by MTT assay
    Cytotoxicity against human MT4 cells assessed as cell viability by MTT assay
    		[PMID: 28628334]
    MT4 CC50
    > 15839 nM
    Compound: EFV, DMP-266
    Cytotoxic activity against human MT4 cells by MTT assay
    Cytotoxic activity against human MT4 cells by MTT assay
    		[PMID: 25418038]
    MT4 CC50
    > 15839 nM
    Compound: EFV, DMP-266
    Cytotoxicity against human MT4 cells assessed as cell viability by MTT assay
    Cytotoxicity against human MT4 cells assessed as cell viability by MTT assay
    		[PMID: 24769348]
    MT4 CC50
    > 2 μM
    Compound: 1; EFV
    Cytotoxicity against human MT4 cells measured after 5 days by MTT assay
    Cytotoxicity against human MT4 cells measured after 5 days by MTT assay
    		[PMID: 31091477]
    MT4 CC50
    > 2 μM
    Compound: EFV
    Cytotoxicity against mock-infected human MT4 cells assessed as cell viability after 5 days by MTT assay
    Cytotoxicity against mock-infected human MT4 cells assessed as cell viability after 5 days by MTT assay
    		[PMID: 23415090]
    MT4 CC50
    > 2000 nM
    Compound: EFV
    Cytotoxicity against human MT4 cells assessed as reduction in cell viability after 4 days by MTT assay
    Cytotoxicity against human MT4 cells assessed as reduction in cell viability after 4 days by MTT assay
    		[PMID: 29353724]
    MT4 CC50
    > 3 μM
    Compound: EFV
    Cytotoxicity against human MT4 cells assessed as induction of cell death by MTT method
    Cytotoxicity against human MT4 cells assessed as induction of cell death by MTT method
    		[PMID: 24933420]
    MT4 CC50
    > 3 μM
    Compound: EFZ
    Cytotoxicity against human MT4 cells by MTT assay
    Cytotoxicity against human MT4 cells by MTT assay
    		[PMID: 18630898]
    MT4 CC50
    > 3.16 μM
    Compound: 3; EFV
    Cytotoxicity against mock-infected human MT4 cells assessed as reduction in cell viability after 5 days by MTT assay
    Cytotoxicity against mock-infected human MT4 cells assessed as reduction in cell viability after 5 days by MTT assay
    		[PMID: 30606670]
    MT4 CC50
    > 3000 nM
    Compound: EFV
    Cytotoxicity against human MT4 cells assessed as reduction in cell viability after 5 days by MTT assay
    Cytotoxicity against human MT4 cells assessed as reduction in cell viability after 5 days by MTT assay
    		[PMID: 30525601]
    MT4 EC50
    > 31.68 μM
    Compound: Efavirenz
    Antiretroviral activity against Human immunodeficiency virus 2 ROD infected in human MT4 cells assessed as inhibition of virus-induced cytopathic effect by MTT assay
    Antiretroviral activity against Human immunodeficiency virus 2 ROD infected in human MT4 cells assessed as inhibition of virus-induced cytopathic effect by MTT assay
    		[PMID: 18541726]
    MT4 EC50
    > 31.68 μM
    Compound: Efavirenz
    Antiretroviral activity against Human immunodeficiency virus 2 EHO infected in human MT4 cells assessed as inhibition of virus-induced cytopathic effect by MTT assay
    Antiretroviral activity against Human immunodeficiency virus 2 EHO infected in human MT4 cells assessed as inhibition of virus-induced cytopathic effect by MTT assay
    		[PMID: 18541726]
    MT4 EC50
    > 31.68 μM
    Compound: Efavirenz
    Antiretroviral activity against Simian immunodeficiency virus MAC 251 infected in human MT4 cells assessed as inhibition of virus-induced cytopathic effect by MTT assay
    Antiretroviral activity against Simian immunodeficiency virus MAC 251 infected in human MT4 cells assessed as inhibition of virus-induced cytopathic effect by MTT assay
    		[PMID: 18541726]
    MT4 EC50
    > 317 nM
    Compound: EFV, DMP-266
    Antiviral activity against HIV1 NL4-3 expressing reverse transcriptase K103N-Y181C mutant infected in human MT4 cells assessed as reduction in virus-induced cell death by MTT assay
    Antiviral activity against HIV1 NL4-3 expressing reverse transcriptase K103N-Y181C mutant infected in human MT4 cells assessed as reduction in virus-induced cell death by MTT assay
    		[PMID: 25418038]
    MT4 EC50
    > 317 nM
    Compound: EFV, DMP-266
    Antiviral activity against HIV1 harboring reverse transcriptase K103N/Y181C double mutant infected in human MT4 cells assessed as inhibition of virus-induced cell death measured after 5 days of infection by MTT method
    Antiviral activity against HIV1 harboring reverse transcriptase K103N/Y181C double mutant infected in human MT4 cells assessed as inhibition of virus-induced cell death measured after 5 days of infection by MTT method
    		[PMID: 24769348]
    MT4 CC50
    > 40196 nM
    Compound: Efavirenz
    Cytotoxicity against human MT4 cells assessed as cell viability by MTT assay
    Cytotoxicity against human MT4 cells assessed as cell viability by MTT assay
    		[PMID: 35175760]
    MT4 CC50
    > 6 μM
    Compound: Efavirenz
    Cytotoxicity against human MT4 cells after 5 days
    Cytotoxicity against human MT4 cells after 5 days
    		[PMID: 19616956]
    MT4 CC50
    > 6.3 μM
    Compound: EFV
    Cytotoxicity against mock-infected human MT4 cells assessed as reduction in cell viability after 4 days by MTT assay
    Cytotoxicity against mock-infected human MT4 cells assessed as reduction in cell viability after 4 days by MTT assay
    		[PMID: 25707013]
    MT4 CC50
    > 6.3 μM
    Compound: EFV
    Cytotoxicity against mock-infected human MT4 cells assessed as reduction in cell viability after 4 days by MTT assay
    Cytotoxicity against mock-infected human MT4 cells assessed as reduction in cell viability after 4 days by MTT assay
    		[PMID: 25626145]
    MT4 CC50
    > 6.3 μM
    Compound: EFV
    Cytotoxicity against mock-infected human MT4 cells assessed as reduction in cell viability measured after 5 days by MTT assay
    Cytotoxicity against mock-infected human MT4 cells assessed as reduction in cell viability measured after 5 days by MTT assay
    		[PMID: 34496571]
    MT4 CC50
    > 6.3 μM
    Compound: EFV
    Cytotoxicity against human MT4 cells assessed as reduction in cell viability incubated for 5 days by MTT assay
    Cytotoxicity against human MT4 cells assessed as reduction in cell viability incubated for 5 days by MTT assay
    		[PMID: 33352387]
    MT4 CC50
    > 6.3 μM
    Compound: 3; EFV
    Cytotoxicity against human MT4 cells assessed as reduction in cell viability measured after 5 days by MTT assay
    Cytotoxicity against human MT4 cells assessed as reduction in cell viability measured after 5 days by MTT assay
    		[PMID: 33340914]
    MT4 CC50
    > 6.3 μM
    Compound: EFV
    Cytotoxicity against human MT4 cells assessed as decrease in cell viability after 5 days by MTT assay
    Cytotoxicity against human MT4 cells assessed as decrease in cell viability after 5 days by MTT assay
    		[PMID: 27750153]
    MT4 CC50
    > 6.3 μM
    Compound: EFV
    Cytotoxicity against mock-infected human MT4 cells assessed as reduction in cell viability after 5 days by MTT assay
    Cytotoxicity against mock-infected human MT4 cells assessed as reduction in cell viability after 5 days by MTT assay
    		[PMID: 27267005]
    MT4 CC50
    > 6.3 μM
    Compound: EFV
    Cytotoxicity against mock-infected human MT4 cells after 5 days by MTT assay
    Cytotoxicity against mock-infected human MT4 cells after 5 days by MTT assay
    		[PMID: 24680058]
    MT4 CC50
    > 6.3 μM
    Compound: EFV, DMP266
    Cytotoxicity against human MT4 cells assessed as cell viability after 5 days by MTT assay
    Cytotoxicity against human MT4 cells assessed as cell viability after 5 days by MTT assay
    		[PMID: 24275349]
    MT4 CC50
    > 6.3 μM
    Compound: EFV
    Cytotoxicity against human MT4 cells after 5 days by MTT assay
    Cytotoxicity against human MT4 cells after 5 days by MTT assay
    		[PMID: 24239481]
    MT4 CC50
    > 6.3 μM
    Compound: EFV
    Cytotoxicity against human MT4 cells after 5 days by MTT assay
    Cytotoxicity against human MT4 cells after 5 days by MTT assay
    		[PMID: 22575532]
    MT4 CC50
    > 6.3 μM
    Compound: EFV
    Cytotoxicity against human MT4 cells after 5 days by MTT assay
    Cytotoxicity against human MT4 cells after 5 days by MTT assay
    		[PMID: 22405288]
    MT4 CC50
    > 6.3 μM
    Compound: Efavirenz
    Cytotoxicity against human MT4 cells assessed as inhibition of cell viability by measuring reduction in absorbance at OD540 by MTT assay
    Cytotoxicity against human MT4 cells assessed as inhibition of cell viability by measuring reduction in absorbance at OD540 by MTT assay
    		[PMID: 31767136]
    MT4 CC50
    > 6.3 μM
    Compound: EFV
    Cytotoxicity against human MT4 cells by MTT assay
    Cytotoxicity against human MT4 cells by MTT assay
    		[PMID: 25150090]
    MT4 CC50
    > 6.3 μM
    Compound: 3, EFV
    Cytotoxicity against human MT4 cells by MTT assay
    Cytotoxicity against human MT4 cells by MTT assay
    		[PMID: 24794751]
    MT4 CC50
    > 6.3 μM
    Compound: EFV
    Cytotoxicity against HIV2 ROD infected in human MT4 cells by MTT assay
    Cytotoxicity against HIV2 ROD infected in human MT4 cells by MTT assay
    		[PMID: 23098609]
    MT4 CC50
    > 6.3 μM
    Compound: EFV
    Cytotoxicity against HIV1 3B infected in human MT4 cells by MTT assay
    Cytotoxicity against HIV1 3B infected in human MT4 cells by MTT assay
    		[PMID: 23098609]
    MT4 CC50
    > 6.3 μM
    Compound: EFV
    Cytotoxicity against human MT4 cells by MTT assay
    Cytotoxicity against human MT4 cells by MTT assay
    		[PMID: 23084898]
    MT4 CC50
    > 6.3 μM
    Compound: EFV
    Cytotoxicity against mock-infected human MT4 cells by MTT assay
    Cytotoxicity against mock-infected human MT4 cells by MTT assay
    		[PMID: 22883027]
    MT4 CC50
    > 6.3 μM
    Compound: Efavirenz
    Cytotoxicity against human MT4 cells after 5 days MTT assay
    Cytotoxicity against human MT4 cells after 5 days MTT assay
    		[PMID: 27112451]
    MT4 CC50
    > 6.33 μM
    Compound: Efavirenz
    Cytotoxicity against human MT4 cells after 4 days by MTT assay
    Cytotoxicity against human MT4 cells after 4 days by MTT assay
    		[PMID: 21824782]
    MT4 CC50
    > 6.33 μM
    Compound: EFV
    Cytotoxicity against human MT4 cells assessed as reduction in cell viability measured after 5 days by MTT assay
    Cytotoxicity against human MT4 cells assessed as reduction in cell viability measured after 5 days by MTT assay
    		[PMID: 35073089]
    MT4 CC50
    > 6.33 μM
    Compound: EFV
    Cytotoxicity against in human MT-4 cells after 5 days by MTT assay
    Cytotoxicity against in human MT-4 cells after 5 days by MTT assay
    		[PMID: 33851529]
    MT4 CC50
    > 6.33 μM
    Compound: Efavirenz
    Cytotoxicity against human MT4 cells after 5 days by MTT assay
    Cytotoxicity against human MT4 cells after 5 days by MTT assay
    		[PMID: 29291935]
    MT4 CC50
    > 6.33 μM
    Compound: Efavirenz
    Cytotoxicity against human MT4 cells assessed as reduction in cell viability after 5 days by MTT assay
    Cytotoxicity against human MT4 cells assessed as reduction in cell viability after 5 days by MTT assay
    		[PMID: 28559060]
    MT4 CC50
    > 6.33 μM
    Compound: 3; EFV
    Cytotoxicity against human MT4 cells assessed as reduction in cell viability incubated for 5 to 7 days by MTT assay
    Cytotoxicity against human MT4 cells assessed as reduction in cell viability incubated for 5 to 7 days by MTT assay
    		[PMID: 35640327]
    MT4 CC50
    > 6.33 μM
    Compound: EFV
    Cytotoxicity against mock infected human MT4 cells by MTT assay
    Cytotoxicity against mock infected human MT4 cells by MTT assay
    		[PMID: 34197708]
    MT4 CC50
    > 6.335 μM
    Compound: EFV
    Cytotoxicity against human MT4 cells assessed as reduction in cell viability incubated for 5 days by MTT assay
    Cytotoxicity against human MT4 cells assessed as reduction in cell viability incubated for 5 days by MTT assay
    		[PMID: 33567378]
    MT4 CC50
    > 6.336 μM
    Compound: EFV
    Cytotoxicity against human MT4 cells as reduction in cell viability after 5 days by MTT assay
    Cytotoxicity against human MT4 cells as reduction in cell viability after 5 days by MTT assay
    		[PMID: 19628308]
    MT4 CC50
    > 6.336 μM
    Compound: EFV
    Cytotoxicity against Homo sapiens (human) MT4 cells by MTT assay
    Cytotoxicity against Homo sapiens (human) MT4 cells by MTT assay
    		10.1007/s00044-009-9220-x
    MT4 CC50
    > 6.336 μM
    Compound: EFV
    Cytotoxicity against human MT4 cells assessed as reduction in cell viability by MTT assay
    Cytotoxicity against human MT4 cells assessed as reduction in cell viability by MTT assay
    		[PMID: 29670703]
    MT4 CC50
    > 6.336 μM
    Compound: EFV
    Cytotoxicity against human MT4 cells by MTT assay
    Cytotoxicity against human MT4 cells by MTT assay
    		[PMID: 19643613]
    MT4 CC50
    > 6.34 μM
    Compound: EFV
    Cytotoxicity against human MT4 cells assessed as reduction in cell viability incubated for 4 days by MTT assay
    Cytotoxicity against human MT4 cells assessed as reduction in cell viability incubated for 4 days by MTT assay
    		[PMID: 31421633]
    MT4 CC50
    > 6.34 μM
    Compound: EFV
    Cytotoxicity against mock infected human MT4 cells after 4 days by MTT assay
    Cytotoxicity against mock infected human MT4 cells after 4 days by MTT assay
    		[PMID: 26994843]
    MT4 CC50
    > 6.34 μM
    Compound: EFV
    Cytotoxicity against human MT4 cells after 4 days by MTT assay
    Cytotoxicity against human MT4 cells after 4 days by MTT assay
    		[PMID: 20307984]
    MT4 CC50
    > 6.34 μM
    Compound: Efavirenz
    Cytotoxicity against human MT4 cells assessed as reduction in cell viability after 5 days by MTT assay
    Cytotoxicity against human MT4 cells assessed as reduction in cell viability after 5 days by MTT assay
    		[PMID: 33979774]
    MT4 CC50
    > 6.34 μM
    Compound: 3; EFV
    Cytotoxicity against human MT4 cells assessed as reduction in cell viability incubated for 5 days by MTT assay
    Cytotoxicity against human MT4 cells assessed as reduction in cell viability incubated for 5 days by MTT assay
    		[PMID: 32977301]
    MT4 CC50
    > 6.34 μM
    Compound: EFV
    Cytotoxicity against human MT4 cells assessed as reduction in cell viability incubated for 5 days by MTT assay
    Cytotoxicity against human MT4 cells assessed as reduction in cell viability incubated for 5 days by MTT assay
    		[PMID: 32712537]
    MT4 CC50
    > 6.34 μM
    Compound: EFV
    Cytotoxicity in mock-infected human MT4 cells assessed as reduction in cell viability incubated for 5 days by MTT assay
    Cytotoxicity in mock-infected human MT4 cells assessed as reduction in cell viability incubated for 5 days by MTT assay
    		[PMID: 31935327]
    MT4 CC50
    > 6.34 μM
    Compound: EFV
    Cytotoxicity against human MT4 cells assessed as reduction in cell viability incubated for 5 days by MTT assay
    Cytotoxicity against human MT4 cells assessed as reduction in cell viability incubated for 5 days by MTT assay
    		[PMID: 31735575]
    MT4 CC50
    > 6.34 μM
    Compound: EFV
    Cytotoxicity against human MT4 cells assessed as reduction in cell viability incubated for 5 days by MTT assay
    Cytotoxicity against human MT4 cells assessed as reduction in cell viability incubated for 5 days by MTT assay
    		[PMID: 31714780]
    MT4 CC50
    > 6.34 μM
    Compound: EFV
    Cytotoxicity against human MT4 cells assessed as reduction in cell viability after 5 days by MTT assay
    Cytotoxicity against human MT4 cells assessed as reduction in cell viability after 5 days by MTT assay
    		[PMID: 30721060]
    MT4 CC50
    > 6.34 μM
    Compound: EFV
    Cytotoxicity against human MT4 cells assessed as decrease in cell viability after 5 days by MTT assay
    Cytotoxicity against human MT4 cells assessed as decrease in cell viability after 5 days by MTT assay
    		[PMID: 29635166]
    MT4 CC50
    > 6.34 μM
    Compound: EFV
    Cytotoxicity against human MT4 cells assessed as reduction in cell viability after 5 days by MTT assay
    Cytotoxicity against human MT4 cells assessed as reduction in cell viability after 5 days by MTT assay
    		[PMID: 29559197]
    MT4 CC50
    > 6.34 μM
    Compound: EFV
    Cytotoxicity against human MT4 cells after 5 days by MTT assay
    Cytotoxicity against human MT4 cells after 5 days by MTT assay
    		[PMID: 29534929]
    MT4 CC50
    > 6.34 μM
    Compound: EFV
    Cytotoxicity against human MT4 cells after 5 days by MTT assay
    Cytotoxicity against human MT4 cells after 5 days by MTT assay
    		[PMID: 28254696]
    MT4 CC50
    > 6.34 μM
    Compound: Efavirenz
    Cytotoxicity against uninfected human MT4 cells assessed as decrease in cell viability after 5 days by MTT assay
    Cytotoxicity against uninfected human MT4 cells assessed as decrease in cell viability after 5 days by MTT assay
    		[PMID: 26385446]
    MT4 CC50
    > 6.34 μM
    Compound: EFV
    Cytotoxicity against mock-infected human MT4 cells after 5 days by MTT assay
    Cytotoxicity against mock-infected human MT4 cells after 5 days by MTT assay
    		[PMID: 25240095]
    MT4 CC50
    > 6.34 μM
    Compound: EFV
    Cytotoxicity against human MT4 cells assessed as growth inhibition after 5 days by MTT assay
    Cytotoxicity against human MT4 cells assessed as growth inhibition after 5 days by MTT assay
    		[PMID: 24602795]
    MT4 CC50
    > 6.34 μM
    Compound: EFV
    Cytotoxicity against human MT4 cells after 5 days by MTT assay
    Cytotoxicity against human MT4 cells after 5 days by MTT assay
    		[PMID: 23707918]
    MT4 EC50
    > 6.34 μM
    Compound: EFV
    Antiviral activity against HIV2 ROD infected in human MT4 cells assessed as inhibition of virus-induced cytopathic effect after 5 days by MTT assay
    Antiviral activity against HIV2 ROD infected in human MT4 cells assessed as inhibition of virus-induced cytopathic effect after 5 days by MTT assay
    		[PMID: 23707918]
    MT4 CC50
    > 6.34 μM
    Compound: EFV
    Cytotoxicity against human MT4 cells after 5 days by MTT assay
    Cytotoxicity against human MT4 cells after 5 days by MTT assay
    		[PMID: 22591854]
    MT4 CC50
    > 6.34 μM
    Compound: EFV
    Cytotoxic activity against human MT4 cells assessed as viability of mock-infected cells after 5 days by MTT assay
    Cytotoxic activity against human MT4 cells assessed as viability of mock-infected cells after 5 days by MTT assay
    		[PMID: 21683601]
    MT4 CC50
    > 6.34 μM
    Compound: EFV
    Cytotoxicity against mock-infected human MT4 cells assessed as decrease in cell viability measured 5 days post-infection by MTT assay
    Cytotoxicity against mock-infected human MT4 cells assessed as decrease in cell viability measured 5 days post-infection by MTT assay
    		10.1039/C3MD00247K
    MT4 CC50
    > 6.34 μM
    Compound: EFV
    Cytotoxicity against HIV-2 ROD mock-infected human MT4 cells assessed as reduction in cell viability by MTT assay
    Cytotoxicity against HIV-2 ROD mock-infected human MT4 cells assessed as reduction in cell viability by MTT assay
    		10.1039/C3MD00028A
    MT4 CC50
    > 6.34 μM
    Compound: EFV
    Cytotoxicity against HIV-1 3B mock-infected human MT4 cells assessed as reduction in cell viability by MTT assay
    Cytotoxicity against HIV-1 3B mock-infected human MT4 cells assessed as reduction in cell viability by MTT assay
    		10.1039/C3MD00028A
    MT4 CC50
    > 6.34 μM
    Compound: Efavirenz
    Cytotoxicity against human MT4 cells assessed as reduction in cell viability by MTT assay
    Cytotoxicity against human MT4 cells assessed as reduction in cell viability by MTT assay
    		[PMID: 35649164]
    MT4 CC50
    > 6.34 μM
    Compound: EFV
    Cytotoxicity against human MT4 cells assessed as reduction in cell viability by MTT assay
    Cytotoxicity against human MT4 cells assessed as reduction in cell viability by MTT assay
    		[PMID: 34432448]
    MT4 CC50
    > 6.34 μM
    Compound: EFV
    Cytotoxicity against human MT4 cells assessed as reduction in cell viability by MTT assay
    Cytotoxicity against human MT4 cells assessed as reduction in cell viability by MTT assay
    		[PMID: 33279288]
    MT4 CC50
    > 6.34 μM
    Compound: EFV
    Cytotoxicity in mock-infected human MT4 cells assessed as reduction in cell viability by MTT assay
    Cytotoxicity in mock-infected human MT4 cells assessed as reduction in cell viability by MTT assay
    		[PMID: 28987601]
    MT4 CC50
    > 6.34 μM
    Compound: Efavirenz
    Cytotoxicity against human MT4 cells measured by MTT assay
    Cytotoxicity against human MT4 cells measured by MTT assay
    		[PMID: 22037050]
    MT4 CC50
    > 6.34 μM
    Compound: EFV
    Cytotoxicity against human MT4 cells after 5 days MTT assay
    Cytotoxicity against human MT4 cells after 5 days MTT assay
    		[PMID: 25537532]
    MT4 CC50
    > 6.35 μM
    Compound: EFV
    Cytotoxicity against mock-infected human MT4 cells incubated for 5 days by MTT assay
    Cytotoxicity against mock-infected human MT4 cells incubated for 5 days by MTT assay
    		[PMID: 34090079]
    MT4 CC50
    > 6.35 μM
    Compound: 3; EFV
    Cytotoxicity against human MT4 cells assessed as reduction in cell viability incubated for 5 days by MTT assay
    Cytotoxicity against human MT4 cells assessed as reduction in cell viability incubated for 5 days by MTT assay
    		[PMID: 31434039]
    MT4 CC50
    > 6.38 μM
    Compound: EFV
    Cytotoxicity against human MT4 cells assessed as reduction in cell viability after 5 days by MTT assay
    Cytotoxicity against human MT4 cells assessed as reduction in cell viability after 5 days by MTT assay
    		[PMID: 32200201]
    MT4 CC50
    > 6.5 μM
    Compound: EFV
    Cytotoxicity against mock-infected human MT4 cells after 5 days by MTT assay
    Cytotoxicity against mock-infected human MT4 cells after 5 days by MTT assay
    		[PMID: 25907370]
    MT4 CC50
    > 63 μM
    Compound: Efavirenz, Sustiva
    Cytotoxicity against human MT4 cells after 4 days by MTT assay
    Cytotoxicity against human MT4 cells after 4 days by MTT assay
    		[PMID: 21903401]
    MT4 CC50
    > 63.36 μM
    Compound: EFV
    Cytotoxicity against human MT4 cells after 4 days by MTT assay
    Cytotoxicity against human MT4 cells after 4 days by MTT assay
    		[PMID: 20570527]
    MT4 CC50
    > 6336 nM
    Compound: 3, EFV
    Cytotoxicity against human MT4 cells assessed as reduction in cell viability incubated for 4 days by MTT assay
    Cytotoxicity against human MT4 cells assessed as reduction in cell viability incubated for 4 days by MTT assay
    		[PMID: 26276435]
    MT4 CC50
    > 6336 nM
    Compound: EFV
    Cytotoxicity against human MT4 cells assessed as reduction of cell viability after 4 days by MTT assay
    Cytotoxicity against human MT4 cells assessed as reduction of cell viability after 4 days by MTT assay
    		[PMID: 25935383]
    MT4 CC50
    > 6340 nM
    Compound: EFV
    Cytotoxicity against human mock-infected MT4 cells assessed as reduction in cell viability after 5 days by MTT assay
    Cytotoxicity against human mock-infected MT4 cells assessed as reduction in cell viability after 5 days by MTT assay
    		[PMID: 27541578]
    MT4 CC50
    > 6340 nM
    Compound: EFV
    Toxicity in mock-infected human MT4 cells assessed as reduction in cell viability by MTT assay
    Toxicity in mock-infected human MT4 cells assessed as reduction in cell viability by MTT assay
    		[PMID: 34890994]
    MT4 CC50
    > 9 μM
    Compound: Efavirenz
    Cytotoxicity against human MT4 cells assessed as decrease in cell viability after 5 days by MTT assay
    Cytotoxicity against human MT4 cells assessed as decrease in cell viability after 5 days by MTT assay
    		[PMID: 28314598]
    MT4 CC50
    ≥ 6.3 μM
    Compound: EFV
    Cytotoxicity against human MT4 cells after 4 days by MTT assay
    Cytotoxicity against human MT4 cells after 4 days by MTT assay
    		[PMID: 20598556]
    MT4 CC50
    ≥ 6.34 μM
    Compound: EFV
    Cytotoxicity against mock-infected human MT4 cells assessed as reduction of cell viability after 5 days by MTT assay
    Cytotoxicity against mock-infected human MT4 cells assessed as reduction of cell viability after 5 days by MTT assay
    		[PMID: 27501911]
    MT4 EC50
    0.0007 μM
    Compound: 2; EFV
    Antiviral activity against HIV1 BH10 harboring wild type reverse transcriptase infected in primary MT4 cells assessed as inhibition of virus-induced cytopathogenicity after 4 days by MTS assay
    Antiviral activity against HIV1 BH10 harboring wild type reverse transcriptase infected in primary MT4 cells assessed as inhibition of virus-induced cytopathogenicity after 4 days by MTS assay
    		[PMID: 26804933]
    MT4 EC50
    0.0009 μM
    Compound: Efavirenz
    Antiviral activity against HIV1 3B infected in human MT4 cells assessed inhibition of viral-induced cytopathic effect after 5 days
    Antiviral activity against HIV1 3B infected in human MT4 cells assessed inhibition of viral-induced cytopathic effect after 5 days
    		[PMID: 20097079]
    MT4 EC50
    0.0009 μM
    Compound: Efavirenz
    Antiviral activity against HIV1 3B infected in human MT4 cells assessed as reduction of virus-induced cytopathic effect after 5 days
    Antiviral activity against HIV1 3B infected in human MT4 cells assessed as reduction of virus-induced cytopathic effect after 5 days
    		[PMID: 19616956]
    MT4 EC50
    0.0009 μM
    Compound: Efavirenz
    Antiviral activity against HIV1 3B in human MT4 cells assessed as virus-induced cytopathogenicity after 5 days
    Antiviral activity against HIV1 3B in human MT4 cells assessed as virus-induced cytopathogenicity after 5 days
    		[PMID: 18585918]
    MT4 EC50
    0.00095 μM
    Compound: Efavirenz
    Antiviral activity against Reverse transcriptase inhibitor-resistant Human immunodeficiency virus 1 infected in human MT4 cells assessed as inhibition of virus-induced cytopathic effect by MTT assay
    Antiviral activity against Reverse transcriptase inhibitor-resistant Human immunodeficiency virus 1 infected in human MT4 cells assessed as inhibition of virus-induced cytopathic effect by MTT assay
    		[PMID: 18541726]
    MT4 IC50
    0.001 μM
    Compound: Efavirenz
    Anti-HIV-1 activity against LAI strain in MT-4 cells by the MTT method
    Anti-HIV-1 activity against LAI strain in MT-4 cells by the MTT method
    		[PMID: 14643315]
    MT4 EC50
    0.001 μM
    Compound: Efavirenz
    Antiviral activity against wild type HIV1 NL4-3 infected in human MT4 cells after 5 days by MTT assay
    Antiviral activity against wild type HIV1 NL4-3 infected in human MT4 cells after 5 days by MTT assay
    		[PMID: 19140683]
    MT4 ED50
    0.001 μM
    Compound: EFV
    Antiviral activity against wild type HIV1 NL4-3 infected in human MT4 cells assessed as virus-induced cell death by MTT method
    Antiviral activity against wild type HIV1 NL4-3 infected in human MT4 cells assessed as virus-induced cell death by MTT method
    		[PMID: 18842407]
    MT4 EC50
    0.001 μM
    Compound: Efavirenz
    Antiviral activity against wild type HIV1 NL4-3 in MT4 cells by MTT assay
    Antiviral activity against wild type HIV1 NL4-3 in MT4 cells by MTT assay
    		[PMID: 16621553]
    MT4 EC50
    0.001 μM
    Compound: EVZ
    Antiviral activity against wild type HIV1 NL4-3 infected MT4 cells by MTT method
    Antiviral activity against wild type HIV1 NL4-3 infected MT4 cells by MTT method
    		[PMID: 16335924]
    MT4 EC50
    0.001 μM
    Compound: efavirenz
    Antiviral activity against HIV1 3B in human MT4 cells by XTT assay
    Antiviral activity against HIV1 3B in human MT4 cells by XTT assay
    		[PMID: 17803290]
    MT4 EC50
    0.001 μM
    Compound: Efavirenz
    Inhibition of wild type HIV-1 3B reverse transcriptase infected in human MT4 cells assessed as inhibition of viral replication after 5 days by cell titer glo based luciferase reporter gene assay
    Inhibition of wild type HIV-1 3B reverse transcriptase infected in human MT4 cells assessed as inhibition of viral replication after 5 days by cell titer glo based luciferase reporter gene assay
    		[PMID: 27371922]
    MT4 EC50
    0.0016 μM
    Compound: Efavirenz
    Antiviral activity against Protease inhibitor-resistant Human immunodeficiency virus 1 infected in human MT4 cells assessed as inhibition of virus-induced cytopathic effect by MTT assay
    Antiviral activity against Protease inhibitor-resistant Human immunodeficiency virus 1 infected in human MT4 cells assessed as inhibition of virus-induced cytopathic effect by MTT assay
    		[PMID: 18541726]
    MT4 EC50
    0.0018 μM
    Compound: 2; EFV
    Antiviral activity against HIV1 harboring reverse transcriptase K103N mutant infected in primary MT4 cells assessed as inhibition of virus-induced cytopathogenicity after 4 days by MTS assay
    Antiviral activity against HIV1 harboring reverse transcriptase K103N mutant infected in primary MT4 cells assessed as inhibition of virus-induced cytopathogenicity after 4 days by MTS assay
    		[PMID: 26804933]
    MT4 EC50
    0.0019 μM
    Compound: Efavirenz
    Antiretroviral activity against Human immunodeficiency virus 1 NL4.3 infected in human MT4 cells assessed as inhibition of virus-induced cytopathic effect by MTT assay
    Antiretroviral activity against Human immunodeficiency virus 1 NL4.3 infected in human MT4 cells assessed as inhibition of virus-induced cytopathic effect by MTT assay
    		[PMID: 18541726]
    MT4 IC50
    0.002 μM
    Compound: Efavirenz
    Anti-HIV-1 activity against K1001 strain was determined in MT-4 cells by the MTT method
    Anti-HIV-1 activity against K1001 strain was determined in MT-4 cells by the MTT method
    		[PMID: 14643315]
    MT4 EC50
    0.002 μM
    Compound: EFV
    Antiviral activity against HIV-1 3B infected in human MT4 cells assessed as protection against virus-induced cytopathic effect after 4 days by MTT assay
    Antiviral activity against HIV-1 3B infected in human MT4 cells assessed as protection against virus-induced cytopathic effect after 4 days by MTT assay
    		[PMID: 26479028]
    MT4 EC50
    0.002 μM
    Compound: efavirenz
    Antiviral activity against HIV1 3B infected in human MT4 cells assessed as protection against virus-induced cytopathogenicity after 4 days by MTT assay
    Antiviral activity against HIV1 3B infected in human MT4 cells assessed as protection against virus-induced cytopathogenicity after 4 days by MTT assay
    		[PMID: 26358281]
    MT4 EC50
    0.002 μM
    Compound: EFV
    Antiviral activity against HIV1 infected in human MT4 cells assessed as protection against viral-induced cytopathogenecity after 4 days by MTT method
    Antiviral activity against HIV1 infected in human MT4 cells assessed as protection against viral-induced cytopathogenecity after 4 days by MTT method
    		[PMID: 25913116]
    MT4 EC50
    0.002 μM
    Compound: EFV
    Antiviral activity against HIV-13B infected in MT4 cells assessed as protection from virus-induced cytopathogenicity after 4 days by MTT method
    Antiviral activity against HIV-13B infected in MT4 cells assessed as protection from virus-induced cytopathogenicity after 4 days by MTT method
    		[PMID: 25014745]
    MT4 EC50
    0.002 μM
    Compound: EFV, DMP266, L-743,726
    Antiviral activity against wild type HIV1 3B infected in human MT4 cells assessed as inhibition of virus-induced cytopathogenicity after 4 days by MTT assay
    Antiviral activity against wild type HIV1 3B infected in human MT4 cells assessed as inhibition of virus-induced cytopathogenicity after 4 days by MTT assay
    		[PMID: 24805780]
    MT4 EC50
    0.002 μM
    Compound: EFV, DMP266, L-743,726
    Antiviral activity against zidovudine-resistant HIV1 harboring RT 67N, 70R, 215F, 219Q mutant infected in human MT4 cells assessed as inhibition of virus-induced cytopathogenicity after 4 days by MTT assay
    Antiviral activity against zidovudine-resistant HIV1 harboring RT 67N, 70R, 215F, 219Q mutant infected in human MT4 cells assessed as inhibition of virus-induced cytopathogenicity after 4 days by MTT assay
    		[PMID: 24805780]
    MT4 EC50
    0.002 μM
    Compound: Efavirenz
    Antiviral activity against Human immunodeficiency virus 1 3B infected in human MT4 cells assessed as inhibition of virus-induced cytopathogenicity after 4 days by MTT assay
    Antiviral activity against Human immunodeficiency virus 1 3B infected in human MT4 cells assessed as inhibition of virus-induced cytopathogenicity after 4 days by MTT assay
    		[PMID: 24489455]
    MT4 EC50
    0.002 μM
    Compound: EFV
    Antiviral activity against HIV1 infected in human MT4 cells assessed as virus-induced cytopathogenicity after 4 days by MTT assay
    Antiviral activity against HIV1 infected in human MT4 cells assessed as virus-induced cytopathogenicity after 4 days by MTT assay
    		[PMID: 22884523]
    MT4 EC50
    0.002 μM
    Compound: Efavirenz
    Antiviral activity against HIV1 3B infected in human MT4 cells assessed as inhibition of virus-induced cytopathogenicity after 4 days by MTT assay
    Antiviral activity against HIV1 3B infected in human MT4 cells assessed as inhibition of virus-induced cytopathogenicity after 4 days by MTT assay
    		[PMID: 22513121]
    MT4 EC50
    0.002 μM
    Compound: EFV
    Antiviral activity against HIV1 3B infected in human MT4 cells assessed as inhibition of virus-induced cytopathogenicity after 4 days by MTT assay
    Antiviral activity against HIV1 3B infected in human MT4 cells assessed as inhibition of virus-induced cytopathogenicity after 4 days by MTT assay
    		[PMID: 22047799]
    MT4 EC50
    0.002 μM
    Compound: EFV
    Antiviral activity against HIV1 3B infected in human MT4 cells assessed as protection against virus-induced cytopathogenicity after 4 days by MTT assay
    Antiviral activity against HIV1 3B infected in human MT4 cells assessed as protection against virus-induced cytopathogenicity after 4 days by MTT assay
    		[PMID: 19775780]
    MT4 EC50
    0.002 μM
    Compound: Efavirenz
    Antiviral activity against HIV1 3B infected in human MT4 cells assessed as protection against virus-induced cytopathogenicity by MTT assay
    Antiviral activity against HIV1 3B infected in human MT4 cells assessed as protection against virus-induced cytopathogenicity by MTT assay
    		[PMID: 26119992]
    MT4 EC50
    0.0027 μM
    Compound: EFV
    Antiviral activity against HIV-1 3B expressing wild type reverse transcriptase infected in human MT4 cells assessed as inhibition of virus-induced cytopathic effect by MTT assay
    Antiviral activity against HIV-1 3B expressing wild type reverse transcriptase infected in human MT4 cells assessed as inhibition of virus-induced cytopathic effect by MTT assay
    		[PMID: 27234889]
    MT4 EC50
    0.003 μM
    Compound: Efavirenz, Sustiva
    Antiviral activity against HIV1 3B infected in human MT4 cells assessed as inhibition of virus-induced cytopathic effect after 4 days by MTT assay
    Antiviral activity against HIV1 3B infected in human MT4 cells assessed as inhibition of virus-induced cytopathic effect after 4 days by MTT assay
    		[PMID: 21903401]
    MT4 EC50
    0.003 μM
    Compound: EFV
    Antiviral activity against wild type HIV1 3B infected in human MT4 cells assessed as inhibition of virus-induced cytopathic effect after 4 days by MTT assay
    Antiviral activity against wild type HIV1 3B infected in human MT4 cells assessed as inhibition of virus-induced cytopathic effect after 4 days by MTT assay
    		[PMID: 20570527]
    MT4 EC50
    0.003 μM
    Compound: EFV
    Antiviral activity against HIV1 3B infected in human MT4 cells assessed as protection from virus-induced cytopathogenicity after 4 days by MTT assay
    Antiviral activity against HIV1 3B infected in human MT4 cells assessed as protection from virus-induced cytopathogenicity after 4 days by MTT assay
    		[PMID: 20307984]
    MT4 EC50
    0.003 μM
    Compound: EFV
    Antiviral activity against wild type HIV1 3B infected in human MT4 cells assessed as protection against virus induced cytopathogenicity after 4 days by MTT assay
    Antiviral activity against wild type HIV1 3B infected in human MT4 cells assessed as protection against virus induced cytopathogenicity after 4 days by MTT assay
    		[PMID: 19781821]
    MT4 EC50
    0.003 μM
    Compound: Efavirenz
    Antiviral activity against HIV1 reverse transcriptase Y188L mutant infected in human MT4 cells after 5 days by MTT assay
    Antiviral activity against HIV1 reverse transcriptase Y188L mutant infected in human MT4 cells after 5 days by MTT assay
    		[PMID: 19140683]
    MT4 EC50
    0.003 μM
    Compound: efavirenz
    Antiviral activity against HIV1 3B infected in MT4 cells by MTT
    Antiviral activity against HIV1 3B infected in MT4 cells by MTT
    		[PMID: 18267363]
    MT4 EC50
    0.003 μM
    Compound: EFV
    Antiviral activity against HIV1 NL4-3 infected in human MT4 cells assessed as inhibition of virus-induced cytopathic effect after 5 days
    Antiviral activity against HIV1 NL4-3 infected in human MT4 cells assessed as inhibition of virus-induced cytopathic effect after 5 days
    		[PMID: 22652226]
    MT4 EC50
    0.003 μM
    Compound: efavirenz
    Antiviral activity against wild type HIV1 NL4-3 in human MT4 cells assessed as inhibition of virus-induced cytopathicity after 5 days by multiple round replication assay
    Antiviral activity against wild type HIV1 NL4-3 in human MT4 cells assessed as inhibition of virus-induced cytopathicity after 5 days by multiple round replication assay
    		[PMID: 19469474]
    MT4 EC50
    0.004 μM
    Compound: Efavirenz
    Concentration required for 50% protection of infected MT-4 cells from wtIIIB-HIV-1-induced cytopathogenicity was determined by the MTT method
    Concentration required for 50% protection of infected MT-4 cells from wtIIIB-HIV-1-induced cytopathogenicity was determined by the MTT method
    		[PMID: 15634015]
    MT4 EC50
    0.004 μM
    Compound: EFV, DMP266, L-743,726
    Antiviral activity against MDR-resistant HIV1 harboring 41L, 74V, 106A, 215Y mutant infected in human MT4 cells assessed as inhibition of virus-induced cytopathogenicity after 4 days by MTT assay
    Antiviral activity against MDR-resistant HIV1 harboring 41L, 74V, 106A, 215Y mutant infected in human MT4 cells assessed as inhibition of virus-induced cytopathogenicity after 4 days by MTT assay
    		[PMID: 24805780]
    MT4 EC50
    0.004 μM
    Compound: EFV, DMP266, L-743,726
    Antiviral activity against saquinavir-resistant HIV1 infected in human MT4 cells assessed as inhibition of virus-induced cytopathogenicity after 4 days by MTT assay
    Antiviral activity against saquinavir-resistant HIV1 infected in human MT4 cells assessed as inhibition of virus-induced cytopathogenicity after 4 days by MTT assay
    		[PMID: 24805780]
    MT4 EC50
    0.004 μM
    Compound: EFV, efavirenz
    Antiviral activity against HIV1 NL43 in MT4 cells assessed as inhibition of viral induced cytopathic effect after 4 days by MTT method
    Antiviral activity against HIV1 NL43 in MT4 cells assessed as inhibition of viral induced cytopathic effect after 4 days by MTT method
    		[PMID: 17910429]
    MT4 EC50
    0.004 μM
    Compound: EFV
    Antiviral activity against HIV-1 3B infected in human MT4 cells assessed as inhibition of virus-induced cytopathic effect by MTT assay
    Antiviral activity against HIV-1 3B infected in human MT4 cells assessed as inhibition of virus-induced cytopathic effect by MTT assay
    		[PMID: 27234889]
    MT4 EC50
    0.004 μM
    Compound: efavirenz
    Antiviral activity against HIV1 NL4-3 with Y181C mutant in human MT4 cells assessed as inhibition of virus-induced cytopathicity after 5 days by multiple round replication assay
    Antiviral activity against HIV1 NL4-3 with Y181C mutant in human MT4 cells assessed as inhibition of virus-induced cytopathicity after 5 days by multiple round replication assay
    		[PMID: 19469474]
    MT4 IC50
    0.004 μM
    Compound: Efavirenz
    Concentration required to protect the cell against HIV-1 strain IIIB viral cytopathogenicity by 50% in MT-4 cells
    Concentration required to protect the cell against HIV-1 strain IIIB viral cytopathogenicity by 50% in MT-4 cells
    		[PMID: 15149669]
    MT4 EC50
    0.0044 μM
    Compound: EFV
    Antiviral activity against Human immunodeficiency virus 1 IIIB infected human MT4 cells assessed as inhibition of virus-induced cytopathicity after 4 days by MTT assay
    Antiviral activity against Human immunodeficiency virus 1 IIIB infected human MT4 cells assessed as inhibition of virus-induced cytopathicity after 4 days by MTT assay
    		10.1007/s00044-009-9220-x
    MT4 EC50
    0.0044 μM
    Compound: EFV
    Antiviral activity against wild type Human immunodeficiency virus 1 3B infected in human MT4 cells assessed as protection against virus-induced cytotoxicity after 5 days by MTT assay
    Antiviral activity against wild type Human immunodeficiency virus 1 3B infected in human MT4 cells assessed as protection against virus-induced cytotoxicity after 5 days by MTT assay
    		[PMID: 21683601]
    MT4 EC50
    0.0044 μM
    Compound: EFV
    Antiviral activity against HIV1 3B infected in human MT4 cells assessed as inhibition of virus induced cytotoxicity after 5 days by MTT assay
    Antiviral activity against HIV1 3B infected in human MT4 cells assessed as inhibition of virus induced cytotoxicity after 5 days by MTT assay
    		[PMID: 19628308]
    MT4 EC50
    0.0044 μM
    Compound: EFV
    Antiviral activity against HIV1 3B infected in human MT4 cells assessed as virus-induced cytopathic effect by MTT assay
    Antiviral activity against HIV1 3B infected in human MT4 cells assessed as virus-induced cytopathic effect by MTT assay
    		[PMID: 19643613]
    MT4 EC50
    0.005 μM
    Compound: EFV
    Antiviral activity against HIV-1 infected in MT4 cells assessed as inhibition of virus-induced cytopathogenicity after 4 days by MTT assay
    Antiviral activity against HIV-1 infected in MT4 cells assessed as inhibition of virus-induced cytopathogenicity after 4 days by MTT assay
    		[PMID: 26443549]
    MT4 EC50
    0.005 μM
    Compound: EFV
    Antiviral activity against HIV1 infected in human MT4 cells assessed as inhibition of virus-induced cytopathogenicity after 4 days by MTT assay
    Antiviral activity against HIV1 infected in human MT4 cells assessed as inhibition of virus-induced cytopathogenicity after 4 days by MTT assay
    		[PMID: 25082514]
    MT4 EC50
    0.005 μM
    Compound: Efavirenz
    Antiviral activity against wild type Human immunodeficiency virus 1 3B infected in human MT4 cells assessed as protection against virus-induced cytopathogenicity after 4 days by MTT assay
    Antiviral activity against wild type Human immunodeficiency virus 1 3B infected in human MT4 cells assessed as protection against virus-induced cytopathogenicity after 4 days by MTT assay
    		[PMID: 21824782]
    MT4 EC50
    0.005 μM
    Compound: EFV
    Antiviral activity against HIV1 3B expressing reverse transcriptase E138K mutant infected in human MT4 cells assessed as reduction of virus-induced cytopathic effect after 5 days by MTT assay
    Antiviral activity against HIV1 3B expressing reverse transcriptase E138K mutant infected in human MT4 cells assessed as reduction of virus-induced cytopathic effect after 5 days by MTT assay
    		[PMID: 26802545]
    MT4 EC50
    0.005 μM
    Compound: EFV
    Antiviral activity against HIV1 3B harboring wild type RT infected in MT4 cells assessed as inhibition of virus-induced cytopathic effect after 5 days by MTT assay
    Antiviral activity against HIV1 3B harboring wild type RT infected in MT4 cells assessed as inhibition of virus-induced cytopathic effect after 5 days by MTT assay
    		[PMID: 22575532]
    MT4 EC50
    0.005 μM
    Compound: EFV
    Antiviral activity against HIV1 3B infected in human MT4 cells assessed as inhibition of virus-induced cytopathic effect by MTT assay
    Antiviral activity against HIV1 3B infected in human MT4 cells assessed as inhibition of virus-induced cytopathic effect by MTT assay
    		[PMID: 23098609]
    MT4 EC50
    0.005 μM
    Compound: EFV
    Antiviral activity against HIV1 3B infected in human MT4 cells assessed as inhibition of virus-induced cytopathicity by MTT assay
    Antiviral activity against HIV1 3B infected in human MT4 cells assessed as inhibition of virus-induced cytopathicity by MTT assay
    		[PMID: 23084898]
    MT4 EC50
    0.005 μM
    Compound: Efavirenz
    Inhibition of reverse transcriptase Y181C mutant in HIV-1 3B infected in human MT4 cells assessed as inhibition of viral replication after 5 days by cell titer glo based luciferase reporter gene assay
    Inhibition of reverse transcriptase Y181C mutant in HIV-1 3B infected in human MT4 cells assessed as inhibition of viral replication after 5 days by cell titer glo based luciferase reporter gene assay
    		[PMID: 27371922]
    MT4 EC50
    0.0053 μM
    Compound: EFV
    Antiviral activity against HIV1 3B infected in human MT4 cells assessed as reduction in virus-induced cytopathogenicity by MTT assay
    Antiviral activity against HIV1 3B infected in human MT4 cells assessed as reduction in virus-induced cytopathogenicity by MTT assay
    		[PMID: 25150090]
    MT4 EC50
    0.0054 μM
    Compound: EFV
    Antiviral activity against wild type HIV1 3B infected in human MT4 cells assessed as cell viability after 4 days by MTT assay
    Antiviral activity against wild type HIV1 3B infected in human MT4 cells assessed as cell viability after 4 days by MTT assay
    		[PMID: 26994843]
    MT4 EC50
    0.0054 μM
    Compound: EFV
    Antiviral activity against wild type HIV1 3B infected in human MT4 cells assessed as reduction of virus-induced cytopathic effect after 5 days by MTT assay
    Antiviral activity against wild type HIV1 3B infected in human MT4 cells assessed as reduction of virus-induced cytopathic effect after 5 days by MTT assay
    		[PMID: 26802545]
    MT4 EC50
    0.0054 μM
    Compound: EFV
    Antiviral activity against wild-type HIV1 3B infected in human MT4 cells assessed as protection of cells from virus-induced cytopathic after 5 days by MTT assay
    Antiviral activity against wild-type HIV1 3B infected in human MT4 cells assessed as protection of cells from virus-induced cytopathic after 5 days by MTT assay
    		[PMID: 25907370]
    MT4 EC50
    0.0054 μM
    Compound: Efavirenz
    Antiviral activity against wild type HIV1 3B infected in human MT4 cells assessed as reduction in virus-induced cytopathogenicity after 5 days by MTT assay
    Antiviral activity against wild type HIV1 3B infected in human MT4 cells assessed as reduction in virus-induced cytopathogenicity after 5 days by MTT assay
    		[PMID: 22037050]
    MT4 EC50
    0.0054 μM
    Compound: EFV
    Antiviral activity against HIV-1 3B infected in human MT4 cells assessed as inhibition of virus-induced cytopathicity by MTT assay
    Antiviral activity against HIV-1 3B infected in human MT4 cells assessed as inhibition of virus-induced cytopathicity by MTT assay
    		10.1039/C3MD00028A
    MT4 EC50
    0.0055 μM
    Compound: EFV
    Antiviral activity against HIV-1 3B harboring RT E138K mutant infected in human MT4 cells assessed as inhibition of virus-induced syncytium formation after 5 days by MTT assay
    Antiviral activity against HIV-1 3B harboring RT E138K mutant infected in human MT4 cells assessed as inhibition of virus-induced syncytium formation after 5 days by MTT assay
    		[PMID: 21872971]
    MT4 EC50
    0.0057 μM
    Compound: EFV
    Antiviral activity against wild type HIV-1 3B infected in human MT4 cells assessed as protection against virus-induced cytopathogenicity after 5 days by MTT assay
    Antiviral activity against wild type HIV-1 3B infected in human MT4 cells assessed as protection against virus-induced cytopathogenicity after 5 days by MTT assay
    		[PMID: 24602795]
    MT4 EC50
    0.006 μM
    Compound: Efavirenz
    Antiviral activity against HIV-1 3B infected in human MT4 cells assessed as reduction of virus-induced cytopathic effect after 5 days by MTT assay
    Antiviral activity against HIV-1 3B infected in human MT4 cells assessed as reduction of virus-induced cytopathic effect after 5 days by MTT assay
    		[PMID: 27112451]
    MT4 EC50
    0.006 μM
    Compound: EFV
    Antiviral activity against HIV1 3B infected in human MT4 cells assessed as reduction in virus-induced cytopathic effect after 5 days by MTT assay
    Antiviral activity against HIV1 3B infected in human MT4 cells assessed as reduction in virus-induced cytopathic effect after 5 days by MTT assay
    		[PMID: 25707013]
    MT4 EC50
    0.006 μM
    Compound: 3, EFV
    Antiviral activity against HIV1 3B infected in human MT4 cells assessed as inhibition of virus-induced cytopathicity measured 5 days post viral infection by MTT assay
    Antiviral activity against HIV1 3B infected in human MT4 cells assessed as inhibition of virus-induced cytopathicity measured 5 days post viral infection by MTT assay
    		[PMID: 24794751]
    MT4 EC50
    0.006 μM
    Compound: EFV, efavirenz
    Antiviral activity against HIV1 with reverse transcriptase Y181C mutation in MT4 cells assessed as inhibition of viral induced cytopathic effect by MTT method
    Antiviral activity against HIV1 with reverse transcriptase Y181C mutation in MT4 cells assessed as inhibition of viral induced cytopathic effect by MTT method
    		[PMID: 17910429]
    MT4 EC50
    0.006 μM
    Compound: Efavirenz
    Antiviral activity against HIV-1 3B infected in human MT4 cells assessed as inhibition of virus-induced cytopathic effect after 5 days
    Antiviral activity against HIV-1 3B infected in human MT4 cells assessed as inhibition of virus-induced cytopathic effect after 5 days
    		[PMID: 24457088]
    MT4 EC50
    0.0062 μM
    Compound: EFV
    Antiviral activity against wild type HIV-1 3B infected in human MT4 cells assessed as reduction of virus-induced cytopathic effect after 5 days by MTT assay
    Antiviral activity against wild type HIV-1 3B infected in human MT4 cells assessed as reduction of virus-induced cytopathic effect after 5 days by MTT assay
    		[PMID: 25537532]
    MT4 EC50
    0.0063 μM
    Compound: Efavirenz
    Antiviral activity against wild type HIV 1 3B infected in human MT4 cells assessed as protection against virus-induced cytopathogenicity after 5 days by MTT assay
    Antiviral activity against wild type HIV 1 3B infected in human MT4 cells assessed as protection against virus-induced cytopathogenicity after 5 days by MTT assay
    		[PMID: 26385446]
    MT4 EC50
    0.0063 μM
    Compound: EFV
    Antiviral activity against HIV1 3B infected in human MT4 cells assessed as inhibition of virus-induced syncytium formation after 5 days by MTT assay
    Antiviral activity against HIV1 3B infected in human MT4 cells assessed as inhibition of virus-induced syncytium formation after 5 days by MTT assay
    		[PMID: 25240095]
    MT4 EC50
    0.0067 μM
    Compound: EFV
    Antiviral activity against wild type HIV-1 3B infected in human MT4 cells assessed as protection against virus-induced cytopathogenicity after 5 days by MTT assay
    Antiviral activity against wild type HIV-1 3B infected in human MT4 cells assessed as protection against virus-induced cytopathogenicity after 5 days by MTT assay
    		[PMID: 24055077]
    MT4 EC50
    0.0068 μM
    Compound: EFV
    Antiviral activity against HIV1 3B expressing wild type reverse transcriptase infected in human MT4 cells assessed as protection against virus-induced cytopathic effect after 5 days by MTT assay
    Antiviral activity against HIV1 3B expressing wild type reverse transcriptase infected in human MT4 cells assessed as protection against virus-induced cytopathic effect after 5 days by MTT assay
    		[PMID: 27267005]
    MT4 EC50
    0.0068 μM
    Compound: EFV
    Antiviral activity against HIV1 3B expressing reverse transcriptase Y181C mutant infected in human MT4 cells assessed as reduction of virus-induced cytopathic effect after 5 days by MTT assay
    Antiviral activity against HIV1 3B expressing reverse transcriptase Y181C mutant infected in human MT4 cells assessed as reduction of virus-induced cytopathic effect after 5 days by MTT assay
    		[PMID: 26802545]
    MT4 EC50
    0.007 μM
    Compound: EFV
    Antiviral activity against HIV1 3B infected in human MT-4 cells assessed as protection against virus-induced cytopathicity after 5 days by MTT assay
    Antiviral activity against HIV1 3B infected in human MT-4 cells assessed as protection against virus-induced cytopathicity after 5 days by MTT assay
    		[PMID: 24239481]
    MT4 EC50
    0.007 μM
    Compound: EFV
    Antiviral activity against wild type HIV1 3B infected in human MT4 cells assessed as protection against virus-induced cytopathicity after 5 days by MTT assay
    Antiviral activity against wild type HIV1 3B infected in human MT4 cells assessed as protection against virus-induced cytopathicity after 5 days by MTT assay
    		[PMID: 23415090]
    MT4 EC50
    0.007 μM
    Compound: EFV
    Antiviral activity against wild type HIV-1 NL4-3 infected in human MT4 cells assessed as inhibition of virus-induced cytopathic effect by MTT method
    Antiviral activity against wild type HIV-1 NL4-3 infected in human MT4 cells assessed as inhibition of virus-induced cytopathic effect by MTT method
    		[PMID: 24933420]
    MT4 EC50
    0.007 μM
    Compound: EFZ
    Antiviral activity against HIV1 NL4-3 in human MT4 cells assessed as inhibition of virus-induced cytopathogenicity by MTT assay
    Antiviral activity against HIV1 NL4-3 in human MT4 cells assessed as inhibition of virus-induced cytopathogenicity by MTT assay
    		[PMID: 18630898]
    MT4 EC50
    0.0074 μM
    Compound: EFV, DMP266
    Antiviral activity against wild-type HIV1 3B infected in human MT4 cells assessed as inhibition of viral cytopathicity after 5 days by MTT assay
    Antiviral activity against wild-type HIV1 3B infected in human MT4 cells assessed as inhibition of viral cytopathicity after 5 days by MTT assay
    		[PMID: 24275349]
    MT4 EC50
    0.008 μM
    Compound: Efavirenz
    Antiviral activity against HIV1 reverse transcriptase Y181C mutant infected in human MT4 cells after 5 days by MTT assay
    Antiviral activity against HIV1 reverse transcriptase Y181C mutant infected in human MT4 cells after 5 days by MTT assay
    		[PMID: 19140683]
    MT4 ED50
    0.008 μM
    Compound: EFV
    Antiviral activity against drug-resistant HIV1 with reverse transcriptase Y181C mutant infected in human MT4 cells assessed as virus-induced cell death by MTT method
    Antiviral activity against drug-resistant HIV1 with reverse transcriptase Y181C mutant infected in human MT4 cells assessed as virus-induced cell death by MTT method
    		[PMID: 18842407]
    MT4 EC50
    0.0089 μM
    Compound: EFV
    Antiviral activity against wild-type HIV-1 3B infected in human MT4 cells assessed as protection against virus-induced cytopathic effect measured 5 days post-infection by MTT assay
    Antiviral activity against wild-type HIV-1 3B infected in human MT4 cells assessed as protection against virus-induced cytopathic effect measured 5 days post-infection by MTT assay
    		10.1039/C3MD00247K
    MT4 EC50
    0.009 μM
    Compound: EFV
    Antiviral activity against wild-type HIV1 3B infected in MT4 cells assessed as reduction in virus-induced cytopathic effect after 5 days by MTT assay
    Antiviral activity against wild-type HIV1 3B infected in MT4 cells assessed as reduction in virus-induced cytopathic effect after 5 days by MTT assay
    		[PMID: 24134904]
    MT4 EC50
    0.01 μM
    Compound: EFV, DMP266, L-743,726
    Antiviral activity against N119-sensitive HIV1 harboring Y181C mutant infected in human MT4 cells assessed as inhibition of virus-induced cytopathogenicity after 4 days by MTT assay
    Antiviral activity against N119-sensitive HIV1 harboring Y181C mutant infected in human MT4 cells assessed as inhibition of virus-induced cytopathogenicity after 4 days by MTT assay
    		[PMID: 24805780]
    MT4 EC50
    0.01 μM
    Compound: EFV
    Antiviral activity against NNRTI-resistant HIV1 N119 with reverse transcriptase Y181C mutant infected in human MT4 cells assessed as protection against virus-induced cytopathogenicity after 4 days by MTT assay
    Antiviral activity against NNRTI-resistant HIV1 N119 with reverse transcriptase Y181C mutant infected in human MT4 cells assessed as protection against virus-induced cytopathogenicity after 4 days by MTT assay
    		[PMID: 19775780]
    MT4 EC50
    0.01 μM
    Compound: EFV
    Antiviral activity against HIV1 3B infected in human MT4 cells assessed as inhibition of virus-induced cytopathic effect after 5 days by MTT assay
    Antiviral activity against HIV1 3B infected in human MT4 cells assessed as inhibition of virus-induced cytopathic effect after 5 days by MTT assay
    		[PMID: 23707918]
    MT4 EC50
    0.01 μM
    Compound: Efavirenz
    Antiviral activity against HIV1 3B expressing reverse transcriptase Y181C mutant infected in human MT4 cells assessed as inhibition of virus-induced cytopathogenicity by MTT assay
    Antiviral activity against HIV1 3B expressing reverse transcriptase Y181C mutant infected in human MT4 cells assessed as inhibition of virus-induced cytopathogenicity by MTT assay
    		[PMID: 19058881]
    MT4 EC50
    0.01 μM
    Compound: table 6,efavirenz
    Antiviral activity against HIV1 with reverse transcriptase Y181C mutation in human MT4 cells assessed as inhibition of virus-induced cytopathogenicity by MTT assay
    Antiviral activity against HIV1 with reverse transcriptase Y181C mutation in human MT4 cells assessed as inhibition of virus-induced cytopathogenicity by MTT assay
    		[PMID: 18226533]
    MT4 EC50
    0.01 μM
    Compound: efavirenz
    Antiviral activity against HIV1 with reverse transcriptase K103N/Y181C mutation in human MT4 cells assessed as reduction of virus-induced cytopathogenicity by MTT assay
    Antiviral activity against HIV1 with reverse transcriptase K103N/Y181C mutation in human MT4 cells assessed as reduction of virus-induced cytopathogenicity by MTT assay
    		[PMID: 18226532]
    MT4 EC50
    0.013 μM
    Compound: EFV
    Antiviral activity against HIV-1 harboring NNTRI-resistant reverse transcriptase Y181C mutant infected in human MT4 cells assessed as inhibition of virus-induced cytopathic effect by MTT method
    Antiviral activity against HIV-1 harboring NNTRI-resistant reverse transcriptase Y181C mutant infected in human MT4 cells assessed as inhibition of virus-induced cytopathic effect by MTT method
    		[PMID: 24933420]
    MT4 EC50
    0.015 μM
    Compound: Efavirenz
    Antiretroviral activity against Human immunodeficiency virus 1 3B infected in human MT4 cells assessed as inhibition of virus-induced cytopathic effect by MTT assay
    Antiretroviral activity against Human immunodeficiency virus 1 3B infected in human MT4 cells assessed as inhibition of virus-induced cytopathic effect by MTT assay
    		[PMID: 18541726]
    MT4 EC50
    0.02 μM
    Compound: EFV
    Antiviral activity against HIV2 ROD infected in human MT4 cells assessed as protection against virus-induced cytopathicity after 5 days by MTT assay
    Antiviral activity against HIV2 ROD infected in human MT4 cells assessed as protection against virus-induced cytopathicity after 5 days by MTT assay
    		[PMID: 23415090]
    MT4 EC50
    0.02 μM
    Compound: EFV
    Antiviral activity against HIV1 3B Y181C resistant mutant in human MT4 cells assessed as protection against viral induced cytopathogenicity by MTT assay
    Antiviral activity against HIV1 3B Y181C resistant mutant in human MT4 cells assessed as protection against viral induced cytopathogenicity by MTT assay
    		[PMID: 18954921]
    MT4 EC50
    0.022 μM
    Compound: EFV
    Antiviral activity against HIV1 3B infected in human MT4 cells assessed as inhibition of viral cytopathogenicity after 5 days by MTT assay
    Antiviral activity against HIV1 3B infected in human MT4 cells assessed as inhibition of viral cytopathogenicity after 5 days by MTT assay
    		[PMID: 24680058]
    MT4 IC50
    0.0226 μM
    Compound: EFV
    Antiviral activity against wild type HIV1 3B infected in human MT4 cells assessed as inhibition of virus-induced cytopathogenicity after 5 days by MTT assay
    Antiviral activity against wild type HIV1 3B infected in human MT4 cells assessed as inhibition of virus-induced cytopathogenicity after 5 days by MTT assay
    		[PMID: 24952305]
    MT4 EC50
    0.025 μM
    Compound: Efavirenz
    Compound concentration required to achieve 50% protection of infected MT-4 cells from Y181C strain was determined by the MTT method
    Compound concentration required to achieve 50% protection of infected MT-4 cells from Y181C strain was determined by the MTT method
    		[PMID: 15634015]
    MT4 EC50
    0.037 μM
    Compound: 2; EFV
    Antiviral activity against HIV1 harboring reverse transcriptase Y181C mutant infected in primary MT4 cells assessed as inhibition of virus-induced cytopathogenicity after 4 days by MTS assay
    Antiviral activity against HIV1 harboring reverse transcriptase Y181C mutant infected in primary MT4 cells assessed as inhibition of virus-induced cytopathogenicity after 4 days by MTS assay
    		[PMID: 26804933]
    MT4 IC50
    0.04 μM
    Compound: Efavirenz
    Anti-HIV-1 activity against K103N strain in MT-4 cells by the MTT method
    Anti-HIV-1 activity against K103N strain in MT-4 cells by the MTT method
    		[PMID: 14643315]
    MT4 IC50
    0.04 μM
    Compound: Efavirenz
    Anti-HIV-1 activity against K103N+Y181C strain was determined in MT-4 cells by the MTT method
    Anti-HIV-1 activity against K103N+Y181C strain was determined in MT-4 cells by the MTT method
    		[PMID: 14643315]
    MT4 IC50
    0.04 μM
    Compound: Efavirenz
    Anti-HIV-1 activity against Y181C strain, in MT-4 cells by the MTT method
    Anti-HIV-1 activity against Y181C strain, in MT-4 cells by the MTT method
    		[PMID: 14643315]
    MT4 EC50
    0.04 μM
    Compound: table 6,efavirenz
    Antiviral activity against HIV1 with reverse transcriptase K103N/Y181C mutation in human MT4 cells assessed as inhibition of virus-induced cytopathogenicity by MTT assay
    Antiviral activity against HIV1 with reverse transcriptase K103N/Y181C mutation in human MT4 cells assessed as inhibition of virus-induced cytopathogenicity by MTT assay
    		[PMID: 18226533]
    MT4 EC50
    0.04 μM
    Compound: efavirenz
    Antiviral activity against HIV1 with reverse transcriptase Y181C mutation in human MT4 cells assessed as reduction of virus-induced cytopathogenicity by MTT assay
    Antiviral activity against HIV1 with reverse transcriptase Y181C mutation in human MT4 cells assessed as reduction of virus-induced cytopathogenicity by MTT assay
    		[PMID: 18226532]
    MT4 EC50
    0.044 μM
    Compound: EFZ
    Antiviral activity against HIV1 isolates with reverse transcriptase Y181C mutation in human MT4 cells assessed as inhibition of virus-induced cytopathogenicity by MTT assay
    Antiviral activity against HIV1 isolates with reverse transcriptase Y181C mutation in human MT4 cells assessed as inhibition of virus-induced cytopathogenicity by MTT assay
    		[PMID: 18630898]
    MT4 EC50
    0.049 μg/mL
    Compound: Efavirenz
    Antiviral activity against HIV 1 RES056 harboring reverse transcriptase K103N/Y181C double mutant infected in human MT4 cells assessed as protection against virus-induced cytopathogenicity after 5 days by MTT assay
    Antiviral activity against HIV 1 RES056 harboring reverse transcriptase K103N/Y181C double mutant infected in human MT4 cells assessed as protection against virus-induced cytopathogenicity after 5 days by MTT assay
    		[PMID: 26385446]
    MT4 EC50
    0.054 μM
    Compound: EFV
    Antiviral activity against HIV-1 3B harboring RT L100I mutant infected in human MT4 cells assessed as inhibition of virus-induced syncytium formation after 5 days by MTT assay
    Antiviral activity against HIV-1 3B harboring RT L100I mutant infected in human MT4 cells assessed as inhibition of virus-induced syncytium formation after 5 days by MTT assay
    		[PMID: 21872971]
    MT4 EC50
    0.057 μM
    Compound: Efavirenz
    Antiviral activity against HIV1 reverse transcriptase K103N mutant infected in human MT4 cells after 5 days by MTT assay
    Antiviral activity against HIV1 reverse transcriptase K103N mutant infected in human MT4 cells after 5 days by MTT assay
    		[PMID: 19140683]
    MT4 EC50
    0.057 μM
    Compound: Efavirenz
    Antiviral activity against HIV1 K103N mutant in MT4 cells by MTT assay
    Antiviral activity against HIV1 K103N mutant in MT4 cells by MTT assay
    		[PMID: 16621553]
    MT4 EC50
    0.057 μM
    Compound: EVZ
    Antiviral activity against HIV1 K103N mutant strain infected MT4 cells by MTT method
    Antiviral activity against HIV1 K103N mutant strain infected MT4 cells by MTT method
    		[PMID: 16335924]
    MT4 EC50
    0.058 μM
    Compound: 2; EFV
    Antiviral activity against HIV1 harboring reverse transcriptase Y181C/K103N double mutant infected in primary MT4 cells assessed as inhibition of virus-induced cytopathogenicity after 4 days by MTS assay
    Antiviral activity against HIV1 harboring reverse transcriptase Y181C/K103N double mutant infected in primary MT4 cells assessed as inhibition of virus-induced cytopathogenicity after 4 days by MTS assay
    		[PMID: 26804933]
    MT4 EC50
    0.06 μM
    Compound: EFV, DMP266, L-743,726
    Antiviral activity against 6-[(3,5-Dimethylphenyl)fluoromethyl]-5-ethyl-1-{[[4-(3-hydroxyprop-1-ynyl)benzyl]oxy]methyl}pyrimidine-2,4(1H,3H)-dione-resistant HIV1 harboring RT 106I, 181C mutant infected in human MT4 cells assessed as inhibition of virus-in
    Antiviral activity against 6-[(3,5-Dimethylphenyl)fluoromethyl]-5-ethyl-1-{[[4-(3-hydroxyprop-1-ynyl)benzyl]oxy]methyl}pyrimidine-2,4(1H,3H)-dione-resistant HIV1 harboring RT 106I, 181C mutant infected in human MT4 cells assessed as inhibition of virus-in
    		[PMID: 24805780]
    MT4 EC50
    0.06 μM
    Compound: EFV
    Antiviral activity against NNRTI-resistant HIV1 A17 with reverse transcriptase K103N, Y181C mutant infected in human MT4 cells assessed as protection against virus-induced cytopathogenicity after 4 days by MTT assay
    Antiviral activity against NNRTI-resistant HIV1 A17 with reverse transcriptase K103N, Y181C mutant infected in human MT4 cells assessed as protection against virus-induced cytopathogenicity after 4 days by MTT assay
    		[PMID: 19775780]
    MT4 EC50
    0.08 μM
    Compound: EFV, DMP266, L-743,726
    Antiviral activity against A17-sensitive HIV1 harboring 103N, 181C mutant infected in human MT4 cells assessed as inhibition of virus-induced cytopathogenicity after 4 days by MTT assay
    Antiviral activity against A17-sensitive HIV1 harboring 103N, 181C mutant infected in human MT4 cells assessed as inhibition of virus-induced cytopathogenicity after 4 days by MTT assay
    		[PMID: 24805780]
    MT4 EC50
    0.08 μM
    Compound: EFV, efavirenz
    Antiviral activity against HIV1 with reverse transcriptase IRLL98 mutation in MT4 cells assessed as inhibition of viral induced cytopathic effect by MTT method
    Antiviral activity against HIV1 with reverse transcriptase IRLL98 mutation in MT4 cells assessed as inhibition of viral induced cytopathic effect by MTT method
    		[PMID: 17910429]
    MT4 EC50
    0.086 μM
    Compound: Efavirenz
    Antiviral activity against non nucleoside reverse transcriptase inhibitor-resistant Human immunodeficiency virus 1 infected in human MT4 cells assessed as inhibition of virus-induced cytopathic effect by MTT assay
    Antiviral activity against non nucleoside reverse transcriptase inhibitor-resistant Human immunodeficiency virus 1 infected in human MT4 cells assessed as inhibition of virus-induced cytopathic effect by MTT assay
    		[PMID: 18541726]
    MT4 EC50
    0.09 μM
    Compound: EFV, DMP266, L-743,726
    Antiviral activity against TMC120-resistant HIV1 harboring RT 100I, 138G mutant infected in human MT4 cells assessed as inhibition of virus-induced cytopathogenicity after 4 days by MTT assay
    Antiviral activity against TMC120-resistant HIV1 harboring RT 100I, 138G mutant infected in human MT4 cells assessed as inhibition of virus-induced cytopathogenicity after 4 days by MTT assay
    		[PMID: 24805780]
    MT4 EC50
    0.09 μM
    Compound: EFV, efavirenz
    Antiviral activity against HIV1 with reverse transcriptase K103N mutation in MT4 cells assessed as inhibition of viral induced cytopathic effect by MTT method
    Antiviral activity against HIV1 with reverse transcriptase K103N mutation in MT4 cells assessed as inhibition of viral induced cytopathic effect by MTT method
    		[PMID: 17910429]
    MT4 EC50
    0.1 μM
    Compound: EFV, DMP266, L-743,726
    Antiviral activity against MC1220-resistant HIV1 harboring RT 100I, 179D, 181C mutant infected in human MT4 cells assessed as inhibition of virus-induced cytopathogenicity after 4 days by MTT assay
    Antiviral activity against MC1220-resistant HIV1 harboring RT 100I, 179D, 181C mutant infected in human MT4 cells assessed as inhibition of virus-induced cytopathogenicity after 4 days by MTT assay
    		[PMID: 24805780]
    MT4 EC50
    0.1 μM
    Compound: EFV
    Antiviral activity against HIV1 3B expressing reverse transcriptase L100I mutant infected in human MT4 cells assessed as reduction of virus-induced cytopathic effect after 5 days by MTT assay
    Antiviral activity against HIV1 3B expressing reverse transcriptase L100I mutant infected in human MT4 cells assessed as reduction of virus-induced cytopathic effect after 5 days by MTT assay
    		[PMID: 26802545]
    MT4 EC50
    0.101 μM
    Compound: Efavirenz
    Inhibition of HIV-1 3B reverse transcriptase K103N mutant infected in human MT4 cells assessed as inhibition of viral replication after 5 days by cell titer glo based luciferase reporter gene assay
    Inhibition of HIV-1 3B reverse transcriptase K103N mutant infected in human MT4 cells assessed as inhibition of viral replication after 5 days by cell titer glo based luciferase reporter gene assay
    		[PMID: 27371922]
    MT4 EC50
    0.108 μM
    Compound: EFV
    Antiviral activity against HIV-1 3B harboring RT K103N mutant infected in human MT4 cells assessed as inhibition of virus-induced syncytium formation after 5 days by MTT assay
    Antiviral activity against HIV-1 3B harboring RT K103N mutant infected in human MT4 cells assessed as inhibition of virus-induced syncytium formation after 5 days by MTT assay
    		[PMID: 21872971]
    MT4 EC50
    0.11 μM
    Compound: EFV
    Antiviral activity against HIV1 with reverse transcriptase K103N, Y181C mutant infected in human MT4 cells assessed as protection against virus-induced cytopathogenicity after 4 days by MTT assay
    Antiviral activity against HIV1 with reverse transcriptase K103N, Y181C mutant infected in human MT4 cells assessed as protection against virus-induced cytopathogenicity after 4 days by MTT assay
    		[PMID: 20598556]
    MT4 EC50
    0.12 μM
    Compound: EFV
    Antiviral activity against HIV1 3B expressing reverse transcriptase K103N mutant infected in human MT4 cells assessed as reduction of virus-induced cytopathic effect after 5 days by MTT assay
    Antiviral activity against HIV1 3B expressing reverse transcriptase K103N mutant infected in human MT4 cells assessed as reduction of virus-induced cytopathic effect after 5 days by MTT assay
    		[PMID: 26802545]
    MT4 ED50
    0.133 μM
    Compound: EFV
    Antiviral activity against drug-resistant HIV1 with reverse transcriptase K103N mutant infected in human MT4 cells assessed as virus-induced cell death by MTT method
    Antiviral activity against drug-resistant HIV1 with reverse transcriptase K103N mutant infected in human MT4 cells assessed as virus-induced cell death by MTT method
    		[PMID: 18842407]
    MT4 EC50
    0.14 μM
    Compound: EFV
    Antiviral activity against HIV1 harboring K103N/Y181C double mutant infected in human MT4 cells assessed as protection of cells from virus-induced cytopathic after 5 days by MTT assay
    Antiviral activity against HIV1 harboring K103N/Y181C double mutant infected in human MT4 cells assessed as protection of cells from virus-induced cytopathic after 5 days by MTT assay
    		[PMID: 25907370]
    MT4 EC50
    0.15 μM
    Compound: Efavirenz
    Compound concentration required to achieve 50% protection of infected MT-4 cells from K103N-Y181C strain was determined by the MTT method
    Compound concentration required to achieve 50% protection of infected MT-4 cells from K103N-Y181C strain was determined by the MTT method
    		[PMID: 15634015]
    MT4 EC50
    0.16 μM
    Compound: EFV
    Antiviral activity against HIV1 RES056 expressing reverse transcriptase K103N/Y181C double mutant infected in human MT4 cells assessed as reduction in virus-induced cytopathic effect after 5 days by MTT assay
    Antiviral activity against HIV1 RES056 expressing reverse transcriptase K103N/Y181C double mutant infected in human MT4 cells assessed as reduction in virus-induced cytopathic effect after 5 days by MTT assay
    		[PMID: 25707013]
    MT4 EC50
    0.16 μM
    Compound: EFV
    Antiviral activity against HIV1 RES056 expressing reverse transcriptase K103N + Y181C double mutant infected in human MT4 cells assessed as reduction in virus-induced cytopathic effect after 5 days by MTT assay
    Antiviral activity against HIV1 RES056 expressing reverse transcriptase K103N + Y181C double mutant infected in human MT4 cells assessed as reduction in virus-induced cytopathic effect after 5 days by MTT assay
    		[PMID: 25626145]
    MT4 EC50
    0.16 μM
    Compound: EFV
    Antiviral activity against HIV-1 RES056 harboring reverse transcriptase K103N/Y181C double mutant infected in human MT4 cells assessed as reduction of virus-induced cytopathic effect after 5 days by MTT assay
    Antiviral activity against HIV-1 RES056 harboring reverse transcriptase K103N/Y181C double mutant infected in human MT4 cells assessed as reduction of virus-induced cytopathic effect after 5 days by MTT assay
    		[PMID: 25537532]
    MT4 EC50
    0.16 μM
    Compound: EFV
    Antiviral activity against HIV1 RES056 expressing reverse transcriptase K103N + Y181C mutant infected in human MT4 cells assessed as inhibition of virus-induced syncytium formation after 5 days by MTT assay
    Antiviral activity against HIV1 RES056 expressing reverse transcriptase K103N + Y181C mutant infected in human MT4 cells assessed as inhibition of virus-induced syncytium formation after 5 days by MTT assay
    		[PMID: 25240095]
    MT4 IC50
    0.16 μM
    Compound: EFV
    Antiviral activity against HIV1 harboring reverse transcriptase K103N/Y181C mutant infected in human MT4 cells assessed as inhibition of virus-induced cytopathogenicity after 5 days by MTT assay
    Antiviral activity against HIV1 harboring reverse transcriptase K103N/Y181C mutant infected in human MT4 cells assessed as inhibition of virus-induced cytopathogenicity after 5 days by MTT assay
    		[PMID: 24952305]
    MT4 EC50
    0.167 μM
    Compound: efavirenz
    Antiviral activity against HIV1 NL4-3 with L100I mutant in human MT4 cells assessed as inhibition of virus-induced cytopathicity after 5 days by multiple round replication assay
    Antiviral activity against HIV1 NL4-3 with L100I mutant in human MT4 cells assessed as inhibition of virus-induced cytopathicity after 5 days by multiple round replication assay
    		[PMID: 19469474]
    MT4 EC50
    0.18 μM
    Compound: EFV
    Antiviral activity against HIV1 expressing reverse transcriptase K103N/Y181C double mutant infected in human MT4 cells assessed as protection against virus-induced cytopathogenicity after 4 days by MTT assay
    Antiviral activity against HIV1 expressing reverse transcriptase K103N/Y181C double mutant infected in human MT4 cells assessed as protection against virus-induced cytopathogenicity after 4 days by MTT assay
    		[PMID: 20307984]
    MT4 EC50
    0.19 μM
    Compound: EFV
    Antiviral activity against HIV-1 3B expressing reverse transcriptase K103N mutant infected in human MT4 cells assessed as inhibition of virus-induced cytopathic effect by MTT assay
    Antiviral activity against HIV-1 3B expressing reverse transcriptase K103N mutant infected in human MT4 cells assessed as inhibition of virus-induced cytopathic effect by MTT assay
    		[PMID: 27234889]
    MT4 IC50
    0.2 μM
    Compound: Efavirenz
    Anti-HIV-1 activity against Y188L strain was determined in MT-4 cells by the MTT method
    Anti-HIV-1 activity against Y188L strain was determined in MT-4 cells by the MTT method
    		[PMID: 14643315]
    MT4 EC50
    0.2 μM
    Compound: Efavirenz
    Antiviral activity against HIV1 IRLL98 in MT4 cells by MTT assay
    Antiviral activity against HIV1 IRLL98 in MT4 cells by MTT assay
    		[PMID: 16621553]
    MT4 EC50
    0.2 μM
    Compound: EVZ
    Antiviral activity against HIV1 IRLL98 mutant strain infected MT4 cells by MTT method
    Antiviral activity against HIV1 IRLL98 mutant strain infected MT4 cells by MTT method
    		[PMID: 16335924]
    MT4 EC50
    0.21 μM
    Compound: EFV
    Antiviral activity against HIV1 RES056 expressing reverse transcriptase F227L/V106A double mutant infected in human MT4 cells assessed as reduction of virus-induced cytopathic effect after 5 days by MTT assay
    Antiviral activity against HIV1 RES056 expressing reverse transcriptase F227L/V106A double mutant infected in human MT4 cells assessed as reduction of virus-induced cytopathic effect after 5 days by MTT assay
    		[PMID: 26802545]
    MT4 EC50
    0.225 μM
    Compound: EFV
    Antiviral activity against HIV1 RES056 harboring reverse transcriptase K103N/YI81C double mutant infected in human MT4 cells assessed as cell viability after 4 days by MTT assay
    Antiviral activity against HIV1 RES056 harboring reverse transcriptase K103N/YI81C double mutant infected in human MT4 cells assessed as cell viability after 4 days by MTT assay
    		[PMID: 26994843]
    MT4 EC50
    0.23 μM
    Compound: EFV
    Antiviral activity against HIV1 RES056 expressing reverse transcriptase K103N/Y181C double mutant infected in human MT4 cells assessed as reduction in virus-induced cytopathogenicity by MTT assay
    Antiviral activity against HIV1 RES056 expressing reverse transcriptase K103N/Y181C double mutant infected in human MT4 cells assessed as reduction in virus-induced cytopathogenicity by MTT assay
    		[PMID: 25150090]
    MT4 EC50
    0.24 μM
    Compound: EFV
    Antiviral activity against HIV1 RES056 expressing reverse transcriptase K103N/Y181C double mutant infected in human MT4 cells assessed as protection against virus-induced cytopathic effect after 5 days by MTT assay
    Antiviral activity against HIV1 RES056 expressing reverse transcriptase K103N/Y181C double mutant infected in human MT4 cells assessed as protection against virus-induced cytopathic effect after 5 days by MTT assay
    		[PMID: 27267005]
    MT4 EC50
    0.27 μM
    Compound: 3, EFV
    Antiviral activity against HIV1 RES056 harboring RT K103N,Y181C double mutant infected in human MT4 cells assessed as inhibition of virus-induced cytopathicity measured 5 days post viral infection by MTT assay
    Antiviral activity against HIV1 RES056 harboring RT K103N,Y181C double mutant infected in human MT4 cells assessed as inhibition of virus-induced cytopathicity measured 5 days post viral infection by MTT assay
    		[PMID: 24794751]
    MT4 EC50
    0.3 μM
    Compound: Efavirenz
    Antiviral activity against HIV1 Y188L mutant in MT4 cells by MTT assay
    Antiviral activity against HIV1 Y188L mutant in MT4 cells by MTT assay
    		[PMID: 16621553]
    MT4 EC50
    0.3 μM
    Compound: EVZ
    Antiviral activity against HIV1 Y188L mutant strain infected MT4 cells by MTT method
    Antiviral activity against HIV1 Y188L mutant strain infected MT4 cells by MTT method
    		[PMID: 16335924]
    MT4 EC50
    0.32 μM
    Compound: EFV
    Antiviral activity against HIV-1 RES056 harboring reverse transcriptase K103N/Y181C double mutant infected in human MT4 cells assessed as protection against virus-induced cytopathogenicity after 5 days by MTT assay
    Antiviral activity against HIV-1 RES056 harboring reverse transcriptase K103N/Y181C double mutant infected in human MT4 cells assessed as protection against virus-induced cytopathogenicity after 5 days by MTT assay
    		[PMID: 24602795]
    MT4 CC50
    0.32 μM
    Compound: Efavirenz
    Cytotoxicity against human MT4 cells by MTT assay
    Cytotoxicity against human MT4 cells by MTT assay
    		10.1039/C4MD00282B
    MT4 EC50
    0.32 μM
    Compound: efavirenz
    Antiviral activity against HIV1 NL4-3 with K103N mutant in human MT4 cells assessed as inhibition of virus-induced cytopathicity after 5 days by multiple round replication assay
    Antiviral activity against HIV1 NL4-3 with K103N mutant in human MT4 cells assessed as inhibition of virus-induced cytopathicity after 5 days by multiple round replication assay
    		[PMID: 19469474]
    MT4 EC50
    0.34 μM
    Compound: EFV
    Antiviral activity against HIV1 3B expressing reverse transcriptase Y188L mutant infected in human MT4 cells assessed as reduction of virus-induced cytopathic effect after 5 days by MTT assay
    Antiviral activity against HIV1 3B expressing reverse transcriptase Y188L mutant infected in human MT4 cells assessed as reduction of virus-induced cytopathic effect after 5 days by MTT assay
    		[PMID: 26802545]
    MT4 EC50
    0.34 μM
    Compound: EFV
    Antiviral activity against HIV-1 harboring NNTRI-resistant reverse transcriptase K103N mutant infected in human MT4 cells assessed as inhibition of virus-induced cytopathic effect by MTT method
    Antiviral activity against HIV-1 harboring NNTRI-resistant reverse transcriptase K103N mutant infected in human MT4 cells assessed as inhibition of virus-induced cytopathic effect by MTT method
    		[PMID: 24933420]
    MT4 EC50
    0.38 μM
    Compound: efavirenz
    Antiviral activity against HIV1 RES056 infected in MT4 cells by MTT
    Antiviral activity against HIV1 RES056 infected in MT4 cells by MTT
    		[PMID: 18267363]
    MT4 EC50
    0.39 μM
    Compound: EFZ
    Antiviral activity against HIV1 isolates with reverse transcriptase K103N mutation in human MT4 cells assessed as inhibition of virus-induced cytopathogenicity by MTT assay
    Antiviral activity against HIV1 isolates with reverse transcriptase K103N mutation in human MT4 cells assessed as inhibition of virus-induced cytopathogenicity by MTT assay
    		[PMID: 18630898]
    MT4 EC50
    0.44 μM
    Compound: EFV
    Antiviral activity against HIV1 RES056 harboring K103N/Y181C RT mutant infected in MT4 cells assessed as inhibition of virus-induced cytopathic effect after 5 days by MTT assay
    Antiviral activity against HIV1 RES056 harboring K103N/Y181C RT mutant infected in MT4 cells assessed as inhibition of virus-induced cytopathic effect after 5 days by MTT assay
    		[PMID: 22575532]
    MT4 EC50
    0.443 μM
    Compound: Efavirenz
    Antiviral activity against wild type Human immunodeficiency virus 1 3B bearing reverse transcriptase K103N and Y181C double mutation infected in human MT4 cells assessed as protection against virus-induced cytopathogenicity after 4 days by MTT assay
    Antiviral activity against wild type Human immunodeficiency virus 1 3B bearing reverse transcriptase K103N and Y181C double mutation infected in human MT4 cells assessed as protection against virus-induced cytopathogenicity after 4 days by MTT assay
    		[PMID: 21824782]
    MT4 EC50
    0.46 μM
    Compound: EFV
    Antiviral activity against HIV-1 RESO56 harboring RT K103N/Y181C double mutant infected in human MT4 cells assessed as protection against virus-induced cytopathogenicity after 5 days by MTT assay
    Antiviral activity against HIV-1 RESO56 harboring RT K103N/Y181C double mutant infected in human MT4 cells assessed as protection against virus-induced cytopathogenicity after 5 days by MTT assay
    		[PMID: 24055077]
    MT4 EC50
    0.5 nM
    Compound: EFV
    Antiviral activity against HIV1 expressing wild type reverse transcriptase infected in human MT4 cells assessed as inhibition of viral replication after 72 hrs by HeLa-CD4-LTR-beta-gal assay
    Antiviral activity against HIV1 expressing wild type reverse transcriptase infected in human MT4 cells assessed as inhibition of viral replication after 72 hrs by HeLa-CD4-LTR-beta-gal assay
    		[PMID: 23137340]
    MT4 EC50
    0.507 μM
    Compound: EFV
    Antiviral activity against HIV1 harboring RT K103N/Y181C double mutant infected in human MT4 cells assessed as inhibition of viral cytopathogenicity after 5 days by MTT assay
    Antiviral activity against HIV1 harboring RT K103N/Y181C double mutant infected in human MT4 cells assessed as inhibition of viral cytopathogenicity after 5 days by MTT assay
    		[PMID: 24680058]
    MT4 EC50
    0.51 μM
    Compound: EFV
    Antiviral activity against HIV1 RES056 expressing RT K103N/Y181C mutant infected in human MT4 cells assessed as inhibition of virus-induced cytopathic effect after 5 days by MTT assay
    Antiviral activity against HIV1 RES056 expressing RT K103N/Y181C mutant infected in human MT4 cells assessed as inhibition of virus-induced cytopathic effect after 5 days by MTT assay
    		[PMID: 23707918]
    MT4 EC50
    0.51 μM
    Compound: Efavirenz
    Antiviral activity against HIV1 harboring reverse transcriptase K103N/Y181C mutant infected in human MT4 cells assessed as reduction in virus-induced cytopathogenicity after 5 days by MTT assay
    Antiviral activity against HIV1 harboring reverse transcriptase K103N/Y181C mutant infected in human MT4 cells assessed as reduction in virus-induced cytopathogenicity after 5 days by MTT assay
    		[PMID: 22037050]
    MT4 EC50
    0.51 μM
    Compound: EFV
    Antiviral activity against HIV-1 RES056 harboring RT K103N+Y181C double mutant infected in human MT4 cells assessed as protection against virus-induced cytopathic effect measured 5 days post-infection by MTT assay
    Antiviral activity against HIV-1 RES056 harboring RT K103N+Y181C double mutant infected in human MT4 cells assessed as protection against virus-induced cytopathic effect measured 5 days post-infection by MTT assay
    		10.1039/C3MD00247K
    MT4 EC50
    0.52 μM
    Compound: EFV, DMP266
    Antiviral activity against HIV1 RES056 harboring reverse transcriptase K103N/Y181C mutant infected in human MT4 cells assessed as inhibition of viral cytopathicity after 5 days by MTT assay
    Antiviral activity against HIV1 RES056 harboring reverse transcriptase K103N/Y181C mutant infected in human MT4 cells assessed as inhibition of viral cytopathicity after 5 days by MTT assay
    		[PMID: 24275349]
    MT4 EC50
    0.52 μM
    Compound: EFV
    Antiviral activity against drug-resistant HIV1 RES056 harboring reverse transcriptase K103N/Y181C double mutant infected in human MT-4 cells assessed as protection against virus-induced cytopathicity after 5 days by MTT assay
    Antiviral activity against drug-resistant HIV1 RES056 harboring reverse transcriptase K103N/Y181C double mutant infected in human MT-4 cells assessed as protection against virus-induced cytopathicity after 5 days by MTT assay
    		[PMID: 24239481]
    MT4 EC50
    0.52 μM
    Compound: EFV
    Antiviral activity against HIV1 harboring reverse transcriptase K103N/Y181C mutant infected in MT4 cells assessed as reduction in virus-induced cytopathic effect after 5 days by MTT assay
    Antiviral activity against HIV1 harboring reverse transcriptase K103N/Y181C mutant infected in MT4 cells assessed as reduction in virus-induced cytopathic effect after 5 days by MTT assay
    		[PMID: 24134904]
    MT4 EC50
    0.55 μM
    Compound: EFV
    Antiviral activity against HIV1 RES056 harboring reverse transcriptase K103N/Y181C mutant infected in human MT4 cells assessed as inhibition of virus-induced cytopathic effect after 5 days by MTT assay
    Antiviral activity against HIV1 RES056 harboring reverse transcriptase K103N/Y181C mutant infected in human MT4 cells assessed as inhibition of virus-induced cytopathic effect after 5 days by MTT assay
    		[PMID: 22591854]
    MT4 EC50
    0.55 μM
    Compound: EFV
    Antiviral activity against HIV-1 RES056 harboring RT K103N/Y181C mutant gene infected human MT4 cells assessed as inhibition in viral syncytium formation by MTT assay
    Antiviral activity against HIV-1 RES056 harboring RT K103N/Y181C mutant gene infected human MT4 cells assessed as inhibition in viral syncytium formation by MTT assay
    		[PMID: 22883027]
    MT4 EC50
    0.56 μM
    Compound: Efavirenz, Sustiva
    Antiviral activity against HIV1 3B expressing reverse transcriptase K103N/Y181C double mutant infected in human MT4 cells assessed as inhibition of virus-induced cytopathic effect after 4 days by MTT assay
    Antiviral activity against HIV1 3B expressing reverse transcriptase K103N/Y181C double mutant infected in human MT4 cells assessed as inhibition of virus-induced cytopathic effect after 4 days by MTT assay
    		[PMID: 21903401]
    MT4 EC50
    0.56 μM
    Compound: EFV
    Antiviral activity against HIV1 bearing reverse transcriptase K103N and Y181C double mutation infected in human MT4 cells assessed as inhibition of virus-induced cytopathic effect after 4 days by MTT assay
    Antiviral activity against HIV1 bearing reverse transcriptase K103N and Y181C double mutation infected in human MT4 cells assessed as inhibition of virus-induced cytopathic effect after 4 days by MTT assay
    		[PMID: 20570527]
    MT4 EC50
    0.57 μM
    Compound: EFV
    Antiviral activity against HIV1 expressing reverse transcriptase K103N/Y181C mutant infected in human MT4 cells assessed as protection against virus-induced cytotoxicity after 5 days by MTT assay
    Antiviral activity against HIV1 expressing reverse transcriptase K103N/Y181C mutant infected in human MT4 cells assessed as protection against virus-induced cytotoxicity after 5 days by MTT assay
    		[PMID: 22405288]
    MT4 EC50
    0.57 μM
    Compound: EFV
    Antiviral activity against HIV1 RES056 harboring reverse transcriptase K103N/Y181C mutant infected in human MT4 cells assessed as inhibition of virus-induced cytopathicity by MTT assay
    Antiviral activity against HIV1 RES056 harboring reverse transcriptase K103N/Y181C mutant infected in human MT4 cells assessed as inhibition of virus-induced cytopathicity by MTT assay
    		[PMID: 23084898]
    MT4 EC50
    0.59 μM
    Compound: EFV
    Antiviral activity against HIV1 RES056 harboring reverse transcriptase K103N/Y181C double mutant infected in human MT4 cells assessed as protection against virus-induced cytopathicity after 5 days by MTT assay
    Antiviral activity against HIV1 RES056 harboring reverse transcriptase K103N/Y181C double mutant infected in human MT4 cells assessed as protection against virus-induced cytopathicity after 5 days by MTT assay
    		[PMID: 23415090]
    MT4 EC50
    0.98 nM
    Compound: Efavirenz
    Antiviral activity against HIV1 3B infected in MT4 cells assessed as inhibition of virus-induced cytopathic effect by MTT assay
    Antiviral activity against HIV1 3B infected in MT4 cells assessed as inhibition of virus-induced cytopathic effect by MTT assay
    		10.1039/C4MD00282B
    MT4 IC50
    1 nM
    Compound: EFV
    Antiviral activity against HIV-1 LAI harboring wild type reverse transcriptase infected in human MT4 cells after 5 days by MTT assay
    Antiviral activity against HIV-1 LAI harboring wild type reverse transcriptase infected in human MT4 cells after 5 days by MTT assay
    		[PMID: 19645483]
    MT4 EC50
    1 nM
    Compound: EFV
    Antiviral activity against NNRTI-resistant HIV HXB2 with reverse transcriptase 225H mutation in human MT4 cells assessed as protection against virus-induced cell death after 5 days by MTT assay
    Antiviral activity against NNRTI-resistant HIV HXB2 with reverse transcriptase 225H mutation in human MT4 cells assessed as protection against virus-induced cell death after 5 days by MTT assay
    		[PMID: 19007201]
    MT4 EC50
    1 nM
    Compound: EFV
    Antiviral activity against NNRTI-resistant HIV HXB2 with reverse transcriptase 227L mutation in human MT4 cells assessed as protection against virus-induced cell death after 5 days by MTT assay
    Antiviral activity against NNRTI-resistant HIV HXB2 with reverse transcriptase 227L mutation in human MT4 cells assessed as protection against virus-induced cell death after 5 days by MTT assay
    		[PMID: 19007201]
    MT4 IC50
    1 nM
    Compound: EFV, efavirenz
    Antiviral activity against HIV1 LAI assessed as inhibition of viral-induced cytopathicity in MT4 cells by MTT method
    Antiviral activity against HIV1 LAI assessed as inhibition of viral-induced cytopathicity in MT4 cells by MTT method
    		[PMID: 17157017]
    MT4 EC50
    1 nM
    Compound: EFV
    Antiviral activity against NNRTI-resistant HIV1 harboring reverse transcriptase Y181C mutant infected in human MT4 cells assessed as inhibition of viral replication after 72 hrs by HeLa-CD4-LTR-beta-gal assay
    Antiviral activity against NNRTI-resistant HIV1 harboring reverse transcriptase Y181C mutant infected in human MT4 cells assessed as inhibition of viral replication after 72 hrs by HeLa-CD4-LTR-beta-gal assay
    		[PMID: 23137340]
    MT4 EC50
    1.57 μM
    Compound: EFZ
    Antiviral activity against HIV1 isolates with reverse transcriptase Y188L mutation in human MT4 cells assessed as inhibition of virus-induced cytopathogenicity by MTT assay
    Antiviral activity against HIV1 isolates with reverse transcriptase Y188L mutation in human MT4 cells assessed as inhibition of virus-induced cytopathogenicity by MTT assay
    		[PMID: 18630898]
    MT4 EC50
    1.6 nM
    Compound: 13, efavirenz
    Antiviral activity against wild type HIV1 LAI infected in MT4 cells by EGFP based replication assay
    Antiviral activity against wild type HIV1 LAI infected in MT4 cells by EGFP based replication assay
    		[PMID: 17223230]
    MT4 IC50
    1.8 nM
    Compound: Efavirenz
    Antiviral activity against wild type HIV1 infected in human MT4 cells assessed as reduction of virus-induced cytopathic effect by replication assay in presence of 10% FBS
    Antiviral activity against wild type HIV1 infected in human MT4 cells assessed as reduction of virus-induced cytopathic effect by replication assay in presence of 10% FBS
    		[PMID: 20829038]
    MT4 EC50
    1.97 μM
    Compound: EFV
    Antiviral activity against HIV-1 harboring NNTRI-resistant reverse transcriptase Y188L mutant infected in human MT4 cells assessed as inhibition of virus-induced cytopathic effect by MTT method
    Antiviral activity against HIV-1 harboring NNTRI-resistant reverse transcriptase Y188L mutant infected in human MT4 cells assessed as inhibition of virus-induced cytopathic effect by MTT method
    		[PMID: 24933420]
    MT4 IC50
    1.99 nM
    Compound: EFV
    Antiviral activity against HIV1 HXB2 harboring Y181C mutant reverse transcriptase infected in human MT4 cells after 5 days by MTT assay
    Antiviral activity against HIV1 HXB2 harboring Y181C mutant reverse transcriptase infected in human MT4 cells after 5 days by MTT assay
    		[PMID: 19645483]
    MT4 IC50
    1.99 nM
    Compound: EFV
    Antiviral activity against HIV1 HXB2 harboring 138K mutant reverse transcriptase infected in human MT4 cells after 5 days by MTT assay
    Antiviral activity against HIV1 HXB2 harboring 138K mutant reverse transcriptase infected in human MT4 cells after 5 days by MTT assay
    		[PMID: 19645483]
    MT4 IC50
    1.99 nM
    Compound: EFV, efavirenz
    Antiviral activity against HIV1 RT 181C mutant assessed as inhibition of viral-induced cytopathicity in MT4 cells by MTT method
    Antiviral activity against HIV1 RT 181C mutant assessed as inhibition of viral-induced cytopathicity in MT4 cells by MTT method
    		[PMID: 17157017]
    MT4 EC50
    10 nM
    Compound: EFV
    Antiviral activity against HIV1 harboring reverse transcriptase Y181C mutant infected in human MT4 cells assessed as inhibition of virus-induced cytopathic effect after 5 days by MTT assay
    Antiviral activity against HIV1 harboring reverse transcriptase Y181C mutant infected in human MT4 cells assessed as inhibition of virus-induced cytopathic effect after 5 days by MTT assay
    		[PMID: 22428851]
    MT4 IC50
    10 nM
    Compound: EFV
    Antiviral activity against HIV1 HXB2 harboring 190A mutant reverse transcriptase infected in human MT4 cells after 5 days by MTT assay
    Antiviral activity against HIV1 HXB2 harboring 190A mutant reverse transcriptase infected in human MT4 cells after 5 days by MTT assay
    		[PMID: 19645483]
    MT4 ED50
    10 nM
    Compound: EFV
    Antiviral activity against HIV1 RT Y181C mutant in MT4 cells by MTT assay
    Antiviral activity against HIV1 RT Y181C mutant in MT4 cells by MTT assay
    		[PMID: 17803291]
    MT4 EC50
    10.1 nM
    Compound: EFV
    Antiviral activity against HIV 1 harboring reverse transcriptase Y181C mutant infected in human MT4 cells assessed as inhibition of virus-induced cytopathic effect after 5 days by MTT assay
    Antiviral activity against HIV 1 harboring reverse transcriptase Y181C mutant infected in human MT4 cells assessed as inhibition of virus-induced cytopathic effect after 5 days by MTT assay
    		[PMID: 21438533]
    MT4 IC50
    1000 nM
    Compound: EFV
    Antiviral activity against HIV1 HXB2 harboring 100I and K103N mutant reverse transcriptase infected in human MT4 cells after 5 days by MTT assay
    Antiviral activity against HIV1 HXB2 harboring 100I and K103N mutant reverse transcriptase infected in human MT4 cells after 5 days by MTT assay
    		[PMID: 19645483]
    MT4 IC50
    1000 nM
    Compound: EFV, efavirenz
    Antiviral activity against HIV1 RT 100I/103N mutant assessed as inhibition of viral-induced cytopathicity in MT4 cells by MTT method
    Antiviral activity against HIV1 RT 100I/103N mutant assessed as inhibition of viral-induced cytopathicity in MT4 cells by MTT method
    		[PMID: 17157017]
    MT4 EC50
    104 nM
    Compound: EFV
    Antiviral activity against HIV1 with reverse transcriptase F227L, V106A mutant infected in human MT4 cells assessed as protection against virus-induced cytopathogenicity after 4 days by MTT assay
    Antiviral activity against HIV1 with reverse transcriptase F227L, V106A mutant infected in human MT4 cells assessed as protection against virus-induced cytopathogenicity after 4 days by MTT assay
    		[PMID: 20598556]
    MT4 EC50
    115.5 nM
    Compound: EFV
    Antiviral activity against HIV1 3B harboring reverse transcriptase L100I mutant infected in human MT4 cells assessed as protection against virus induced cytotoxicity after 5 days by MTT assay
    Antiviral activity against HIV1 3B harboring reverse transcriptase L100I mutant infected in human MT4 cells assessed as protection against virus induced cytotoxicity after 5 days by MTT assay
    		[PMID: 27541578]
    MT4 EC50
    12 nM
    Compound: EFV
    Antiviral activity against NNRTI-resistant HIV HXB2 with reverse transcriptase 101E mutation in human MT4 cells assessed as protection against virus-induced cell death after 5 days by MTT assay
    Antiviral activity against NNRTI-resistant HIV HXB2 with reverse transcriptase 101E mutation in human MT4 cells assessed as protection against virus-induced cell death after 5 days by MTT assay
    		[PMID: 19007201]
    MT4 EC50
    130 nM
    Compound: EFV, DMP-266
    Antiviral activity against HIV1 NL4-3 expressing reverse transcriptase K103N mutant infected in human MT4 cells assessed as reduction in virus-induced cell death by MTT assay
    Antiviral activity against HIV1 NL4-3 expressing reverse transcriptase K103N mutant infected in human MT4 cells assessed as reduction in virus-induced cell death by MTT assay
    		[PMID: 25418038]
    MT4 EC50
    130 nM
    Compound: EFV, DMP-266
    Antiviral activity against HIV1 harboring reverse transcriptase K103N mutant infected in human MT4 cells assessed as inhibition of virus-induced cell death measured after 5 days of infection by MTT method
    Antiviral activity against HIV1 harboring reverse transcriptase K103N mutant infected in human MT4 cells assessed as inhibition of virus-induced cell death measured after 5 days of infection by MTT method
    		[PMID: 24769348]
    MT4 EC50
    1460 nM
    Compound: 13, efavirenz
    Antiviral activity against HIV1 LAI with RT L100I and K103N mutation in MT4 cells by EGFP based replication assay
    Antiviral activity against HIV1 LAI with RT L100I and K103N mutation in MT4 cells by EGFP based replication assay
    		[PMID: 17223230]
    MT4 EC50
    15.9 nM
    Compound: EFV, DMP-266
    Antiviral activity against HIV1 NL4-3 infected in human MT4 cells assessed as reduction in virus-induced cell death by MTT assay
    Antiviral activity against HIV1 NL4-3 infected in human MT4 cells assessed as reduction in virus-induced cell death by MTT assay
    		[PMID: 25418038]
    MT4 EC50
    15.9 nM
    Compound: EFV, DMP-266
    Antiviral activity against HIV1 NL4.3 infected in human MT4 cells assessed as inhibition of virus-induced cell death measured after 5 days of infection by MTT method
    Antiviral activity against HIV1 NL4.3 infected in human MT4 cells assessed as inhibition of virus-induced cell death measured after 5 days of infection by MTT method
    		[PMID: 24769348]
    MT4 EC50
    155 nM
    Compound: 3, EFV
    Antiviral activity against HIV1 3B expressing reverse transcriptase K103N + Y181C mutant infected in human MT4 cells assessed as reduction in virus-induced cytopathogenicity incubated for 4 days by MTT method
    Antiviral activity against HIV1 3B expressing reverse transcriptase K103N + Y181C mutant infected in human MT4 cells assessed as reduction in virus-induced cytopathogenicity incubated for 4 days by MTT method
    		[PMID: 26276435]
    MT4 EC50
    155 nM
    Compound: EFV
    Antiviral activity against HIV-1 RES056 harboring reverse transcriptase K103N/Y181C double mutant infected in human MT4 cells assessed as protection from virus-induced cytopathicity after 4 days by MTT assay
    Antiviral activity against HIV-1 RES056 harboring reverse transcriptase K103N/Y181C double mutant infected in human MT4 cells assessed as protection from virus-induced cytopathicity after 4 days by MTT assay
    		[PMID: 25935383]
    MT4 EC50
    156.1 nM
    Compound: EFV
    Antiviral activity against HIV1 RES056 harboring reverse transcriptase K103N/Y181C double mutant infected in human MT4 cells assessed as protection against virus induced cytotoxicity after 5 days by MTT assay
    Antiviral activity against HIV1 RES056 harboring reverse transcriptase K103N/Y181C double mutant infected in human MT4 cells assessed as protection against virus induced cytotoxicity after 5 days by MTT assay
    		[PMID: 27541578]
    MT4 EC50
    157 nM
    Compound: EFV
    Antiviral activity against NNRTI-resistant HIV1 harboring reverse transcriptase Y188L mutant infected in human MT4 cells assessed as inhibition of viral replication after 72 hrs by HeLa-CD4-LTR-beta-gal assay
    Antiviral activity against NNRTI-resistant HIV1 harboring reverse transcriptase Y188L mutant infected in human MT4 cells assessed as inhibition of viral replication after 72 hrs by HeLa-CD4-LTR-beta-gal assay
    		[PMID: 23137340]
    MT4 EC50
    157.5 nM
    Compound: EFV
    Antiviral activity against HIV1 containing reverse transcriptase Y181C mutant infected in human MT4 cells assessed as inhibition of virus-induced cytopathicity measured 5 days post infection by MTT assay
    Antiviral activity against HIV1 containing reverse transcriptase Y181C mutant infected in human MT4 cells assessed as inhibition of virus-induced cytopathicity measured 5 days post infection by MTT assay
    		[PMID: 22712652]
    MT4 IC50
    158 nM
    Compound: EFV
    Antiviral activity against HIV1 HXB2 harboring Y188L mutant reverse transcriptase infected in human MT4 cells after 5 days by MTT assay
    Antiviral activity against HIV1 HXB2 harboring Y188L mutant reverse transcriptase infected in human MT4 cells after 5 days by MTT assay
    		[PMID: 19645483]
    MT4 IC50
    158 nM
    Compound: EFV
    Antiviral activity against HIV1 HXB2 harboring 227C mutant reverse transcriptase infected in human MT4 cells after 5 days by MTT assay
    Antiviral activity against HIV1 HXB2 harboring 227C mutant reverse transcriptase infected in human MT4 cells after 5 days by MTT assay
    		[PMID: 19645483]
    MT4 IC50
    158 nM
    Compound: EFV
    Antiviral activity against HIV1 HXB2 harboring 101E and K103N mutant reverse transcriptase infected in human MT4 cells after 5 days by MTT assay
    Antiviral activity against HIV1 HXB2 harboring 101E and K103N mutant reverse transcriptase infected in human MT4 cells after 5 days by MTT assay
    		[PMID: 19645483]
    MT4 IC50
    158 nM
    Compound: EFV, efavirenz
    Antiviral activity against HIV1 RT 188L mutant assessed as inhibition of viral-induced cytopathicity in MT4 cells by MTT method
    Antiviral activity against HIV1 RT 188L mutant assessed as inhibition of viral-induced cytopathicity in MT4 cells by MTT method
    		[PMID: 17157017]
    MT4 EC50
    160 nM
    Compound: EFV, DMP-266
    Antiviral activity against HIV1 NL4-3 expressing reverse transcriptase Y181C mutant infected in human MT4 cells assessed as reduction in virus-induced cell death by MTT assay
    Antiviral activity against HIV1 NL4-3 expressing reverse transcriptase Y181C mutant infected in human MT4 cells assessed as reduction in virus-induced cell death by MTT assay
    		[PMID: 25418038]
    MT4 EC50
    160 nM
    Compound: EFV, DMP-266
    Antiviral activity against HIV1 harboring reverse transcriptase Y181C mutant infected in human MT4 cells assessed as inhibition of virus-induced cell death measured after 5 days of infection by MTT method
    Antiviral activity against HIV1 harboring reverse transcriptase Y181C mutant infected in human MT4 cells assessed as inhibition of virus-induced cell death measured after 5 days of infection by MTT method
    		[PMID: 24769348]
    MT4 EC50
    1600 nM
    Compound: EFV
    Antiviral activity against HIV1 harboring reverse transcriptase Y188L mutant infected in human MT4 cells assessed as inhibition of virus-induced cytopathic effect after 5 days by MTT assay
    Antiviral activity against HIV1 harboring reverse transcriptase Y188L mutant infected in human MT4 cells assessed as inhibition of virus-induced cytopathic effect after 5 days by MTT assay
    		[PMID: 22428851]
    MT4 EC50
    1615 nM
    Compound: EFV
    Antiviral activity against HIV 1 harboring reverse transcriptase Y188L mutant infected in human MT4 cells assessed as inhibition of virus-induced cytopathic effect after 5 days by MTT assay
    Antiviral activity against HIV 1 harboring reverse transcriptase Y188L mutant infected in human MT4 cells assessed as inhibition of virus-induced cytopathic effect after 5 days by MTT assay
    		[PMID: 21438533]
    MT4 IC50
    18 nM
    Compound: efv
    Antiviral activity against wild type HIV-1 LAI infected in human MT4 cells assessed as inhibition of viral replication after 5 days by MTT assay in presence of 40% human serum
    Antiviral activity against wild type HIV-1 LAI infected in human MT4 cells assessed as inhibition of viral replication after 5 days by MTT assay in presence of 40% human serum
    		10.1039/C0MD00009D
    MT4 EC50
    18 nM
    Compound: EFV
    Antiviral activity against wild type HIV HXB2 in human MT4 cells assessed as protection against virus-induced cell death after 5 days by MTT assay in presence of 40% human serum
    Antiviral activity against wild type HIV HXB2 in human MT4 cells assessed as protection against virus-induced cell death after 5 days by MTT assay in presence of 40% human serum
    		[PMID: 19007201]
    MT4 IC50
    18.1 nM
    Compound: Efavirenz
    Antiviral activity against wild type HIV1 infected in human MT4 cells assessed as reduction of virus-induced cytopathic effect by replication assay in presence of 40% human serum
    Antiviral activity against wild type HIV1 infected in human MT4 cells assessed as reduction of virus-induced cytopathic effect by replication assay in presence of 40% human serum
    		[PMID: 20829038]
    MT4 IC50
    2 nM
    Compound: efv
    Antiviral activity against wild type HIV-1 LAI infected in human MT4 cells assessed as inhibition of viral replication after 5 days by MTT assay
    Antiviral activity against wild type HIV-1 LAI infected in human MT4 cells assessed as inhibition of viral replication after 5 days by MTT assay
    		10.1039/C0MD00009D
    MT4 EC50
    2 nM
    Compound: EFV
    Antiviral activity against NNRTI-resistant HIV HXB2 with reverse transcriptase 138K mutation in human MT4 cells assessed as protection against virus-induced cell death after 5 days by MTT assay
    Antiviral activity against NNRTI-resistant HIV HXB2 with reverse transcriptase 138K mutation in human MT4 cells assessed as protection against virus-induced cell death after 5 days by MTT assay
    		[PMID: 19007201]
    MT4 EC50
    2 nM
    Compound: EFV
    Antiviral activity against NNRTI-resistant HIV HXB2 with reverse transcriptase 181I mutation in human MT4 cells assessed as protection against virus-induced cell death after 5 days by MTT assay
    Antiviral activity against NNRTI-resistant HIV HXB2 with reverse transcriptase 181I mutation in human MT4 cells assessed as protection against virus-induced cell death after 5 days by MTT assay
    		[PMID: 19007201]
    MT4 EC50
    2.1 nM
    Compound: EFV
    Antiviral activity against wild type HIV1 3B infected in human MT4 cells assessed as protection against virus-induced cytopathogenicity after 4 days by MTT assay
    Antiviral activity against wild type HIV1 3B infected in human MT4 cells assessed as protection against virus-induced cytopathogenicity after 4 days by MTT assay
    		[PMID: 20598556]
    MT4 EC50
    2.2 nM
    Compound: EFV
    Antiviral activity against wild type HIV1 LAI infected in human MT4 cells assessed as protection against virus-induced cytopathogenicity after 4 days by MTT assay
    Antiviral activity against wild type HIV1 LAI infected in human MT4 cells assessed as protection against virus-induced cytopathogenicity after 4 days by MTT assay
    		[PMID: 20598556]
    MT4 EC50
    20 nM
    Compound: EFV
    Antiviral activity against NNRTI-resistant HIV1 harboring reverse transcriptase K103N mutant infected in human MT4 cells assessed as inhibition of viral replication after 72 hrs by HeLa-CD4-LTR-beta-gal assay
    Antiviral activity against NNRTI-resistant HIV1 harboring reverse transcriptase K103N mutant infected in human MT4 cells assessed as inhibition of viral replication after 72 hrs by HeLa-CD4-LTR-beta-gal assay
    		[PMID: 23137340]
    MT4 CC50
    20.6 μM
    Compound: Efavirenz
    Cytotoxicity against human MT4 cells assessed as decrease in cell viability after 5 days by cell titer glo based luciferase reporter gene assay
    Cytotoxicity against human MT4 cells assessed as decrease in cell viability after 5 days by cell titer glo based luciferase reporter gene assay
    		[PMID: 27371922]
    MT4 ED50
    200 nM
    Compound: EFV
    Antiviral activity against HIV1 RT K103N-Y181C mutant in MT4 cells by MTT assay
    Antiviral activity against HIV1 RT K103N-Y181C mutant in MT4 cells by MTT assay
    		[PMID: 17803291]
    MT4 EC50
    22 nM
    Compound: EFV, DMP-266
    Antiviral activity against HIV1 NL4-3 expressing reverse transcriptase L100I mutant infected in human MT4 cells assessed as reduction in virus-induced cell death by MTT assay
    Antiviral activity against HIV1 NL4-3 expressing reverse transcriptase L100I mutant infected in human MT4 cells assessed as reduction in virus-induced cell death by MTT assay
    		[PMID: 25418038]
    MT4 EC50
    22 nM
    Compound: EFV, DMP-266
    Antiviral activity against HIV1 harboring reverse transcriptase L1001 mutant infected in human MT4 cells assessed as inhibition of virus-induced cell death measured after 5 days of infection by MTT method
    Antiviral activity against HIV1 harboring reverse transcriptase L1001 mutant infected in human MT4 cells assessed as inhibition of virus-induced cell death measured after 5 days of infection by MTT method
    		[PMID: 24769348]
    MT4 EC50
    222 nM
    Compound: EFV
    Antiviral activity against HIV1 with reverse transcriptase Y188L mutant infected in human MT4 cells assessed as protection against virus-induced cytopathogenicity after 4 days by MTT assay
    Antiviral activity against HIV1 with reverse transcriptase Y188L mutant infected in human MT4 cells assessed as protection against virus-induced cytopathogenicity after 4 days by MTT assay
    		[PMID: 20598556]
    MT4 IC50
    25.1 nM
    Compound: EFV
    Antiviral activity against HIV1 HXB2 harboring 227L and 106A mutant reverse transcriptase infected in human MT4 cells after 5 days by MTT assay
    Antiviral activity against HIV1 HXB2 harboring 227L and 106A mutant reverse transcriptase infected in human MT4 cells after 5 days by MTT assay
    		[PMID: 19645483]
    MT4 IC50
    251 nM
    Compound: EFV
    Antiviral activity against HIV1 HXB2 harboring 190S mutant reverse transcriptase infected in human MT4 cells after 5 days by MTT assay
    Antiviral activity against HIV1 HXB2 harboring 190S mutant reverse transcriptase infected in human MT4 cells after 5 days by MTT assay
    		[PMID: 19645483]
    MT4 IC50
    3 nM
    Compound: efv
    Antiviral activity against NNRTI-resistant HIV-1 LAI harboring reverse transcriptase Y181C mutant infected in human MT4 cells assessed as inhibition of viral replication after 5 days by MTT assay
    Antiviral activity against NNRTI-resistant HIV-1 LAI harboring reverse transcriptase Y181C mutant infected in human MT4 cells assessed as inhibition of viral replication after 5 days by MTT assay
    		10.1039/C0MD00009D
    MT4 EC50
    3 nM
    Compound: EFV
    Antiviral activity against NNRTI-resistant HIV HXB2 with reverse transcriptase 108I mutation in human MT4 cells assessed as protection against virus-induced cell death after 5 days by MTT assay
    Antiviral activity against NNRTI-resistant HIV HXB2 with reverse transcriptase 108I mutation in human MT4 cells assessed as protection against virus-induced cell death after 5 days by MTT assay
    		[PMID: 19007201]
    MT4 EC50
    3 nM
    Compound: EFV
    Antiviral activity against NNRTI-resistant HIV HXB2 with reverse transcriptase 181C mutation in human MT4 cells assessed as protection against virus-induced cell death after 5 days by MTT assay
    Antiviral activity against NNRTI-resistant HIV HXB2 with reverse transcriptase 181C mutation in human MT4 cells assessed as protection against virus-induced cell death after 5 days by MTT assay
    		[PMID: 19007201]
    MT4 ED50
    3 nM
    Compound: EFV
    Antiviral activity against HIV1 3B in MT4 cells by MTT assay
    Antiviral activity against HIV1 3B in MT4 cells by MTT assay
    		[PMID: 17803291]
    MT4 EC50
    3.17 nM
    Compound: EFV
    Antiviral activity against wild type HIV 1 NL4-3 infected in human MT4 cells assessed as inhibition of virus-induced cytopathic effect after 5 days by MTT assay
    Antiviral activity against wild type HIV 1 NL4-3 infected in human MT4 cells assessed as inhibition of virus-induced cytopathic effect after 5 days by MTT assay
    		[PMID: 21438533]
    MT4 EC50
    3.9 nM
    Compound: 13, efavirenz
    Antiviral activity against HIV1 LAI with RT Y181C mutation in MT4 cells by EGFP based replication assay
    Antiviral activity against HIV1 LAI with RT Y181C mutation in MT4 cells by EGFP based replication assay
    		[PMID: 17223230]
    MT4 IC50
    3.98 nM
    Compound: EFV
    Antiviral activity against HIV1 HXB2 harboring 100I mutant reverse transcriptase infected in human MT4 cells after 5 days by MTT assay
    Antiviral activity against HIV1 HXB2 harboring 100I mutant reverse transcriptase infected in human MT4 cells after 5 days by MTT assay
    		[PMID: 19645483]
    MT4 IC50
    3.98 nM
    Compound: EFV, efavirenz
    Antiviral activity against HIV1 RT 100I mutant assessed as inhibition of viral-induced cytopathicity in MT4 cells by MTT method
    Antiviral activity against HIV1 RT 100I mutant assessed as inhibition of viral-induced cytopathicity in MT4 cells by MTT method
    		[PMID: 17157017]
    MT4 CC50
    30 μM
    Compound: efavirenz
    Protection against HIV1 HTLV 3B-induced cytopathogenicity in human MT4 cells by MTT assay
    Protection against HIV1 HTLV 3B-induced cytopathogenicity in human MT4 cells by MTT assay
    		[PMID: 17904371]
    MT4 EC50
    31 nM
    Compound: 13, efavirenz
    Antiviral activity against HIV1 LAI with RT L100I mutation in MT4 cells by EGFP based replication assay
    Antiviral activity against HIV1 LAI with RT L100I mutation in MT4 cells by EGFP based replication assay
    		[PMID: 17223230]
    MT4 EC50
    315 nM
    Compound: EFV
    Antiviral activity against HIV1 containing reverse transcriptase Y188L mutant infected in human MT4 cells assessed as inhibition of virus-induced cytopathicity measured 5 days post infection by MTT assay
    Antiviral activity against HIV1 containing reverse transcriptase Y188L mutant infected in human MT4 cells assessed as inhibition of virus-induced cytopathicity measured 5 days post infection by MTT assay
    		[PMID: 22712652]
    MT4 CC50
    3167.8 nM
    Compound: EFV
    Cytotoxicity against human MT4 cells assessed as cell viability by MTT assay
    Cytotoxicity against human MT4 cells assessed as cell viability by MTT assay
    		[PMID: 21438533]
    MT4 EC50
    32 nM
    Compound: EFV
    Antiviral activity against HIV1 with reverse transcriptase L100I mutant infected in human MT4 cells assessed as protection against virus-induced cytopathogenicity after 4 days by MTT assay
    Antiviral activity against HIV1 with reverse transcriptase L100I mutant infected in human MT4 cells assessed as protection against virus-induced cytopathogenicity after 4 days by MTT assay
    		[PMID: 20598556]
    MT4 CC50
    3200 nM
    Compound: EFV
    Cytotoxicity against human MT4 cells after 5 days by MTT assay
    Cytotoxicity against human MT4 cells after 5 days by MTT assay
    		[PMID: 22428851]
    MT4 CC50
    32314 nM
    Compound: 13, efavirenz
    Cytotoxicity against human MT4 cells after 3 days by EGFP based replication assay
    Cytotoxicity against human MT4 cells after 3 days by EGFP based replication assay
    		[PMID: 17223230]
    MT4 EC50
    340 nM
    Compound: EFV
    Antiviral activity against HIV1 harboring reverse transcriptase K103N mutant infected in human MT4 cells assessed as inhibition of virus-induced cytopathic effect after 5 days by MTT assay
    Antiviral activity against HIV1 harboring reverse transcriptase K103N mutant infected in human MT4 cells assessed as inhibition of virus-induced cytopathic effect after 5 days by MTT assay
    		[PMID: 22428851]
    MT4 EC50
    343.4 nM
    Compound: EFV
    Antiviral activity against HIV 1 harboring reverse transcriptase K103N mutant infected in human MT4 cells assessed as inhibition of virus-induced cytopathic effect after 5 days by MTT assay
    Antiviral activity against HIV 1 harboring reverse transcriptase K103N mutant infected in human MT4 cells assessed as inhibition of virus-induced cytopathic effect after 5 days by MTT assay
    		[PMID: 21438533]
    MT4 EC50
    348.5 nM
    Compound: EFV
    Antiviral activity against HIV1 3B harboring reverse transcriptase F227L/V106A double mutant infected in human MT4 cells assessed as protection against virus induced cytotoxicity after 5 days by MTT assay
    Antiviral activity against HIV1 3B harboring reverse transcriptase F227L/V106A double mutant infected in human MT4 cells assessed as protection against virus induced cytotoxicity after 5 days by MTT assay
    		[PMID: 27541578]
    MT4 CC50
    35 μM
    Compound: EFV
    Cytotoxicity against Homo sapiens (human) MT4 cells after 96 hr by MTT assay
    Cytotoxicity against Homo sapiens (human) MT4 cells after 96 hr by MTT assay
    		10.1007/s00044-008-9149-5
    MT4 CC50
    35 μM
    Compound: EFV
    Cytotoxicity against human MT4 cells assessed as reduction of cell viability after 96 hrs by MTT assay
    Cytotoxicity against human MT4 cells assessed as reduction of cell viability after 96 hrs by MTT assay
    		[PMID: 19781821]
    MT4 CC50
    37 μM
    Compound: EFV
    Cytotoxicity against human MT4 cells assessed as cell viability after 96 hrs by MTT method
    Cytotoxicity against human MT4 cells assessed as cell viability after 96 hrs by MTT method
    		[PMID: 25913116]
    MT4 CC50
    37 μM
    Compound: EFV
    Cytotoxicity against human MT4 cells after 96 hrs by MTT assay
    Cytotoxicity against human MT4 cells after 96 hrs by MTT assay
    		[PMID: 22884523]
    MT4 CC50
    38 μM
    Compound: EFV
    Cytotoxicity against human MT4 cells assessed as cell viability after 96 hrs by MTT assay
    Cytotoxicity against human MT4 cells assessed as cell viability after 96 hrs by MTT assay
    		[PMID: 26443549]
    MT4 CC50
    38 μM
    Compound: EFV
    Cytotoxicity against mock-infected human MT4 cells after 96 hrs by MTT assay
    Cytotoxicity against mock-infected human MT4 cells after 96 hrs by MTT assay
    		[PMID: 25082514]
    MT4 IC50
    39.8 nM
    Compound: EFV
    Antiviral activity against HIV1 HXB2 harboring K103N mutant reverse transcriptase infected in human MT4 cells after 5 days by MTT assay
    Antiviral activity against HIV1 HXB2 harboring K103N mutant reverse transcriptase infected in human MT4 cells after 5 days by MTT assay
    		[PMID: 19645483]
    MT4 IC50
    39.8 nM
    Compound: EFV
    Antiviral activity against HIV1 HXB2 harboring 106A mutant reverse transcriptase infected in human MT4 cells after 5 days by MTT assay
    Antiviral activity against HIV1 HXB2 harboring 106A mutant reverse transcriptase infected in human MT4 cells after 5 days by MTT assay
    		[PMID: 19645483]
    MT4 IC50
    39.8 nM
    Compound: EFV
    Antiviral activity against HIV1 HXB2 harboring K103N and Y181C mutant reverse transcriptase infected in human MT4 cells after 5 days by MTT assay
    Antiviral activity against HIV1 HXB2 harboring K103N and Y181C mutant reverse transcriptase infected in human MT4 cells after 5 days by MTT assay
    		[PMID: 19645483]
    MT4 IC50
    39.8 nM
    Compound: EFV, efavirenz
    Antiviral activity against HIV1 with RT 103N mutant assessed as inhibition of viral-induced cytopathicity in MT4 cells by MTT method
    Antiviral activity against HIV1 with RT 103N mutant assessed as inhibition of viral-induced cytopathicity in MT4 cells by MTT method
    		[PMID: 17157017]
    MT4 IC50
    39.8 nM
    Compound: EFV, efavirenz
    Antiviral activity against HIV1 RT 103N/181C mutant assessed as inhibition of viral-induced cytopathicity in MT4 cells by MTT method
    Antiviral activity against HIV1 RT 103N/181C mutant assessed as inhibition of viral-induced cytopathicity in MT4 cells by MTT method
    		[PMID: 17157017]
    MT4 EC50
    4 nM
    Compound: EFV
    Antiviral activity against NNRTI-resistant HIV HXB2 with reverse transcriptase 188H mutation in human MT4 cells assessed as protection against virus-induced cell death after 5 days by MTT assay
    Antiviral activity against NNRTI-resistant HIV HXB2 with reverse transcriptase 188H mutation in human MT4 cells assessed as protection against virus-induced cell death after 5 days by MTT assay
    		[PMID: 19007201]
    MT4 EC50
    4.1 nM
    Compound: 13, efavirenz
    Antiviral activity against HIV1 LAI with RT F227C and V106A mutation in MT4 cells by EGFP based replication assay
    Antiviral activity against HIV1 LAI with RT F227C and V106A mutation in MT4 cells by EGFP based replication assay
    		[PMID: 17223230]
    MT4 CC50
    40 μM
    Compound: Efavirenz
    Cytotoxicity against human MT4 cells assessed as reduction in cell viability after 48 to 96 hrs by MTT assay
    Cytotoxicity against human MT4 cells assessed as reduction in cell viability after 48 to 96 hrs by MTT assay
    		[PMID: 29339251]
    MT4 CC50
    40 μM
    Compound: EFV
    Cytotoxicity against human MT4 cells assessed as decrease in cell viability after 96 hrs by MTT assay
    Cytotoxicity against human MT4 cells assessed as decrease in cell viability after 96 hrs by MTT assay
    		[PMID: 29028528]
    MT4 CC50
    40 μM
    Compound: EFV
    Cytotoxicity against human MT4 cells assessed as reduction in cell proliferation after 96 hrs by MTT assay
    Cytotoxicity against human MT4 cells assessed as reduction in cell proliferation after 96 hrs by MTT assay
    		[PMID: 26479028]
    MT4 CC50
    40 μM
    Compound: efavirenz
    Cytotoxicity against mock-infected human MT4 cells assessed as reduction in cell viability after 96 hrs by MTT assay
    Cytotoxicity against mock-infected human MT4 cells assessed as reduction in cell viability after 96 hrs by MTT assay
    		[PMID: 26358281]
    MT4 CC50
    40 μM
    Compound: EFV
    Cytotoxicity against mock-infected human MT4 cells assessed as reduction in proliferation after 96 hrs by MTT method
    Cytotoxicity against mock-infected human MT4 cells assessed as reduction in proliferation after 96 hrs by MTT method
    		[PMID: 25014745]
    MT4 CC50
    40 μM
    Compound: EFV, DMP266, L-743,726
    Cytotoxicity against human MT4 cells after 96 hrs by MTT assay
    Cytotoxicity against human MT4 cells after 96 hrs by MTT assay
    		[PMID: 24805780]
    MT4 CC50
    40 μM
    Compound: Efavirenz
    Cytotoxicity against human MT4 cells after 96 hrs by MTT assay
    Cytotoxicity against human MT4 cells after 96 hrs by MTT assay
    		[PMID: 22513121]
    MT4 CC50
    40 μM
    Compound: EFV
    Cytotoxicity against human MT4 cells after 96 hrs by MTT assay
    Cytotoxicity against human MT4 cells after 96 hrs by MTT assay
    		[PMID: 22047799]
    MT4 CC50
    45 μM
    Compound: EFV
    Cytotoxicity against human MT4 cells assessed as reduction of cell viability after 4 days by MTT assay
    Cytotoxicity against human MT4 cells assessed as reduction of cell viability after 4 days by MTT assay
    		[PMID: 19775780]
    MT4 CC50
    45 μM
    Compound: Efavirenz
    Cytotoxicity against human MT4 cells after 96 hrs by MTT assay
    Cytotoxicity against human MT4 cells after 96 hrs by MTT assay
    		[PMID: 24489455]
    MT4 EC50
    46.4 nM
    Compound: 13, efavirenz
    Antiviral activity against HIV1 LAI with RT K103N mutation in MT4 cells by EGFP based replication assay
    Antiviral activity against HIV1 LAI with RT K103N mutation in MT4 cells by EGFP based replication assay
    		[PMID: 17223230]
    MT4 EC50
    46.9 nM
    Compound: 13, efavirenz
    Antiviral activity against HIV1 LAI with RT F227C mutation in MT4 cells by EGFP based replication assay
    Antiviral activity against HIV1 LAI with RT F227C mutation in MT4 cells by EGFP based replication assay
    		[PMID: 17223230]
    MT4 EC50
    5 nM
    Compound: EFV
    Antiviral activity against wild type HIV1 3B harboring reverse transcriptase infected in human MT4 cells assessed as protection against virus induced cytotoxicity after 5 days by MTT assay
    Antiviral activity against wild type HIV1 3B harboring reverse transcriptase infected in human MT4 cells assessed as protection against virus induced cytotoxicity after 5 days by MTT assay
    		[PMID: 27541578]
    MT4 IC50
    5.01 nM
    Compound: EFV
    Antiviral activity against HIV1 HXB2 harboring 179E mutant reverse transcriptase infected in human MT4 cells after 5 days by MTT assay
    Antiviral activity against HIV1 HXB2 harboring 179E mutant reverse transcriptase infected in human MT4 cells after 5 days by MTT assay
    		[PMID: 19645483]
    MT4 EC50
    5.2 nM
    Compound: EFV
    Antiviral activity against HIV1 3B harboring reverse transcriptase E138K mutant infected in human MT4 cells assessed as protection against virus induced cytotoxicity after 5 days by MTT assay
    Antiviral activity against HIV1 3B harboring reverse transcriptase E138K mutant infected in human MT4 cells assessed as protection against virus induced cytotoxicity after 5 days by MTT assay
    		[PMID: 27541578]
    MT4 EC50
    5.4 nM
    Compound: EFV
    Antiviral activity against HIV1 with reverse transcriptase E138K mutant infected in human MT4 cells assessed as protection against virus-induced cytopathogenicity after 4 days by MTT assay
    Antiviral activity against HIV1 with reverse transcriptase E138K mutant infected in human MT4 cells assessed as protection against virus-induced cytopathogenicity after 4 days by MTT assay
    		[PMID: 20598556]
    MT4 EC50
    5.4 nM
    Compound: EFV
    Antiviral activity against HIV1 3B infected in human MT4 cells assessed as protection against virus-induced cytotoxicity after 5 days by MTT assay
    Antiviral activity against HIV1 3B infected in human MT4 cells assessed as protection against virus-induced cytotoxicity after 5 days by MTT assay
    		[PMID: 22405288]
    MT4 EC50
    5.7 nM
    Compound: EFV
    Antiviral activity against HIV1 with reverse transcriptase Y181C mutant infected in human MT4 cells assessed as protection against virus-induced cytopathogenicity after 4 days by MTT assay
    Antiviral activity against HIV1 with reverse transcriptase Y181C mutant infected in human MT4 cells assessed as protection against virus-induced cytopathogenicity after 4 days by MTT assay
    		[PMID: 20598556]
    MT4 IC50
    5.7 nM
    Compound: Efavirenz
    Antiviral activity against HIV1 harboring reverse transcriptase V106A mutant infected in human MT4 cells assessed as reduction of virus-induced cytopathic effect by replication assay in presence of 10% FBS
    Antiviral activity against HIV1 harboring reverse transcriptase V106A mutant infected in human MT4 cells assessed as reduction of virus-induced cytopathic effect by replication assay in presence of 10% FBS
    		[PMID: 20829038]
    MT4 EC50
    514.8 nM
    Compound: EFV
    Antiviral activity against HIV1 3B harboring reverse transcriptase Y188L mutant infected in human MT4 cells assessed as protection against virus induced cytotoxicity after 5 days by MTT assay
    Antiviral activity against HIV1 3B harboring reverse transcriptase Y188L mutant infected in human MT4 cells assessed as protection against virus induced cytotoxicity after 5 days by MTT assay
    		[PMID: 27541578]
    MT4 EC50
    55 nM
    Compound: 13, efavirenz
    Antiviral activity against HIV1 LAI with RT Y188L mutation in MT4 cells by EGFP based replication assay
    Antiviral activity against HIV1 LAI with RT Y188L mutation in MT4 cells by EGFP based replication assay
    		[PMID: 17223230]
    MT4 EC50
    55 nM
    Compound: 13, efavirenz
    Antiviral activity against HIV1 LAI with RT K103N and Y181C mutation in MT4 cells by EGFP based replication assay
    Antiviral activity against HIV1 LAI with RT K103N and Y181C mutation in MT4 cells by EGFP based replication assay
    		[PMID: 17223230]
    MT4 EC50
    6 nM
    Compound: EFV
    Antiviral activity against NNRTI-resistant HIV HXB2 with reverse transcriptase 190A mutation in human MT4 cells assessed as protection against virus-induced cell death after 5 days by MTT assay
    Antiviral activity against NNRTI-resistant HIV HXB2 with reverse transcriptase 190A mutation in human MT4 cells assessed as protection against virus-induced cell death after 5 days by MTT assay
    		[PMID: 19007201]
    MT4 EC50
    6 nM
    Compound: EFV
    Antiviral activity against NNRTI-resistant HIV HXB2 with reverse transcriptase 106A mutation in human MT4 cells assessed as protection against virus-induced cell death after 5 days by MTT assay
    Antiviral activity against NNRTI-resistant HIV HXB2 with reverse transcriptase 106A mutation in human MT4 cells assessed as protection against virus-induced cell death after 5 days by MTT assay
    		[PMID: 19007201]
    MT4 EC50
    6 μM
    Compound: EFV, DMP266, L-743,726
    Antiviral activity against efavirenz-resistant HIV1 harboring RT 100I, 103R, 179D, 225H mutant infected in human MT4 cells assessed as inhibition of virus-induced cytopathogenicity after 4 days by MTT assay
    Antiviral activity against efavirenz-resistant HIV1 harboring RT 100I, 103R, 179D, 225H mutant infected in human MT4 cells assessed as inhibition of virus-induced cytopathogenicity after 4 days by MTT assay
    		[PMID: 24805780]
    MT4 CC50
    6 μM
    Compound: efavirenz
    Cytotoxicity against human MT4 cells by MTT assay
    Cytotoxicity against human MT4 cells by MTT assay
    		[PMID: 17803290]
    MT4 EC50
    6.3 nM
    Compound: 3, EFV
    Antiviral activity against HIV1 3B infected in human MT4 cells assessed as reduction in virus-induced cytopathogenicity incubated for 4 days by MTT method
    Antiviral activity against HIV1 3B infected in human MT4 cells assessed as reduction in virus-induced cytopathogenicity incubated for 4 days by MTT method
    		[PMID: 26276435]
    MT4 EC50
    6.3 nM
    Compound: EFV
    Antiviral activity against wild type HIV1 3B infected in human MT4 cells assessed as protection from virus-induced cytopathicity after 4 days by MTT assay
    Antiviral activity against wild type HIV1 3B infected in human MT4 cells assessed as protection from virus-induced cytopathicity after 4 days by MTT assay
    		[PMID: 25935383]
    MT4 EC50
    6.3 nM
    Compound: EFV
    Antiviral activity against HIV1 3B infected in human MT4 cells assessed as reduction in virus-induced cytopathic effect after 5 days by MTT assay
    Antiviral activity against HIV1 3B infected in human MT4 cells assessed as reduction in virus-induced cytopathic effect after 5 days by MTT assay
    		[PMID: 25626145]
    MT4 IC50
    6.3 nM
    Compound: EFV
    Antiviral activity against HIV1 HXB2 harboring 101E mutant reverse transcriptase infected in human MT4 cells after 5 days by MTT assay
    Antiviral activity against HIV1 HXB2 harboring 101E mutant reverse transcriptase infected in human MT4 cells after 5 days by MTT assay
    		[PMID: 19645483]
    MT4 EC50
    6.3 nM
    Compound: EFV
    Antiviral activity against HIV1 NL4-3 infected in human MT4 cells assessed as inhibition of virus-induced cytopathicity measured 5 days post infection by MTT assay
    Antiviral activity against HIV1 NL4-3 infected in human MT4 cells assessed as inhibition of virus-induced cytopathicity measured 5 days post infection by MTT assay
    		[PMID: 22712652]
    MT4 CC50
    6.3 μM
    Compound: Efavirenz
    Cytotoxicity against human MT4 cells assessed as reduction in cell viability after 5 days by MTT assay
    Cytotoxicity against human MT4 cells assessed as reduction in cell viability after 5 days by MTT assay
    		[PMID: 28314514]
    MT4 CC50
    6.3 μM
    Compound: EFV
    Cytotoxicity against mock-infected human MT4 cells after 5 days by MTT assay
    Cytotoxicity against mock-infected human MT4 cells after 5 days by MTT assay
    		[PMID: 24134904]
    MT4 CC50
    6.3356 μM
    Compound: EFV
    Cytotoxicity against human MT4 cells after 5 days by MTT assay
    Cytotoxicity against human MT4 cells after 5 days by MTT assay
    		[PMID: 24952305]
    MT4 CC50
    6.34 μM
    Compound: EFV
    Cytotoxicity against human MT4 cells assessed as cell growth inhibition incubated for 5 days by MTT assay
    Cytotoxicity against human MT4 cells assessed as cell growth inhibition incubated for 5 days by MTT assay
    		[PMID: 35679690]
    MT4 CC50
    6.34 μM
    Compound: EFV
    Cytotoxicity against human MT4 cells assessed as cell viability after 5 days by MTT assay
    Cytotoxicity against human MT4 cells assessed as cell viability after 5 days by MTT assay
    		[PMID: 24055077]
    MT4 EC50
    6.57 nM
    Compound: EFV
    Antiviral activity against HIV1 3B infected in human MT4 cells assessed as inhibition of virus-induced cytopathic effect after 5 days by MTT assay
    Antiviral activity against HIV1 3B infected in human MT4 cells assessed as inhibition of virus-induced cytopathic effect after 5 days by MTT assay
    		[PMID: 22591854]
    MT4 EC50
    6.6 μM
    Compound: EFV
    Antiviral activity against HIV-1 3B infected human MT4 cells assessed as inhibition in viral syncytium formation by MTT assay
    Antiviral activity against HIV-1 3B infected human MT4 cells assessed as inhibition in viral syncytium formation by MTT assay
    		[PMID: 22883027]
    MT4 EC50
    633.5 nM
    Compound: EFV
    Antiviral activity against multidrug-resistant HIV 1 IRLL98 harboring reverse transcriptase K101Q/Y181C/G190a mutant infected in human MT4 cells assessed as virus-induced cytopathic effect after 5 days by MTT assay
    Antiviral activity against multidrug-resistant HIV 1 IRLL98 harboring reverse transcriptase K101Q/Y181C/G190a mutant infected in human MT4 cells assessed as virus-induced cytopathic effect after 5 days by MTT assay
    		[PMID: 21438533]
    MT4 IC50
    65 nM
    Compound: efv
    Antiviral activity against NNRTI-resistant HIV-1 LAI harboring reverse transcriptase K103N mutant infected in human MT4 cells assessed as inhibition of viral replication after 5 days by MTT assay
    Antiviral activity against NNRTI-resistant HIV-1 LAI harboring reverse transcriptase K103N mutant infected in human MT4 cells assessed as inhibition of viral replication after 5 days by MTT assay
    		10.1039/C0MD00009D
    MT4 EC50
    66 nM
    Compound: EFV
    Antiviral activity against HIV1 with reverse transcriptase K103N mutant infected in human MT4 cells assessed as protection against virus-induced cytopathogenicity after 4 days by MTT assay
    Antiviral activity against HIV1 with reverse transcriptase K103N mutant infected in human MT4 cells assessed as protection against virus-induced cytopathogenicity after 4 days by MTT assay
    		[PMID: 20598556]
    MT4 EC50
    66 nM
    Compound: EFV
    Antiviral activity against NNRTI-resistant HIV HXB2 with reverse transcriptase 103N mutation in human MT4 cells assessed as protection against virus-induced cell death after 5 days by MTT assay
    Antiviral activity against NNRTI-resistant HIV HXB2 with reverse transcriptase 103N mutation in human MT4 cells assessed as protection against virus-induced cell death after 5 days by MTT assay
    		[PMID: 19007201]
    MT4 EC50
    69.3 nM
    Compound: EFV
    Antiviral activity against HIV1 containing reverse transcriptase K103N mutant infected in human MT4 cells assessed as inhibition of virus-induced cytopathicity measured 5 days post infection by MTT assay
    Antiviral activity against HIV1 containing reverse transcriptase K103N mutant infected in human MT4 cells assessed as inhibition of virus-induced cytopathicity measured 5 days post infection by MTT assay
    		[PMID: 22712652]
    MT4 EC50
    7 nM
    Compound: EFV
    Antiviral activity against NNRTI-resistant HIV HXB2 with reverse transcriptase 100I mutation in human MT4 cells assessed as protection against virus-induced cell death after 5 days by MTT assay
    Antiviral activity against NNRTI-resistant HIV HXB2 with reverse transcriptase 100I mutation in human MT4 cells assessed as protection against virus-induced cell death after 5 days by MTT assay
    		[PMID: 19007201]
    MT4 EC50
    7 μM
    Compound: EFV, DMP266, L-743,726
    Antiviral activity against TMC125-resistant HIV1 harboring RT 109M, 138K, 190E mutant infected in human MT4 cells assessed as inhibition of virus-induced cytopathogenicity after 4 days by MTT assay
    Antiviral activity against TMC125-resistant HIV1 harboring RT 109M, 138K, 190E mutant infected in human MT4 cells assessed as inhibition of virus-induced cytopathogenicity after 4 days by MTT assay
    		[PMID: 24805780]
    MT4 EC50
    7 μM
    Compound: EFV
    Antiviral activity against HIV1 EFV with reverse transcriptase K103R, V179D, P225H mutant infected in human MT4 cells assessed as protection against virus-induced cytopathogenicity after 4 days by MTT assay
    Antiviral activity against HIV1 EFV with reverse transcriptase K103R, V179D, P225H mutant infected in human MT4 cells assessed as protection against virus-induced cytopathogenicity after 4 days by MTT assay
    		[PMID: 19775780]
    MT4 EC50
    7.3 nM
    Compound: EFV
    Antiviral activity against wild type HIV1 NL4-3 infected in human MT4 cells assessed as inhibition of virus-induced cytopathic effect after 5 days by MTT assay
    Antiviral activity against wild type HIV1 NL4-3 infected in human MT4 cells assessed as inhibition of virus-induced cytopathic effect after 5 days by MTT assay
    		[PMID: 22428851]
    MT4 EC50
    760 nM
    Compound: EFV, DMP-266
    Antiviral activity against HIV1 NL4-3 expressing reverse transcriptase Y188L mutant infected in human MT4 cells assessed as reduction in virus-induced cell death by MTT assay
    Antiviral activity against HIV1 NL4-3 expressing reverse transcriptase Y188L mutant infected in human MT4 cells assessed as reduction in virus-induced cell death by MTT assay
    		[PMID: 25418038]
    MT4 EC50
    760 nM
    Compound: EFV, DMP-266
    Antiviral activity against HIV1 harboring reverse transcriptase Y188L mutant infected in human MT4 cells assessed as inhibition of virus-induced cell death measured after 5 days of infection by MTT method
    Antiviral activity against HIV1 harboring reverse transcriptase Y188L mutant infected in human MT4 cells assessed as inhibition of virus-induced cell death measured after 5 days of infection by MTT method
    		[PMID: 24769348]
    MT4 EC50
    8 nM
    Compound: EFV
    Antiviral activity against NNRTI-resistant HIV HXB2 with reverse transcriptase 179D mutation in human MT4 cells assessed as protection against virus-induced cell death after 5 days by MTT assay
    Antiviral activity against NNRTI-resistant HIV HXB2 with reverse transcriptase 179D mutation in human MT4 cells assessed as protection against virus-induced cell death after 5 days by MTT assay
    		[PMID: 19007201]
    MT4 EC50
    8.2 nM
    Compound: EFV
    Antiviral activity against HIV1 3B harboring reverse transcriptase Y181C mutant infected in human MT4 cells assessed as protection against virus induced cytotoxicity after 5 days by MTT assay
    Antiviral activity against HIV1 3B harboring reverse transcriptase Y181C mutant infected in human MT4 cells assessed as protection against virus induced cytotoxicity after 5 days by MTT assay
    		[PMID: 27541578]
    MT4 CC50
    80 μM
    Compound: Efavirenz
    Cytotoxic concentration that reduces the MT-4 cell viability by 50%
    Cytotoxic concentration that reduces the MT-4 cell viability by 50%
    		[PMID: 15149669]
    MT4 EC50
    80.1 nM
    Compound: EFV
    Antiviral activity against HIV1 3B harboring reverse transcriptase K103N mutant infected in human MT4 cells assessed as protection against virus induced cytotoxicity after 5 days by MTT assay
    Antiviral activity against HIV1 3B harboring reverse transcriptase K103N mutant infected in human MT4 cells assessed as protection against virus induced cytotoxicity after 5 days by MTT assay
    		[PMID: 27541578]
    MT4 IC50
    82.8 nM
    Compound: Efavirenz
    Antiviral activity against HIV1 harboring reverse transcriptase K103N/Y181C double mutant infected in human MT4 cells assessed as reduction of virus-induced cytopathic effect by replication assay in presence of 10% FBS
    Antiviral activity against HIV1 harboring reverse transcriptase K103N/Y181C double mutant infected in human MT4 cells assessed as reduction of virus-induced cytopathic effect by replication assay in presence of 10% FBS
    		[PMID: 20829038]
    MT4 EC50
    980 nM
    Compound: EFV
    Antiviral activity against HIV1 IRLL98 containing reverse transcriptase K101Q, Y181C and G190A mutant infected in human MT4 cells assessed as inhibition of virus-induced cytopathicity measured 5 days post infection by MTT assay
    Antiviral activity against HIV1 IRLL98 containing reverse transcriptase K101Q, Y181C and G190A mutant infected in human MT4 cells assessed as inhibition of virus-induced cytopathicity measured 5 days post infection by MTT assay
    		[PMID: 22712652]
    PBMC CC50
    > 100 μM
    Compound: EFV
    Cytotoxicity against HIV1 infected human PBMC cells assessed as reduction in cell viability after 7 days by MTT assay
    Cytotoxicity against HIV1 infected human PBMC cells assessed as reduction in cell viability after 7 days by MTT assay
    		[PMID: 27390064]
    PBMC EC50
    0.0003 μM
    Compound: EFV
    Antiviral activity against HIV1 subtype B-92US076 infected in 1 hr-pretreated PBMC cells assessed as inhibition of p24 antigen production measured on day 5 postinfection by ELISA
    Antiviral activity against HIV1 subtype B-92US076 infected in 1 hr-pretreated PBMC cells assessed as inhibition of p24 antigen production measured on day 5 postinfection by ELISA
    		[PMID: 18316521]
    PBMC EC50
    0.0004 μM
    Compound: EFV
    Antiviral activity against HIV1 subtype B-ASM 034 infected in 1 hr-pretreated PBMC cells assessed as inhibition of p24 antigen production measured on day 5 postinfection by ELISA
    Antiviral activity against HIV1 subtype B-ASM 034 infected in 1 hr-pretreated PBMC cells assessed as inhibition of p24 antigen production measured on day 5 postinfection by ELISA
    		[PMID: 18316521]
    PBMC EC50
    0.0005 μM
    Compound: EFV
    Antiviral activity against HIV1 subtype B-ASM 044 infected in 1 hr-pretreated PBMC cells assessed as inhibition of p24 antigen production measured on day 5 postinfection by ELISA
    Antiviral activity against HIV1 subtype B-ASM 044 infected in 1 hr-pretreated PBMC cells assessed as inhibition of p24 antigen production measured on day 5 postinfection by ELISA
    		[PMID: 18316521]
    PBMC EC50
    0.0007 μM
    Compound: EFV
    Antiviral activity against HIV1 subtype B-93US143 infected in 1 hr-pretreated PBMC cells assessed as inhibition of p24 antigen production measured on day 5 postinfection by ELISA
    Antiviral activity against HIV1 subtype B-93US143 infected in 1 hr-pretreated PBMC cells assessed as inhibition of p24 antigen production measured on day 5 postinfection by ELISA
    		[PMID: 18316521]
    PBMC EC50
    0.12 nM
    Compound: EFV
    Antiviral activity against Human immunodeficiency virus 1 subtype G isolate G3 infected in human PBMC cells by cell based assay
    Antiviral activity against Human immunodeficiency virus 1 subtype G isolate G3 infected in human PBMC cells by cell based assay
    		[PMID: 19933797]
    PBMC EC50
    0.15 nM
    Compound: EFV
    Antiviral activity against Human immunodeficiency virus 1 subtype F isolate 93BR019 infected in human PBMC cells by cell based assay
    Antiviral activity against Human immunodeficiency virus 1 subtype F isolate 93BR019 infected in human PBMC cells by cell based assay
    		[PMID: 19933797]
    PBMC EC50
    0.16 nM
    Compound: EFV
    Antiviral activity against Human immunodeficiency virus 1 subtype B isolate WEJO infected in human PBMC cells by cell based assay
    Antiviral activity against Human immunodeficiency virus 1 subtype B isolate WEJO infected in human PBMC cells by cell based assay
    		[PMID: 19933797]
    PBMC EC50
    0.19 nM
    Compound: EFV
    Antiviral activity against Human immunodeficiency virus 1 subtype C isolate 93MW959 infected in human PBMC cells by cell based assay
    Antiviral activity against Human immunodeficiency virus 1 subtype C isolate 93MW959 infected in human PBMC cells by cell based assay
    		[PMID: 19933797]
    PBMC EC50
    0.3 nM
    Compound: EFV
    Antiviral activity against Human immunodeficiency virus 1 subtype A isolate 92RW020 infected in human PBMC cells by cell based assay
    Antiviral activity against Human immunodeficiency virus 1 subtype A isolate 92RW020 infected in human PBMC cells by cell based assay
    		[PMID: 19933797]
    PBMC EC50
    0.34 nM
    Compound: EFV
    Antiviral activity against Human immunodeficiency virus 1 subtype D isolate 92UG035 infected in human PBMC cells by cell based assay
    Antiviral activity against Human immunodeficiency virus 1 subtype D isolate 92UG035 infected in human PBMC cells by cell based assay
    		[PMID: 19933797]
    PBMC EC50
    0.39 nM
    Compound: EFV
    Antiviral activity against Human immunodeficiency virus 1 subtype E isolate 93TH073 infected in human PBMC cells by cell based assay
    Antiviral activity against Human immunodeficiency virus 1 subtype E isolate 93TH073 infected in human PBMC cells by cell based assay
    		[PMID: 19933797]
    PBMC EC50
    0.42 nM
    Compound: EFV
    Antiviral activity against Human immunodeficiency virus 1 subtype F isolate 93BR029 infected in human PBMC cells by cell based assay
    Antiviral activity against Human immunodeficiency virus 1 subtype F isolate 93BR029 infected in human PBMC cells by cell based assay
    		[PMID: 19933797]
    PBMC EC50
    0.48 nM
    Compound: EFV
    Antiviral activity against Human immunodeficiency virus 1 subtype E isolate 92TH006 infected in human PBMC cells by cell based assay
    Antiviral activity against Human immunodeficiency virus 1 subtype E isolate 92TH006 infected in human PBMC cells by cell based assay
    		[PMID: 19933797]
    PBMC EC50
    0.52 nM
    Compound: EFV
    Antiviral activity against Human immunodeficiency virus 1 subtype G isolate RU132 infected in human PBMC cells by cell based assay
    Antiviral activity against Human immunodeficiency virus 1 subtype G isolate RU132 infected in human PBMC cells by cell based assay
    		[PMID: 19933797]
    PBMC EC50
    0.53 nM
    Compound: EFV
    Antiviral activity against Human immunodeficiency virus 1 subtype D isolate 92UG001 infected in human PBMC cells by cell based assay
    Antiviral activity against Human immunodeficiency virus 1 subtype D isolate 92UG001 infected in human PBMC cells by cell based assay
    		[PMID: 19933797]
    PBMC EC50
    0.62 nM
    Compound: EFV
    Antiviral activity against Human immunodeficiency virus 1 subtype A isolate 92UG029 infected in human PBMC cells by cell based assay
    Antiviral activity against Human immunodeficiency virus 1 subtype A isolate 92UG029 infected in human PBMC cells by cell based assay
    		[PMID: 19933797]
    PBMC EC50
    0.7 nM
    Compound: EFV
    Antiviral activity against Human immunodeficiency virus 1 subtype G isolate JV1083 infected in human PBMC cells by cell based assay
    Antiviral activity against Human immunodeficiency virus 1 subtype G isolate JV1083 infected in human PBMC cells by cell based assay
    		[PMID: 19933797]
    PBMC EC50
    0.72 nM
    Compound: EFV
    Antiviral activity against Human immunodeficiency virus 1 subtype D isolate 92UG024 infected in human PBMC cells by cell based assay
    Antiviral activity against Human immunodeficiency virus 1 subtype D isolate 92UG024 infected in human PBMC cells by cell based assay
    		[PMID: 19933797]
    PBMC EC50
    0.74 nM
    Compound: EFV
    Antiviral activity against Human immunodeficiency virus 1 subtype F isolate 93BR020 infected in human PBMC cells by cell based assay
    Antiviral activity against Human immunodeficiency virus 1 subtype F isolate 93BR020 infected in human PBMC cells by cell based assay
    		[PMID: 19933797]
    PBMC EC50
    0.76 nM
    Compound: EFV
    Antiviral activity against Human immunodeficiency virus 1 subtype B isolate JR-CSF infected in human PBMC cells by cell based assay
    Antiviral activity against Human immunodeficiency virus 1 subtype B isolate JR-CSF infected in human PBMC cells by cell based assay
    		[PMID: 19933797]
    PBMC EC50
    0.78 nM
    Compound: EFV
    Antiviral activity against Human immunodeficiency virus 1 subtype E isolate CMU08 infected in human PBMC cells by cell based assay
    Antiviral activity against Human immunodeficiency virus 1 subtype E isolate CMU08 infected in human PBMC cells by cell based assay
    		[PMID: 19933797]
    PBMC EC50
    1.11 nM
    Compound: EFV
    Antiviral activity against Human immunodeficiency virus 1 subtype A isolate 92UG037 infected in human PBMC cells by cell based assay
    Antiviral activity against Human immunodeficiency virus 1 subtype A isolate 92UG037 infected in human PBMC cells by cell based assay
    		[PMID: 19933797]
    PBMC EC50
    1.17 nM
    Compound: EFV
    Antiviral activity against Human immunodeficiency virus 1 subtype B isolate 93BR021 infected in human PBMC cells by cell based assay
    Antiviral activity against Human immunodeficiency virus 1 subtype B isolate 93BR021 infected in human PBMC cells by cell based assay
    		[PMID: 19933797]
    PBMC EC50
    1.47 nM
    Compound: EFV
    Antiviral activity against Human immunodeficiency virus 1 subtype C isolate 93IN101 infected in human PBMC cells by cell based assay
    Antiviral activity against Human immunodeficiency virus 1 subtype C isolate 93IN101 infected in human PBMC cells by cell based assay
    		[PMID: 19933797]
    PBMC EC50
    194 nM
    Compound: EFV
    Antiviral activity against Human immunodeficiency virus 1 subtype O isolate BCF03 infected in human PBMC cells by cell based assay
    Antiviral activity against Human immunodeficiency virus 1 subtype O isolate BCF03 infected in human PBMC cells by cell based assay
    		[PMID: 19933797]
    PBMC EC50
    2.08 nM
    Compound: EFV
    Antiviral activity against Human immunodeficiency virus 1 subtype C isolate 92BR025 infected in human PBMC cells by cell based assay
    Antiviral activity against Human immunodeficiency virus 1 subtype C isolate 92BR025 infected in human PBMC cells by cell based assay
    		[PMID: 19933797]
    PBMC EC50
    57.2 nM
    Compound: EFV
    Antiviral activity against Human immunodeficiency virus 1 subtype O isolate BCF02 infected in human PBMC cells by cell based assay
    Antiviral activity against Human immunodeficiency virus 1 subtype O isolate BCF02 infected in human PBMC cells by cell based assay
    		[PMID: 19933797]
    PBMC EC50
    72.8 nM
    Compound: EFV
    Antiviral activity against Human immunodeficiency virus 1 subtype O misolate BCF01 infected in human PBMC cells by cell based assay
    Antiviral activity against Human immunodeficiency virus 1 subtype O misolate BCF01 infected in human PBMC cells by cell based assay
    		[PMID: 19933797]
    SUP-T1 EC50
    0.5 nM
    Compound: EFV
    Antiviral activity against HIV1 infected in SupT1 cells assessed as accumulation of integrated junction products after 48 hrs by Alu-PCR assay
    Antiviral activity against HIV1 infected in SupT1 cells assessed as accumulation of integrated junction products after 48 hrs by Alu-PCR assay
    		[PMID: 19104010]
    SUP-T1 IC50
    1.4 nM
    Compound: Efavirenz
    Antiviral activity against VSV-G pseudotyped HIV1 infected in human SupT1 cells after 48 hrs by luciferase reporter gene assay
    Antiviral activity against VSV-G pseudotyped HIV1 infected in human SupT1 cells after 48 hrs by luciferase reporter gene assay
    		[PMID: 27434426]
    SUP-T1 EC50
    5 nM
    Compound: EFV
    Antiviral activity against HIV1 infected in SupT1 cells assessed as accumulation of late RT products after 12 hrs
    Antiviral activity against HIV1 infected in SupT1 cells assessed as accumulation of late RT products after 12 hrs
    		[PMID: 19104010]
    T-cell EC50
    15 nM
    Compound: Efavirenz
    Antiviral activity against HIV-1 X4 expressing wild-type reverse transcriptase infected in human CD4+ T cells for 3 days by FACS analysis
    Antiviral activity against HIV-1 X4 expressing wild-type reverse transcriptase infected in human CD4+ T cells for 3 days by FACS analysis
    		[PMID: 26487915]
    T-cell EC50
    41 nM
    Compound: Efavirenz
    Antiviral activity against HIV-1 X4 expressing reverse transcriptase Y181C mutant infected in human CD4+ T cells for 3 days by FACS analysis
    Antiviral activity against HIV-1 X4 expressing reverse transcriptase Y181C mutant infected in human CD4+ T cells for 3 days by FACS analysis
    		[PMID: 26487915]
    T-cell EC50
    836 nM
    Compound: Efavirenz
    Antiviral activity against HIV-1 X4 expressing reverse transcriptase K103N mutant infected in human CD4+ T cells for 3 days by FACS analysis
    Antiviral activity against HIV-1 X4 expressing reverse transcriptase K103N mutant infected in human CD4+ T cells for 3 days by FACS analysis
    		[PMID: 26487915]
    T-cell EC50
    870 nM
    Compound: Efavirenz
    Antiviral activity against HIV-1 X4 expressing reverse transcriptase K101P mutant infected in human CD4+ T cells for 3 days by FACS analysis
    Antiviral activity against HIV-1 X4 expressing reverse transcriptase K101P mutant infected in human CD4+ T cells for 3 days by FACS analysis
    		[PMID: 26487915]
    TZM CC50
    > 50 μM
    Compound: Efavirenz
    Cytotoxicity against human TZM-bl cells assessed as cell viability after 48 hrs by WST1 assay
    Cytotoxicity against human TZM-bl cells assessed as cell viability after 48 hrs by WST1 assay
    		[PMID: 25199582]
    TZM CC50
    > 6300 nM
    Compound: 3; EFV
    Cytotoxicity against human TZM-bl cells assessed as reduction in cell viability measured after 1 day by CytoTox-Glo assay
    Cytotoxicity against human TZM-bl cells assessed as reduction in cell viability measured after 1 day by CytoTox-Glo assay
    		[PMID: 33340914]
    Vero CC50
    > 100 μM
    Compound: EFV
    Cytotoxicity against HIV1 infected African green monkey Vero cells assessed as reduction in cell viability after 7 days by MTT assay
    Cytotoxicity against HIV1 infected African green monkey Vero cells assessed as reduction in cell viability after 7 days by MTT assay
    		[PMID: 27390064]
    體外研究
    (In Vitro)

    Efavirenz (L-743726) is found to be capable of inhibiting, with 95% inhibitory concentrations of ≤ 1.5μM, a panel of nonnucleoside reverse transcriptase (RT) inhibitors (NNRTIs)-resistant mutant viruses, each of which expresses a single RT amino acid substitution. Efavirenz is also tested for its activity against a variety of polymerase enzymes and is found to be inactive (IC50>300μM). Efavirenz effectively inhibits several wild-type T-lymphoid cell line-adapted variants. Identical activity (IC95, 1.5 to 3.0 nM) is seen with wild-type primary isolates of the virus in both primary lymphoid and monocytoid cell cultures. Efavirenz also effectively inhibits HIV-1 variants that expressed RT amino acid substitutions which confer the loss of susceptibility to other NNRTIs. For purposes of comparison[1]. Efavirenz is a non-nucleoside analog reverse transcriptase inhibitor (NNRTI) with IC50 of 60 nM[2]. Efavirenz inhibits synthesis using an RNA PPT-primed substrate with an IC50 of 17 nM[3].

    MCE has not independently confirmed the accuracy of these methods. They are for reference only.
    體內(nèi)研究
    (In Vivo)

    After i.v. administration, Efavirenz (L-743726) is cleared rapidly from rats, but it is cleared considerably more slowly from monkeys. The large volume of distribution (two to four times the amount of body water) in both species indicates extensive tissue binding. The oral bioavailability in rats is 16%. In monkeys, the half-life of Efavirenz after administration of a 1 mg/kg i.v. dose exceeded 2.5 h. Efavirenz is well absorbed orally. Administration to monkeys of oral doses as fine suspensions in 0.5% aqueous methylcellulose yields consistently high levels in plasma. A 2.0 mg/kg dose produces peak levels of 0.5μM at approximately 3.0 h. The absolute bioavailability is estimated to be 42%. A 10 mg/kg dose yields a peak level in plasma of 3.22 μM. A 10 mg/kg oral dose given to a single chimpanzee gave concentrations in plasma of 4.12, 2.95, and 2.69 μM at 2, 8, and 24 h after dosing, respectively[1].

    MCE has not independently confirmed the accuracy of these methods. They are for reference only.
    Clinical Trial
    分子量

    315.68

    Formula

    C14H9ClF3NO2
    CAS 號
    性狀

    固體

    顏色

    White to off-white

    中文名稱

    依法韋侖；施多寧；依法韋倫；依法維侖；依氟維綸；依非韋倫；艾法韋侖
    結(jié)構(gòu)分類
    初始來源
    運輸條件

    Room temperature in continental US; may vary elsewhere.
    儲存方式
    Powder -20°C 3 years
    4°C 2 years
    In solvent -80°C 6 months
    -20°C 1 month
    溶解性數(shù)據(jù)
    細胞實驗： 

    DMSO 中的溶解度 : ≥ 38 mg/mL (120.38 mM; 吸濕的 DMSO 對產(chǎn)品的溶解度有顯著影響，請使用新開封的 DMSO)

    * "≥" means soluble, but saturation unknown.

    配制儲備液
    濃度 溶劑體積 質(zhì)量 1 mg 5 mg 10 mg
    1 mM 3.1678 mL 15.8388 mL 31.6776 mL
    5 mM 0.6336 mL 3.1678 mL 6.3355 mL
    查看完整儲備液配制表

    * 請根據(jù)產(chǎn)品在不同溶劑中的溶解度選擇合適的溶劑配制儲備液；一旦配成溶液，請分裝保存，避免反復凍融造成的產(chǎn)品失效。
    儲備液的保存方式和期限：-80°C, 6 months; -20°C, 1 month。-80°C儲存時，請在6個月內(nèi)使用，-20°C儲存時，請在1個月內(nèi)使用。

    • 摩爾計算器

    • 稀釋計算器

    Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

    質(zhì)量
    =
    濃度
    ×
    體積
    ×
    分子量 *

    Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

    This equation is commonly abbreviated as: C1V1 = C2V2

    濃度 (start)

    C1

    ×
    體積 (start)

    V1

    =
    濃度 (final)

    C2

    ×
    體積 (final)

    V2

    動物實驗：

    請根據(jù)您的 實驗動物和給藥方式 選擇適當?shù)娜芙夥桨浮?

    以下溶解方案都請先按照 In Vitro 方式配制澄清的儲備液，再依次添加助溶劑：
    ——為保證實驗結(jié)果的可靠性，澄清的儲備液可以根據(jù)儲存條件，適當保存；體內(nèi)實驗的工作液，建議您現(xiàn)用現(xiàn)配，當天使用；
    以下溶劑前顯示的百分比是指該溶劑在您配制終溶液中的體積占比；如在配制過程中出現(xiàn)沉淀、析出現(xiàn)象，可以通過加熱和/或超聲的方式助溶

    • 方案 一

      請依序添加每種溶劑： 10% DMSO    40% PEG300    5% Tween-80    45% Saline

      Solubility: ≥ 2.08 mg/mL (6.59 mM); 澄清溶液

      此方案可獲得 ≥ 2.08 mg/mL（飽和度未知）的澄清溶液。

      以 1 mL 工作液為例，取 100 μL 20.8 mg/mL 的澄清 DMSO 儲備液加到 400 μL PEG300 中，混合均勻；再向上述體系中加入 50 μL Tween-80，混合均勻；然后再繼續(xù)加入 450 μL 生理鹽水 定容至 1 mL。

      生理鹽水的配制：將 0.9 g 氯化鈉，溶解于 ddH?O 并定容至 100 mL，可以得到澄清透明的生理鹽水溶液。
    • 方案 二

      請依序添加每種溶劑： 10% DMSO    90% (20% SBE-β-CD in Saline)

      Solubility: ≥ 2.08 mg/mL (6.59 mM); 澄清溶液

      此方案可獲得 ≥ 2.08 mg/mL（飽和度未知）的澄清溶液。

      以 1 mL 工作液為例，取 100 μL 20.8 mg/mL 的澄清 DMSO 儲備液加到 900 μL 20% 的 SBE-β-CD 生理鹽水水溶液 中，混合均勻。

      2 g SBE-β-CD（磺丁基醚 β-環(huán)糊精）粉末定容于 10 mL 的生理鹽水中，完全溶解至澄清透明。
    動物溶解方案計算器
    請輸入動物實驗的基本信息：

    給藥劑量

    mg/kg

    動物的平均體重

    g

    每只動物的給藥體積

    μL

    動物數(shù)量

    只
    由于實驗過程有損耗，建議您多配一只動物的量
    請輸入您的動物體內(nèi)配方組成：
    %
    DMSO +
    % 
    +
    %
    Tween-80 +
    %
    Saline
    如果您的動物是免疫缺陷鼠或者體弱鼠，建議 DMSO 中的在最后工作液體系中的占比盡量不超過 2%。
    方案所需 助溶劑 包括：DMSO， ，均可在 MCE 網(wǎng)站選購。 ，Tween 80，均可在 MCE 網(wǎng)站選購。
    計算結(jié)果
    工作液所需濃度 : mg/mL
    儲備液配制方法 : mg 藥物溶于 μL  DMSO（母液濃度為 mg/mL）。
    您所需的儲備液濃度超過該產(chǎn)品的實測溶解度，以下方案僅供參考，如有需要，請與 MCE 中國技術(shù)支持聯(lián)系。
    動物實驗體內(nèi)工作液的配制方法 : 取 μL DMSO 儲備液，加入 μL 。 μL ，混合均勻至澄清，再加 μL Tween 80，混合均勻至澄清，再加 μL 生理鹽水。
    連續(xù)給藥周期超過半月以上，請謹慎選擇該方案。
    請確保第一步儲備液溶解至澄清狀態(tài)，從左到右依次添加助溶劑。您可采用超聲加熱 （超聲清洗儀，建議頻次 20-40 kHz），渦旋吹打等方式輔助溶解。
    純度 & 產(chǎn)品資料

    純度: 99.93%

    參考文獻
    Animal Administration
    [1]

    Mice[1]
    Studies are performed in rats, rhesus monkeys, and a single chimpanzee. For analyses of the drug given to rats intravenously (i.v.), a group (n=4 or 5) of fasted male Sprague-Dawley rats (weight, 250 to 450 g) receive a bolus (at a volume of 1mL/kg of body weight) of Efavirenz in DMSO via a cannula implanted in the right jugular vein. For oral studies, rats are dosed by gavage by using a suspension of Efavirenz prepared in 0.5% aqueous methylcellulose. Similarly, four monkeys receive either an i.v. bolus of the compound in DMSO via the saphenous vein at a volume of 0.1 mL/kg or are administered the compound orally in suspension by using a nasogastric tube. Monkeys are fasted for 18 h prior to dosing. One nonanesthetized, nonfasted male chimpanzee (weight, approximately 60 kg) is dosed orally by voluntary ingestion by using an aqueous suspension of the compound. In all studies, heparinized blood is obtained at appropriate times. Plasma is separated immediately by centrifugation and is stored at -20°C until analysis. Plasma samples are extracted with methylene chloride; this is followed by analysis by high-performance liquid chromatography.

    MCE has not independently confirmed the accuracy of these methods. They are for reference only.
    參考文獻

    完整儲備液配制表

    * 請根據(jù)產(chǎn)品在不同溶劑中的溶解度選擇合適的溶劑配制儲備液；一旦配成溶液，請分裝保存，避免反復凍融造成的產(chǎn)品失效。
    儲備液的保存方式和期限：-80°C, 6 months; -20°C, 1 month。-80°C儲存時，請在6個月內(nèi)使用，-20°C儲存時，請在1個月內(nèi)使用。

    可選溶劑 濃度 溶劑體積 質(zhì)量 1 mg 5 mg 10 mg 25 mg
    DMSO 1 mM 3.1678 mL 15.8388 mL 31.6776 mL 79.1941 mL
    5 mM 0.6336 mL 3.1678 mL 6.3355 mL 15.8388 mL
    10 mM 0.3168 mL 1.5839 mL 3.1678 mL 7.9194 mL
    15 mM 0.2112 mL 1.0559 mL 2.1118 mL 5.2796 mL
    20 mM 0.1584 mL 0.7919 mL 1.5839 mL 3.9597 mL
    25 mM 0.1267 mL 0.6336 mL 1.2671 mL 3.1678 mL
    30 mM 0.1056 mL 0.5280 mL 1.0559 mL 2.6398 mL
    40 mM 0.0792 mL 0.3960 mL 0.7919 mL 1.9799 mL
    50 mM 0.0634 mL 0.3168 mL 0.6336 mL 1.5839 mL
    60 mM 0.0528 mL 0.2640 mL 0.5280 mL 1.3199 mL
    80 mM 0.0396 mL 0.1980 mL 0.3960 mL 0.9899 mL
    100 mM 0.0317 mL 0.1584 mL 0.3168 mL 0.7919 mL
    Help & FAQs
    • Do most proteins show cross-species activity?

      Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

    您最近查看的產(chǎn)品:

    Your information is safe with us. * Required Fields.

       產(chǎn)品名稱：

    		  

    * 需求量：

    * 客戶姓名：

    		 

    * Email：

    * 電話：

    		 

    * 公司或機構(gòu)名稱：

       留言給我們：

    Bulk Inquiry

    Inquiry Information

    產(chǎn)品名稱：
    Efavirenz
    目錄號：
    HY-10572
    需求量：